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 Abbreviations 
AA Ascending aorta 
AIx Augmentation index 
AP Augmented pressure 
ATP Adult treatment panel 
AUC Area under the curve 
BMI Body mass index 
BSA Body surface area 
CA Carotid artery 
CC Cross-sectional compliance 
Cf Carotid-femoral 
CHD Coronary heart disease 
CI Cardiac index 
CKD Chronic kidney disease 
CO Cardiac output 
CSAao aortic cross-sectional area 
CV Cardiovascular 
CVD Cardiovascular disease 
CV-RFs Cardiovascular risk factors 
DBP Diastolic blood pressure 
DC Distensibility coefficient 
eGFR Estimated glomerular filtration rate. 
Einc  Incremental elastic modulus 
ESC European Society of Cardiology 
ESH European Society of Hypertension 
FA Femoral artery 
FF Form factor 
FP Fractional polynomial 
 FRS Framingham risk score 
FVI Flow velocity integral 
HDL High-density lipoprotein 
HR Heart rate 
ICD International Classification of Diseases 
IFG Impaired fasting glycaemia 
IMT Intima-media thickness 
IOP Intra-ocular pressure 
LDL Low-density lipoprotein 
LVH Left ventricular hypertrophy 
MAP Mean arterial pressure 
MRI Magnetic resonance imaging 
NRI Net reclassification improvement 
NTG Normal-tension glaucoma 
PP Pulse pressure 
PWF Pressure waveform 
PWV Pulse wave velocity 
RM Reflection magnitude 
SAC Total arterial compliance 
SBP Systolic blood pressure 
SCORE Systematic COronary Risk Evaluation 
SPARTE Statégie de Prévention Cardiovasculaire Basée sur la Rigi-
dité Arterielle 
SV Stroke volume 
TB Truncus brachiocephalicus 
TOD Target organ damage  
TPRI Total peripheral resistance index 
WCSA Wall Cross-Sectional Area 
WHO World Health Organization 
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Chapter 1 Introduction 
According to WHO (World Health Organization) statistics, cardiovascular 
disease (CVD) is the main cause of morbidity and mortality worldwide.
1
 In 
2008, 17.3 million people worldwide died of CVD. It is estimated that in 
2030 this number will reach 23 million. In Belgium the same pattern emerg-
es: in 2009, 32 599 out of 103 816 deaths, were attributable to CVD, making 
it also here the leading cause of death.
2
 
Based on the International Classification of Diseases (ICD-10), the most fre-
quent types of CVD and their corresponding ICD-codes are
3
: 
 Ischemic heart disease (I20-I25): e.g. angina pectoris, myocardial in-
farction, coronary atherosclerosis 
 Other heart diseases (I30-I52): e.g. heart valve disease, cardiomyo-
pathy, heart failure, left ventricular hypertrophy 
 Cerebrovascular diseases (I60-I69): e.g. stroke (cerebral hemor-
rhage or infarction) 
 Diseases of the arteries, arterioles and capillaries (I70-I79): e.g. pe-
ripheral artery disease (PAD), aneurysm, arterial embolism and 
thrombosis 
 
Despite reaching epidemiological proportions, CVD is a non-communicable 
disease, meaning it is non-infectious and non-transmissible among people. 
CVD is also largely preventable and treatable, providing many routes for 
intervention. The latter is a consequence of the slow but progressive nature 
of the disease, building with time. The pathophysiology of CVD represents a 
continuum, including an early preclinical phase, which is hard to diagnose 
but more easy to reverse, and a late clinical phase, which can be easily diag-
nosed but is often irreversible.
4
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1.1 Pathophysiology of CVD 
By definition, CVD involves diseases of the heart (cardio) and the blood ves-
sels (vascular). However, since all organs (including the heart) rely on blood 
vessels to be nourished, at the root of CVD often lies a vascular problem. As 
a result, atherosclerosis is the leading cause of cardiovascular morbidity and 
mortality.
5
 
Atherosclerosis is a disease of the innermost layer of the arterial wall or 
endothelium. It involves a gradual process, in which some key stages can be 
distinguished: (1) endothelial dysfunction, (2) lipoprotein deposition and 
formation of ‘foam cells’, (3) inflammation and plaque growth (4) fibrous 
cap formation and (5) plaque rupture (Figure 1.1).
6
  
 
Figure 1.1 The pathogenesis of atherosclerosis. Adopted with permission from Nature (2002)6 
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Rupture or erosion of plaque material is the final and crucial stage in this 
process. This leads to a cascade of events, including activation of clotting 
factors and platelet aggregation, creating a thrombotic (hypercoagulable) 
state. The end-result is either a narrowed lumen (healing response), or 
worse, thrombus formation. The latter is responsible for the majority of fatal 
cardiovascular (CV) events.
7
 When a thrombus completely blocks an artery, 
blood supply to downstream organs is restricted, causing ischemia and 
eventually loss of function. The implications depend on the location of the 
blockage, such as myocardial infarction (when coronary arteries are affect-
ed) or a stroke (cerebral arteries). In addition to thrombus formation, the 
arterial wall may also be significantly weakened to the extent an aneurysm 
forms, carrying a significant risk of rupture and internal bleeding.
8
  
Whatever the outcome, all types of atherosclerotic disease are character-
ized by a silent development, often only revealing itself on an unexpected, 
fatal event before becoming symptomatic (e.g. angina pectoris, claudica-
tion). Fortunately, various tools are available to track the progression of 
atherosclerosis in its preclinical phase. Those are called risk markers or bi-
omarkers. Ideally, a biomarker can be measured non-invasively (i.e. without 
significantly harming the human body) and yet shows a strong correlation 
with outcome. Furthermore, when a risk marker is also considered to play a 
more causative role, contributing to the disease process, it is called a risk 
factor.
9
 Cardiovascular risk factors (CV-RFs) constitute the mainstay for CVD 
prevention, diagnosis, treatment and prognosis. Most of them are modifia-
ble (e.g. smoking), while others are genetically determined (e.g. sex, family 
history), or a combination of the two (e.g. hypertension).  
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1.2 Risk factors for CVD 
CV-RFs adopted by the European Society of Hypertension (ESH) are listed in 
Table 1.1.
10
  
Table 1.1 
Risk factors for CVD according to 2013 ESH guidelines. 
Non-modifiable risk factors 
Age: men ≥55 years; women ≥65 years 
Sex: male 
Family history of premature CVD: men aged <55 years; women aged <65 years 
Modifiable risk factors  
Hypertension: SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg 
Smoking 
Dyslipidemia: Total cholesterol > 190 mg/dL, and/or LDL cholesterol >115 mg/dL, and/or 
HDL cholesterol: men  < 40 mg/dL, women < 46 mg/dL, and/or triglycerides > 150 mg/dL 
Fasting plasma glucose: >102 mg/dL 
Abnormal glucose tolerance test 
Obesity: BMI ≥30 kg/m²  
Abdominal obesity: waist circumference: men ≥102 cm; women ≥88 cm (in Caucasians) 
SBP = systolic blood pressure. DBP = diastolic blood pressure. HDL = High-density lipoprotein. 
LDL = Low-density lipoprotein. BMI = body mass index 
 
If an individual carries one or more of these CV-RFs, this indicates he is at 
greater risk for developing CVD. However, it may not necessarily be the 
absolute value of a single risk factor, but rather the total number of risk 
factors that matters.
11
 To illustrate, a subject with very high cholesterol 
levels but otherwise no risk factors may have a much better prognosis than 
someone having mild hypertension and mild abdominal obesity. This syner-
gistic effect of risk factors (i.e. the sum being greater than its parts) has led 
to the development of risk scores which integrate several risk factors into a 
single value. The classical example of this is the Framingham risk score (FRS), 
developed in the United States.
12
 The FRS indicates the risk of cardiovascular 
disease in the next 10 years. In Europe, a similar system called “Systematic 
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COronary Risk Evaluation” (SCORE), indicates the probability of dying of CVD 
within the next 10 year.
13
 Based on this evaluation, a physician can then 
decide whether to advise lifestyle modifications, medication, or more severe 
treatment strategies. SCORE charts have been calibrated for high-risk and 
low-risk countries, and sometimes even tailored to national mortality statis-
tics and risk factor distributions, as was done in Belgium (Figure 1.2). 
 
Figure 1.2 Belgian SCORE risk chart indicating the probability of dying from CVD within the next 
10 year. Adopted with permission from the International journal of cardiology.13 
Although this system has been validated on a large prospective study sam-
ple, it is still imperfect.13 If a 5% risk score was used as a cut-off point for 
intervention, this would yield a sensitivity/specificity ratio of 72%/78%. 
Although superior to many other systems, this means a large number of 
subjects would still be misclassified. In particular, 28% of subjects at in-
creased risk would not be classified as such, and hence be deprived of nec-
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essary treatment. Conversely 22% of subjects at low risk would wrongly end 
up in the high-risk group, receiving unnecessary treatment. Anecdotal evi-
dence supports this limitation. Everybody knows the apparently healthy 
runner dying of an unexpected CV event, and the chain smoker living on for 
decades. One of the reasons for these inconsistencies is that not everybody 
responds in the same way to his or her risk profile.
14
 While some people are 
extremely sensitive to the effect of certain CV-RFs, others seem to be im-
mune to them and escape their predicted fate. What is needed, therefore, is 
a better way to quantify the true damage from exposure to CV-RFs. In other 
words, measures have to be established to identify those subjects in which 
CV-RFs are translated into real risk. This led to the development of target 
organ damage (TOD) as a tool for risk stratification.  
1.3 Target organ damage 
Asymptomatic organ damage is now considered an intermediate end-point 
in the continuum of CVD. It represents a state in which long-term exposure 
to CV-RFs has led to significant damage to a certain organ (e.g. the heart, 
brain or kidneys), but without any clear symptoms or complaints. Measures 
of TOD adopted by the ESH are listed in Table 1.2.  
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Table 1.2 
Measures of TOD according to 2013 ESH guidelines. 
Pulse pressure: (in the elderly) ≥60 mmHg 
Electrocardiographic LVH: Sokolow–Lyon index >3.5 mV; RaVL >1.1 mV; Cornell voltage dura-
tion product >244 mV*ms 
Echocardiographic LVH: LVM index: men >115 g/m²; women >95 g/m² (BSA) 
Carotid wall thickening: IMT >0.9 mm or plaque 
Carotid–femoral PWV: >10 m/s 
Ankle-brachial index:  <0.9 
CKD with eGFR: 30–60 ml/min/1.73 m2 (BSA) 
Microalbuminuria: 30–300 mg/24h, or albumin–creatinine ratio: 30–300 mg/g; 3.4–34 
mg/mmol 
LVH = left ventricular hypertrophy. LVM = left ventricular mass. BSA = body surface area. IMT = 
intima-media thickness. PWV = pulse wave velocity. CKD = chronic kidney disease. eGFR = 
estimated glomerular filtration rate.  
Four markers [microalbuminuria, increased carotid-femoral pulse-wave 
velocity (PWV), left ventricular hypertrophy (LVH) and carotid plaques] have 
been shown to carry additional predictive value above and beyond SCORE 
classification.
15
 Moreover, similar to the cumulative effect of CV-RFs, risk 
increases as the number of damaged organs goes up.
16
 As such, asympto-
matic organ damage is explicitly included in the ESH/ESC guidelines, and is 
receiving increasingly more attention with every update.
10
 
This manuscript will focus on two specific types of vascular TOD, i.e. (1) 
carotid wall thickening (or more broadly, ‘arterial wall thickening’), and (2) 
carotid-femoral PWV (or more broadly, ‘arterial stiffness’). Both will be dis-
cussed in more detail in the following sections, including their definition and 
predictive value. 
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 Arterial wall thickening 1.3.1
1.3.1.1 Definition 
When an atherosclerotic plaque is growing, this automatically leads to 
thickening of the arterial wall. Hence, measuring wall thickness allows di-
rectly assessing the atherosclerotic damage at a certain vascular site. Since 
the presence of atherosclerosis at one location correlates with atherosclero-
sis elsewhere along the arterial tree (e.g. at the coronary arteries), local wall 
thickening can be used as a proxy for systemic atherosclerosis.
17
 Arterial 
wall thickening is usually assessed at the carotid artery, and to a lesser de-
gree at the femoral artery. Different phenotypes include intima-media 
thickness (IMT) and plaque (Figure 1.3). 
 
Figure 1.3 Example of a carotid ultrasonogram. Indications represent common carotid artery-
IMT (large arrows), carotid plaque (small arrows) and the carotid bifurcation (arrowhead). 
Adopted with permission from American Journal of Neuroradiology.18  
 
IMT is a measure of the thickness of the two innermost layers of the arterial 
wall, i.e. the intima and media. The concept was first described in 1986 by 
Panoli et al,
19
 employing ultrasound. By taking advantage of the echogenic 
properties of the adventitia and intima, it is possible to measure the thick-
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ness of the layer in between adventitia and the lumen, which is the inti-
ma+media. Nowadays, high-resolution echotracking is used for this purpose, 
yielding a resolution of 21µm.
20
 The rationale behind measurement of IMT is 
that, at the carotid artery, intima-medial thickening is closely related to 
intimal thickening which may be an early feature of atherosclerosis. Micro-
scopic examinations on samples derived from autopsy confirm IMT is a valid 
surrogate for intimal thickness, at least for the carotid artery.
19
 However, 
intimal thickening is not always malignant, as in intimal hyperplasia and 
intimal fibrocellular hypertrophy.
21
 In addition, particularly at the femoral 
artery, medial thickening may also be responsible for increased IMT (e.g. in 
resistance-trained athletes, whose arteries are often under extremely high 
pressures).
22
 An overview of the possible confounding factors leading to an 
increased carotid IMT is provided in Table 1.3. The existence of these con-
founders represents the major limitation of IMT as a measure of vascular 
TOD. However, the cut-off value for increased carotid IMT as proposed by 
consensus guidelines, and adopted by the ESH, (i.e. > 900 µm) is of such 
large size that at least some degree of atherosclerosis is assumed to be pre-
sent. For femoral IMT, no such threshold has been established, making it 
hard to distinguish benign from malignant arterial remodeling. 
10 
 
Table 1.3 
Possible confounding factors linked with an increased carotid IMT.  
Increased tensile stress (e.g. in athletes): carotid IMT is greater in elite footballers.23 
Blood flow effects: carotid IMT is associated with low levels of shear stress.24 
Heritability: IMT is more heritable than plaque score and maximal stenosis, suggesting IMT 
reflects (genetic) differences in structure, rather than the (environmental) impact of atheroscle-
rosis.25 
Response to radiotherapy: IMT is increased following radiation of the neck. However, this 
increase diminishes with time and may therefore reflect acute rather than chronic (i.e. athero-
sclerotic) changes.26 
Plaque refers to a thickening of the intima-media layer to the extent a sig-
nificant lesion protrudes into the lumen. According to consensus guidelines, 
a lesion must fulfil one of the following three criteria to be considered a 
plaque
27
 
 Encroaching at least 0.5 mm into the arterial lumen  
 Exceeding the surrounding IMT value by 50%  
 Demonstrating an absolute thickness of 1.5 mm 
In contrast to IMT, plaque is a more direct measure of atherosclerosis,
28
 less 
confounded by the secondary factors listed in Table 1.3.  
However, overall, ultrasound imaging may not be the best way to investi-
gate the extent of atherosclerotic burden, as deep arteries are not well suit-
ed, and so are calcifications.
29
   
1.3.1.2 Predictive value 
The predictive value of arterial wall thickening is highly dependent on the 
arterial territory (carotid or femoral).  
At the carotid artery, both increased IMT and presence of plaques predict 
incident CVD, independent of each other.
30
 In addition, progression over 
time may be deterred by targeted interventions.
31
 However, measurement 
11 
 
of carotid IMT in clinical practice is questionable, since it does not lead to a 
significant reclassification above FRS or SCORE.
32
 In addition, two meta-
analyses have been published showing no association between carotid IMT 
and cardiovascular risk.
33,34
 Plaques, on the other hand, more accurately 
predict coronary artery disease,
35–37
 and provide additional information on 
top of FRS or SCORE.
16
 This may reflect the notion that a plaque constitutes 
a more advanced stage in the continuum of an atherosclerotic lesion,
38
 
while the meaning of an increased IMT is still controversial.
39
   
For the femoral artery, outcome studies are scarce, and the incremental 
value of femoral IMT and femoral plaque has been demonstrated only 
once.
40
 As a result, the predictive value is weaker compared to the carotid 
artery. However, femoral IMT and femoral plaques have been shown to 
correlate with atherosclerosis of the coronary arteries,
41–43
 and with LV 
mass.
44
 In the Asklepios study, femoral artery plaque showed the strongest 
association with oxidized LDL levels, independent of carotid artery plaque or 
IMT.
45
 
 Arterial stiffness 1.3.2
1.3.2.1 Definition  
Arteries provide the circuit for the heart to distribute blood. But besides 
their conduit function, they also act as a buffer to cushion large pulsations 
generated by the heart and transform these into a steady blood flow.
46
 This 
is particularly relevant for the large elastic arteries, such as the aorta and 
the carotid arteries.
47
 However, through repetitive cycles and aggravated by 
oxidative stress,
48
 arteries may show signs of ‘material fatigue’, character-
ized by a loss of elasticity.
49
 This phenomenon has several unfavorable im-
plications for the human body as a whole. When arteries are stiffened, this 
puts an increased burden on the heart, which has to work harder against an 
12 
 
elevated afterload.
50
 In addition, the loss of buffering function results in 
transmission of large pulsations into the microcirculation, which may induce 
remodeling of arterioles
51
 or cause damage to the capillaries of e.g. the 
brain, kidney or eye.
52
 
Thus, arterial stiffness is at the same time a consequence of damage done to 
the vasculature, but also a cause of further harm, constituting an intermedi-
ate end-point.
53
 Therefore, the importance of assessing arterial stiffness for 
risk classification cannot be overestimated. However, there is no single 
measure of a person’s arterial stiffness. Because the arterial tree is com-
posed of heterogeneous arteries, varying in histologic and/or elastic proper-
ties,
54
 the ‘arterial stiffness’ will differ depending on the specific location.
54
 
When interpreting stiffness measurements, the context (i.e. its location) is 
therefore of critical importance. For example, stiffness measured at the 
carotid artery is often referred to as ‘elastic artery stiffness’, while the same 
measurement done at the femoral artery is considered ‘muscular artery 
stiffness’. Comparing femoral to carotid stiffness would be like comparing 
apples to oranges. The same holds true for e.g. carotid-femoral and brachial-
ankle stiffness, which span different segments with differing elastic proper-
ties, and therefore should not be used interchangeably.  
Another (more terminological) distinction that deserves some attention is 
the one between compliance and distensibility as measures of arterial stiff-
ness. Both terms are used quite randomly (and often incorrect) in literature. 
However, although compliance is related to arterial stiffness, it is actually a 
measure of the buffering capacity of the artery, which is also dependent on 
the vessel caliber. Therefore, arterial distensibility, which is less dependent 
on arterial dimensions, can be considered a better marker for (the inverse 
of) arterial stiffness.  
13 
 
In what follows, arterial stiffness measures will be further classified depend-
ing on the length of the segment under consideration. As such, we distin-
guish local, regional and global stiffness measures. 
Local stiffness is defined as the arterial stiffness of a particular cross-
sectional site. It can be determined on almost all superficial large and medi-
um-sized arteries (e.g. on the brachial, carotid and femoral artery) using 
ultrasound. Because of limited resolution, ultrasound is not well suited to 
measure local stiffness of deeper lying arteries (e.g. the aorta).
55
 However, 
by reducing the distance between transducer and artery (e.g. using 
transesophageal echocardiography, TEE)
56
 or by using non-ultrasound-based 
methods (e.g. magnetic resonance imaging, MRI) it is possible to measure 
local stiffness of the aorta.
57
 Nevertheless, these techniques are not widely 
applied and local stiffness is most frequently examined using ultrasound on 
the carotid artery (to measure elastic artery stiffness) and femoral artery (to 
measure muscular artery stiffness). Elastic arteries are probably the most 
interesting to consider, since these are abundant in elastin molecules, which 
are prone to degeneration due to ageing or oxidative stress.
58
 However, 
knowing the stiffness of the femoral (muscular) artery may as well provide 
complementary information. Muscular artery stiffness may reflect the status 
of smooth muscle cells, regulating vascular tone.
59
 In addition, it has been 
postulated that when elastic arteries lose their elasticity, their buffering 
function is transferred to muscular (e.g. femoral) arteries, which limit the 
loss of compliance through an increase in diameter.
60,61
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Figure 1.4 Overview of pressure and distension waveforms aligned in time (left), resulting in an 
approximation of the pressure-volume relationship between diastole and systole (right).  
Measuring local stiffness of an artery requires knowing the relative change 
in volume, for a given change in pressure (Figure 1.4). This yields a complete 
description of the pressure-volume relationship (or more correctly, the 
pressure-cross-sectional area relationship, as we will see further) 
Because of the phenomenon of pulse pressure amplification
1
, brachial pulse 
pressure (PP) should not be used for calculation of local stiffness. However, 
at most superficial arteries, it is impossible to measure the local PP using 
conventional methods. Instead applanation tonometry is employed, which 
allows to capture the arterial pressure wave shape at a particular arterial 
(e.g. femoral or carotid) site. This, however, only yields a curve without 
reliable absolute levels of arterial pressure. To overcome this, a calibration 
scheme is employed: 
                                                                
1
 The pulse pressure (PP) at a given location is the amplitude of the blood pressure wave. This 
wave has a forward and backward component, the latter arising from wave reflections. The 
closer to the reflection sites (i.e., the further in the periphery), the earlier the forward and 
backward waves interact, boosting the amplitude of the blood pressure wave. Hence, PP will 
physiologically increase going from central (e.g. carotid artery (ca)) to peripheral (e.g. brachial 
artery (ba)) arteries. The central-to-brachial pulse pressure amplification is calculated as 
PPba/PPca. 
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 1/ Blood pressure is measured at the brachial artery, yielding the brachial 
PP.  
2/ Waveforms are measured at the brachial artery, yielding a brachial form 
factor (FF), which is a measure of how peaked the waveform is (see Figure 
2.2 on p32).
62
 Brachial FF is calculated using formula 1.1 
 Brachial FF = (MAP - DBP) / Brachial PP  (1.1) 
In which FF = form factor, MAP = mean arterial pressure, DBP = diastolic 
blood pressure, PP = pulse pressure. 
3/ Waveforms are also measured at the local (e.g. carotid or femoral) level, 
yielding a local FF.  
 
Local FF = (MAP - DBP) / Local PP (1.2) 
4/ Assuming (MAP - DBP) will hardly change across the arterial tree,
63
 equa-
tions (1.1) and (1.2) can be merged, yielding formula (1.3) to calculate local 
PP  
 Local PP = (brachial FF / local FF) x Brachial PP (1.3) 
Since applanation tonometry is not applicable in all individuals (particularly 
due to obesity),
64
 arterial distension waves can also be used as an alterna-
tive to calculate local PP. The approach is similar, with the only exception 
that the FF’s from equations (1.1) and (1.2) are then derived from distension 
curves instead of pressure curves.
65
 
Volume and volume change are approximated by cross-sectional area and 
cross-sectional area change respectively, assuming that longitudinal move-
ment of the vessel wall is negligible.
66
 These can be determined using ultra-
sound. In particular, algorithms based on echotracking have been devel-
16 
 
oped, which allow to accurately (resolution = 1.7 µm)
67
 follow displacement 
of arterial wall in time. This yields measures of diastolic diameter, systolic 
diameter, and distension, which is the difference between these two. When 
diameter, distension and PP are known, functional wall properties can be 
calculated. As noted above, it is important to make a clear distinction be-
tween cross-sectional compliance (CC), which is an indicator of the buffering 
capacity, and the distensibility coefficient (DC) as a measure of elasticity (or 
the inverse of stiffness). From (1.4) and (1.5) we can deduce that CC relates 
to DC as CC = DC x A. In other words, compliance is the product of elasticity 
and total cross-sectional area.
61
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(1.5) 
In which, ΔA = change in arterial cross-sectional area at a given location; ΔP 
= local pulse pressure (PP) at a given location; Ds = arterial diameter at end-
systole; Dd = arterial diameter at end-diastole; A = arterial cross-sectional 
area at end-diastole. 
Regional stiffness corresponds with the stiffness of a large or medium-
sized segment, often containing multiple arterial beds. It always refers to a 
measure of (the inverse of) distensibility. The stiffness of a certain arterial 
region can be quantified using the concept of pulse-wave velocity (PWV), 
which is based on the assumption that waves are transmitted faster through 
a segment with stiff vessel walls than through a segment with distensible 
walls. From the Moens-Korteweg
68
 (1.6) and Bramwell-Hill
69
 (1.7) equations, 
17 
 
it follows that PWV is inversely proportional to the elasticity of the vessel 
wall.  
In which, h = wall thickness, Einc = incremental elastic modulus, ρ = blood 
density and D = lumen diameter 
 
     √
 
      
 (1.7) 
In which, ρ = blood density and DC = cross-sectional distensibility coefficient 
PWV can be measured between any two arterial sites, but the vast majority 
of the studies focus on carotid-femoral PWV (cf-PWV). This is because 1) 
carotid and femoral arteries are easily accessible and 2) in between carotid 
and femoral artery lies the aorta, which is of major interest. Indeed, the 
aorta and its primary branches are what the heart sees and is thus most 
affected by.
70
 In addition, the aorta is made up of (mainly) elastic tissue 
(with exception of the abdominal aortic and iliac part), which is more sensi-
tive to the effects of ageing and CV-RFs compared to muscular wall materi-
al.
71
 Therefore, the gold standard method for assessing regional stiffness is 
carotid-femoral PWV. (Figure 1.5) 
 
     √
        
     
 (1.6) 
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Figure 1.5 Overview of the measurement locations along the arterial tree, accompanied by 
sample pressure waveforms (left) obtained at either site. ΔL represents the direct distance, Δt 
the transit time.  
To measure cf-PWV, travelled distance (ΔL) is divided by transit time (Δt), or 
Transit time can be measured non-invasively by detection of pressure, flow 
or distension waves at each respective site.
72
 This can be done simultane-
ously or sequentially, by gating both signals to the R-top of an electrocardio-
gram. Travelled distance is harder to estimate non-invasively. The arterial 
travelled paths cannot be seen from the outside and have to be approxi-
mated by superficial measurements. In addition, a correction factor needs 
to be incorporated, since waves are travelling at the same time in opposite 
directions.
73
 This is dealt with by measuring the direct distance between 
femoral and carotid measurement sites, and then multiplying this number 
with 0.8, which is known as the “80%-rule”.
74
  
 
     
  
  
 (1.8) 
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Global stiffness refers to the stiffness of the entire arterial tree. However, 
the term ‘stiffness’ is actually a misnomer here, since this always corre-
sponds with a measure of the total arterial compliance. Therefore, the term 
‘systemic arterial compliance’ (SAC) would be more appropriate. SAC can be 
approximated by looking at the pressure change (PP) for a given stroke vol-
ume (SV), or  
      
  
  
 (1.9) 
However, this is merely an approximation, since it assumes the entire stroke 
volume is stored in the large elastic arteries, neglecting peripheral outflow.  
To more accurately determine TAC, three- or four-element Windkessel 
models should be employed.
75,76
 This strategy is used by a commercially 
available device, which combines information of blood flow, pressure and 
pressure decay to obtain the SAC.
77
 Another device provides estimates of 
large artery compliance (C1) and small artery compliance (C2), based on the 
decay of the radial pressure waveform alone.
78,79
 However, its working prin-
ciple has been called into question.
80
 A more detailed description of tech-
niques to measure SAC and their limitations is beyond the scope of this 
thesis. 
1.3.2.2 Predictive value 
Regional stiffness, and in particular cf-PWV, has the most firmly estab-
lished predictive value of all stiffness measures. This was demonstrated in 
large epidemiological studies
81
 and in two meta-analyses.
82,83
 Recently, it 
has been shown that cf-PWV improves incident CVD prediction (both stroke, 
CHD and CV death) beyond classical risk factors.
82
 In addition, Guerin et al. 
have shown that reduction of cf-PWV (or rather the absence of a reduction) 
predicts outcome in end-stage renal disease patients, suggesting cf-PWV is a 
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good surrogate end-point for all-cause and CV mortality.
84
 Therefore, cf-
PWV is considered the gold standard measure of aortic stiffness.
85
 
Local stiffness has also been shown to carry prognostic value, but this 
depends on the type of artery under consideration (elastic/muscular).  
Most studies so far have focused on the carotid artery stiffness. The ARIC
86
 
and Hoorn studies
87
 showed associations between lower carotid DC (i.e. 
increased stiffness) and incident stroke,
86
 incident CV events
87
 and all-cause 
mortality,
87
 independent of CV-RFs and cf-PWV. In addition, some earlier 
studies in small samples
88–90
 or in specific (patient) populations
91–93
 have 
shown predictive value of carotid DC for CVD and/or mortality, whereas 
others did not.
94–97
  
Femoral artery stiffness is not commonly incorporated in vascular meas-
urement protocols, and is in general less extensively studied. As such, its 
predictive value is less well established. However, recent data from the 
Hoorn study showed that the predictive value of local carotid artery stiffness 
was extended to the femoral artery.
87
 Furthermore, in patients in the early 
stages of metabolic disease, such as diabetes
98
 and mild non-familiar hyper-
cholesterolemia,
99
 femoral stiffness has been reported to be increased 
whereas aortic and carotid stiffness were not altered. In addition, femoral 
artery stiffness is closely associated with prevalent lower limb arterial dis-
ease,
100,101
 which is a clinically important cardiovascular outcome. 
A meta-analysis on the predictive value of local stiffness has not been pub-
lished so far. Therefore, all available outcome studies that measured carotid 
and/or femoral artery stiffness are listed in Table 1.4.  
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Table 1.4 Overview of outcome studies measuring local arterial stiffness. 
First author (year, country) Follow-up  
(year) 
Type of patient (number) Mean age 
 (year)  
Low DC group Outcome measure Adj. HR   
(95% CI) 
Ref 
Carotid artery        
Blacher (1998, Fr) 2.1 ESRD (79) 58 Q1 (lower quartile)  All-cause mortality 6.4 (1.8-23.3) 90 
Barenbrock (2001, Ge) 7.9 ESRD (68) 43 - 1 x 10-3 kPa-1 CV events 1.27 (p<0.05) 89 
Störk (2004, Nl) 2.0 Elderly (367) 78 - 1 x 10-3 kPa-1 All-cause mortality 1.01 (0.95-1.08) 93 
     CV mortality 1.05 (0.94-1.16)  
Haluska (2010, Au) 7.3 General population (373) 55 < 24 x 10-3 kPa-1 All-cause mortality 1.85 (1.10-3.13) 91 
Karras (2012, Fr) 5.0 CKD (439) 60 - 1 SD mortality 1.62 (1.17-2.23) 88 
     CV events 1.69 (1.31-2.17)  
Yang (2012, Fr) 13.8 General population (10 407) 55 - 1 SD Stroke 1.19 (1.02-1.39) 86 
     CHD 1.01 (0.94-1.09)  
van Sloten (2014, Nl) 7.6 General population (579) 67 - 1 SD All-cause mortality 1.51 (1.11; 2.06) 87 
     CV mortality 1.22 (0.95-1.56)  
Femoral artery        
van Sloten (2014, Nl) 7.6 General population (579) 67 - 1 SD All-cause mortality 1.27 (0.90-1.79) 87 
     CV mortality 1.39 (1.06-1.83)  
ESRD = End-stage renal disease. CKD = chronic kidney disease. CHD = Coronary heart disease. Adj. HR = Adjusted hazard ratio. CI = confidence interval. SD = standard devia-
tion. 
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Systemic stiffness, in the form it is represented here, has the least number of 
studies showing predictive value. However, SV/PP predicts CV morbidity in 
hypertensives,
102
 and CHD mortality in elderly men.
103
 In the Hoorn study, SAC 
was calculated using the SV/PP and the pressure decay method, but neither was 
predictive for cardiovascular or all-cause mortality. In the MESA study,
87
 de-
creased C2 (small artery compliance), but not C1 (large artery compliance) cor-
related with CVD.
104
 However, the exact meaning of these parameters is not 
fully understood and debated. 
1.4 Problem statement and aims of the thesis 
Both arterial wall thickening and arterial stiffness have predictive value and can 
be measured with high reproducibility.
105
 However, their clinical applicability is 
limited. Nowadays primary prevention is still based on classical CV-RFs and in 
general focused on normalizing arterial blood pressure and lipid profiles. Even 
the most advanced measure, cf-PWV, has barely made its way into the doctor’s 
office. Among other factors, obstacles impeding translation to clinical practice 
include the (often) time-consuming measurement procedure, lack of methodo-
logical consensus and the absence of reference values. Therefore, the general 
aim of this thesis is to bring non-invasive measurements of vascular TOD to 
routine clinical practice, by helping them overcome current obstacles. This aim 
will be approached from five different angles, corresponding with five specific 
study objectives. (Table 1.5) 
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Table 1.5 
Five specific study objectives of the thesis. 
1) to investigate the impact of body side and size on carotid-femoral-PWV. 
2) to investigate the left-right distribution of carotid and femoral atherosclerosis. 
3) to establish normal values for carotid artery stiffness. 
4) to establish normal values for femoral artery stiffness. 
5) to examine the utility of cardiovascular structure and function measurements in patients 
with normal-tension glaucoma. 
 
Study objective n°1 
In recent years, much energy has been invested in making cf-PWV more appli-
cable to the clinic and to research in general. Reference intervals exist
106
 and 
consensus operating procedures have been established.
74
 The purpose of this 
study is therefore limited to merely fine-tuning of these already quite detailed 
guidelines. To provide context, current guidelines are tabulated on the next 
page (Table 1.6).
74
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Table 1.6 
Consensus guidelines for measurement of cf-PWV.74 
1) Measurements should be performed in a quiet room with stable room temperature. 
2) Perform measurements in supine position after at least 10 min of rest. 
3) Measurements should preferentially be done at the right common carotid and common 
femoral arteries. 
4) Because of diurnal variations repeated measurements should be done at the same time 
of the day. 
5) No meal, caffeine or smoking is allowed within 3 h before measurement. 
6) Speaking and sleeping are not allowed during measurements. 
7) Data should be mean of registrations during at least one respiratory cycle (about 5–6 s). 
8) Be aware of possible white coat effects. 
9) Measure distance in a straight line. If not possible with a tape measure, the upside-down 
use of an infantometer may be helpful. 
10) Take mean of at least two measurements; if difference between the two measurements 
is more than 0.5 m/s, perform a third measurement and take the median value. 
11) Situations in which measurement of cfPWV should not be performed: arrhythmia, un-
stable clinical situation, high-grade stenosis of carotid artery, carotid sinus syndrome. 
As can be interpreted from guideline 3 (Table 1.6), measurements should be 
done on the right side of the body. However, this is an arbitrary choice, and 
there are no indications left-sided arteries are less well suited for measure-
ments. It is conceivable that both sides cannot be used interchangeably, (bear-
ing in mind the asymmetric architecture of the arterial tree), but this should be 
investigated. Indeed, a substantial difference in anatomy exists between the left 
and right common carotid artery, which differ in their origin, and between right 
and left iliac-femoral path, the latter of which is expected to be shorter (since 
the aortic midline is on average oriented to the left of the body).
107
 However, 
the impact of these asymmetries on the difference in total real travelled path 
length between left and right side is currently unknown. Apart from these bilat-
eral differences in arterial geometry, another source of error in cf-PWV may be 
introduced by differences in body contours. Particularly in obese people, large 
abdomen and/or breast size may have a substantial impact on the distance 
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measured by tape measure, while the real (intra-arterial) distance is considered 
unaffected. As pointed out in guideline 9 (Table 1.6), it is therefore recom-
mended to make use of a sliding caliper such as an anthropometer if measure-
ment in a straight line is impossible with a tape. The size of the error introduced 
when using a tape has been examined in only one study, in which the authors 
concluded that it is crucial to always use a sliding caliper for distance measure-
ments.
108
 This finding is (partially) in contrast with the guidelines, which only 
offer the option to use an anthropometer, but do not necessitate this in all 
subjects. Therefore, this topic deserves further investigation, including a com-
parison with the ‘real’ intra-arterial distances. As such, study objective n°1 is to 
investigate the impact of body side and body size on cf-PWV. 
Study objective n°2 
For arterial wall thickening (IMT/plaque), the level of clinical applicability is 
similar to that of cf-PWV. Reference values have been established,
109
 and up-
dated guidelines are available for measuring carotid IMT and plaque.
27 To pro-
vide context, these guidelines are tabulated on the next page (Table 1.7).  
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Table 1.7 
Consensus guidelines for measurement of IMT.27 
1) Edge detection systems provide accurate measurements of IMT, and should be preferred 
above manual measurements, which are more observer dependent and more time-
consuming 
2) Inter-adventitial and intraluminal diameters should also be measured as IMT is signifi-
cantly correlated with arterial diameter. 
3) Mean IMT values averaged across the entire distance are less susceptible to outliers, 
whereas the maximal IMT may reflect more advanced stages with focal thickening or 
plaque formation.  
IMT values from the left and right side can be averaged although there is a significant dif-
ference between the left and right CCA IMT, with higher values on the left side. 
4) Vascular laboratories should always report intra-class correlation coefficients for intra- 
and inter-observer variability, both for IMT and plaque measurements. 
However, there is still room for improvement. Guideline 3 (Table 1.7), providing 
instructions on the measurement side, may cause confusion among operators. 
If there is indeed a significant difference between right and left carotid IMT, 
then a clear distinction should be made between measurements done on the 
left, right or both sides. Standardization with regard to body side is often poor: 
although some studies report measurements of only one side of the body,
110,111
 
others show both values,
112,113
 or average out the IMT from left and right 
side.
114
 The suggestion of a higher left common carotid IMT, as proposed by the 
guidelines (Table 1.7), was based on two studies.
115,116
 However, other studies 
do not show a significant left-right difference in carotid IMT,
112,117
 or plaque 
prevalence.
118
 Reference values for carotid IMT also do not make a distinction 
between left and right side IMT,
109
 although they should if there is indeed a 
substantial difference. Therefore, this topic deserves further investigation. In 
addition, no guidelines have been established for femoral IMT, for which some 
studies also noted a difference between left and right side.
42,119
 Therefore, 
study objective n°2 is to investigate the left-right distribution of atherosclerosis 
at the carotid and femoral artery.  
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In addition, comparing left to right-sided arteries provides a paired test to as-
sess the influence of local geometry on atherosclerosis. Results of such compar-
ison may improve our mechanistic understanding of how local factors influence 
the progression of an atherosclerotic lesion. 
Study objective n°3 
Measuring local arterial stiffness is more cumbersome than regional stiffness 
(cf-PWV), and its predictive value is less well established. As a result, local stiff-
ness measurements are much further away from implementation in routine 
clinical practice. Accordingly, more work needs to be done towards clinical im-
plementation. In particular, at present, no normal or reference values have 
been established for carotid stiffness. This makes it hard to interpret individual 
measurements obtained in clinical practice or research. Therefore, study objec-
tive n°3 is to establish normal values for carotid artery stiffness, based on a 
pooled dataset of various European cohorts. 
Study objective n°4 
With the same underlying motivation as described for study objective n°3, study 
objective n°4 is to establish normal values for femoral artery stiffness. In addi-
tion, such analysis may significantly improve our understanding of arterial phys-
iology. By setting up normal values for carotid and femoral artery stiffness, in a 
synchronized and uniform fashion, a standardized comparison can be made 
between two histologically quite distinct arteries.
54
 Identifying similarities and 
discrepancies between muscular and elastic artery stiffness, including their 
relationship with age, CV risk factors, and underlying mechanisms, is therefore a 
secondary goal of these studies.  
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Study objective n°5 
The 5
th
 and final specific study objective of this thesis can be regarded as an 
application of all of the above. In particular, this study involves looking at the 
utility of cardiovascular structure and function measurements in patients with 
vascular dysregulation. To this aim, a specific population of Normal-tension 
glaucoma (NTG) patients will be recruited for which there are indications they 
might have an altered vascular phenotype.
120
 Glaucoma is the second leading 
cause of blindness worldwide
121
 and is characterized by typical damage to the 
optic nerve head, termed ‘glaucomatous optic neuropathy’. NTG, a subtype of 
the disease, represents a challenge to researchers.
122
 Unlike the majority of 
glaucoma sufferers, NTG patients exhibit intra-ocular pressures within the nor-
mal range, suggesting other (systemic) factors are involved.
123
 However, there is 
a lot of controversy around the true identity of these factors. It is now accepted 
that NTG patients exhibit vascular dysregulation, i.e. an inappropriate response 
to certain stimuli.
124
 But the actual mechanism has not been revealed yet. 
Therefore, study objective n°5 is to examine the utility of cardiovascular struc-
ture and function measurements in patients with normal-tension glaucoma.  
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Chapter 2 Methods 
To answer the research questions and study goals posed in chapter 1, several 
methods and population samples were used, which are described in more detail 
in sections 2.1 and 2.3 respectively. Table 2.1 provides an overview of when 
each method/population is applied in the following chapters.  
Table 2.1 Methods and populations used in this thesis. 
  Chapter 3 Chapter 4 Chapter 5 Chapter 6 Chapter 7 
Methods      
Standardized measurement conditions     X 
Blood pressure 
    
X 
Local arterial stiffness  
  
X X X 
Local pulse pressure 
  
X X X 
Regional stiffness 
    
X 
Wave reflections 
    
X 
Augmentation index 
    
X 
Reflection magnitude 
    
X 
Total peripheral resistance 
    
X 
Cardiac output 
    
X 
Intima-media thickness 
 
X 
  
X 
Plaque 
 
X 
   Real travelled path lengths  X 
    Magnetic resonance imaging X 
    MRI post-processing X 
     
Populations      
Asklepios population  X X X  
NTG patients and matched controls     X 
Healthy volunteers eligible for MRI  X     
Various other population samples   X X  
MRI = magnetic resonance imaging. NTG = Normal-tension glaucoma. 
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2.1 Description of the methods 
 Standardized measurement conditions 2.1.1
Hemodynamic measurements were done in supine position and under stand-
ardized conditions (derived from the Task Force III, clinical applications for arte-
rial stiffness)
125
 in a temperature controlled room (22±1°C). Subjects were asked 
not to eat, smoke, and drink caffeine containing beverages for at least 3h be-
fore and during the measurements. They also had to refrain from drinking alco-
hol for at least 10h before measurements. 
 Blood pressure 2.1.2
Supine brachial SBP and DBP and heart rate (HR) were recorded at the domi-
nant arm with a validated semi-automated oscillometric device (OMRON M6, 
OMRON Healthcare, Hoofddorp, The Netherlands). Mean arterial pressure 
(MAP) was calculated by taking the area under the curve (AUC) of scaled bra-
chial artery pressure waveforms (PWFs) obtained by applanation tonometry. 
 Local arterial stiffness and buffering capacity 2.1.3
Arterial cross-sectional compliance (CC, a measure of the buffering capacity) 
and distensibility coefficient (DC, the inverse of the stiffness) were calculated 
using the formulas (1.4) and (1.5), shown in section 1.3.2.1  
Diastolic external diameter (D) and change in diameter during the heart cycle 
were measured on the right common carotid artery and on the right common 
femoral artery, 2 cm proximal to the bifurcation. For this purpose, a 10 MHz 
pulsed ultrasound echotracking system (Wall Track system®, AU5, Esaote Pie 
Medical, Maastricht, The Netherlands) was used. This system allows analyzing 
radiofrequency signals originating from an M line perpendicular to the longitu-
dinal axis of the artery, selected on the two-dimensional B-mode image.
126
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2.1.3.1 Local pulse pressure 
Carotid and femoral PP were obtained by recording local pressure waveforms 
(PWFs) non-invasively and calibrating them using brachial artery DBP and 
MAP.
127
 PWFs were obtained using applanation tonometry (Sphygmocor®, 
AtCor Medical, Sydney, Australia). Pulse-pressure amplification was calculated 
by dividing peripheral (brachial) over central (carotid) PP. 
 Regional stiffness 2.1.4
Regional stiffness was quantified by the carotid-to-femoral pulse wave velocity 
(cf-PWV). Cf-PWV was calculated using the 80%-rule, i.e. 0.8 x direct carotid-
femoral distance/transit time. To calculate the transit time, pressure waveforms 
were obtained non-invasively at the common carotid artery and the common 
femoral artery using applanation tonometry (Sphygmocor®, AtCor Medical, 
Sydney, Australia). The transit time was then the time delay between the feet of 
the 2 waveforms, which were identified using the intersecting tangents algo-
rithm.
128
 The travelled distance was estimated by taking the surface distance 
between the recording sites in the supine position using a tape measure, or 
anthropometer (Figure 2.1) if a straight line could not be obtained. 
 
Figure 2.1 Image of a sliding caliper or anthropometer. 
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 Wave reflections 2.1.5
Pressure waves have a forward and backward component, the latter arising 
from wave reflections. 
2.1.5.1 Augmentation index 
Augmentation index (AIx) has been proposed as a surrogate measure for wave 
reflection. Central augmentation index (AIx) was calculated from the carotid 
PWFs as the ratio of the amplitude of the pressure wave above its systolic 
shoulder, or P2/P1. Carotid AIx is a surrogate for aortic AIx.
129
 Although AIx is 
being widely used, it is a rather poor measure of the magnitude of wave reflec-
tions (due to its dependency on wave speed, heart rate and height).
130
 
 
 
Figure 2.2 Arterial pressure wave, indicating the first (P1) and second (P2) inflection points used to 
calculate the augmentation index (AIx) 131 
2.1.5.2 Reflection magnitude 
The reflection magnitude (RM) has been proposed as a more accurate measure, 
with a better prognostic value than AIx.
132
 The RM is calculated by taking the 
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ratio of the backward and forward pressure wave (2.1), obtained through wave 
separation analysis.  
 RM = Pb/Pf 
(2.1) 
In which Pb is the amplitude of the backward pressure wave, and Pf the ampli-
tude of the forward pressure wave. 
Wave separation requires knowing both pressure and flow, preferably meas-
ured simultaneously on the same location. When no flow data is available, RM 
can also be estimated based on information of the pressure curve alone, as in 
the ‘triangulation method’.
133
 However, as Kips et al. have shown, better results 
are obtained when using an averaged physiological waveform for all subjects,
134
 
which is the method used in this thesis.   
 Total peripheral resistance 2.1.6
Total peripheral resistance (TPR) determines the relationship between mean 
arterial pressure (MAP) and cardiac output (CO), as shown in formula (2.2). As 
such, it represents the state of the microcirculation (TPR is mainly regulated by 
arterioles). 
 TPR = MAP / CO (2.2) 
By normalizing for body surface area (BSA), the total peripheral resistance index 
(TPRI) is obtained. BSA was obtained through the Gehan and George formula 
(2.3).
135
  
 BSA (m²) = 0.0235 x Height(cm)
0.42246
 x Weight(kg)
0.51456
 (2.3) 
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2.1.6.1 Cardiac output 
Cardiac output (CO) was measured using echocardiography (AU5, Esaote, Gen-
oa, Italy). Aortic diameter (D) was measured at least three times using pulsed 
ultrasound at 2.5 MHz from a standard two-dimensional long-axis parasternal 
view at the site of the aortic annulus. Aortic blood velocity profiles (at least five 
beats) were measured across the aortic valve with continuous ultrasound using 
an apical window. Stroke volume (SV) was calculated from aortic cross-sectional 
area (CSAao = π x (D/2)²) multiplied by the flow velocity integral (FVI). CO was 
calculated by multiplying SV with HR and divided by BSA to obtain the cardiac 
index (CI).  
 Preclinical atherosclerosis 2.1.7
2.1.7.1 Intima-media thickness 
In the Glaucoma study, wall thickness (IMT) was measured on the right com-
mon carotid artery and on the right common femoral artery, during diastole, 2 
cm proximal to the bifurcation. For this purpose, a 10 MHz pulsed ultrasound 
echotracking system (Wall Track system®, AU5, Esaote Pie Medical, Maastricht, 
The Netherlands) was used. This system allows analyzing radiofrequency signals 
originating from a single (cross-sectional) M-line perpendicular to the longitudi-
nal axis of the artery, selected on the two-dimensional B-mode image. 
Because IMT is influenced by the variations in internal diameter, due to the 
(near) incompressibility of the wall material, Wall Cross-Sectional Area (WCSA) 
is a better parameter for evaluating arterial remodeling (assuming that remod-
eling has a negligible effect on the length of the artery).
136
 WCSA (mm²) is calcu-
lated by subtracting luminal area [π x (D/2- IMT)²] from total arterial circumfer-
ence [π x (D/2) ²], or  
35 
 
 
WCSA = [π x (D/2)²] - [ π x (D/2 - IMT)²]  (2.4) 
In the ASKLEPIOS study, wall thickness (IMT) was measured at the left and 
right carotid and femoral arteries (VIVID 7, GE Vingmed Ultrasound).
27,137–139
 
Analysis of the ECG-gated cineloops was performed offline by a single, meas-
urement-dedicated reader (Ernst Rietzschel), who was blinded for patient char-
acteristics.
27
 IMT was defined as the distance from the leading edge of the lu-
men-intima interface to the leading edge of the media-adventitia interface, 
measured in end diastole, at the far wall, in the common carotid artery, over a 
segment from 0 mm to 15 mm proximal to the bifurcation.
27,137–139
 The reported 
number corresponds with the maximum value over the observed segment. 
Intra-observer variability of IMT was 5%.
139
 Presence of plaque at an IMT meas-
uring site precludes IMT measurement at that site. This, together with difficult 
imaging (often related to obesity) resulted in missing IMT values in 8, 168, and 
198 subjects for the right carotid, left femoral and right femoral arteries, re-
spectively. Carotid IMT-values were categorized using the cut-off value of 0.9 
mm.
10
 In the absence of an established cut-off for femoral IMT, the same 
threshold (0.9 mm) was used to categorize femoral IMT measurements.   
2.1.7.2 Plaque 
In the ASKLEPIOS study, carotid and femoral arteries were scanned bilaterally 
by a single skilled operator (Ernst Rietzschel) for the presence of plaque (a focal 
protrusion >50% compared to adjacent sites with an absolute thickness >1.5 
mm or with a protrusion into the lumen of >0.5 mm). The variable “vascular 
target organ damage” (TOD) was defined as either IMT > 0.9 mm or presence of 
a plaque. 
 Real travelled path lengths of cf-PWV 2.1.8
MRI examinations were performed on a 1.5 T Magnetom Avanto scanner (Sie-
mens Medical Solutions, Erlangen). All images were scanned with a slice thick-
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ness of 6 mm and an interslice gap of 0.6 mm. In order to image the complete 
vasculature from carotid to femoral artery, two image series of the neck, thorax 
and abdomen with different table position were acquired per subject. Both 
series were merged to one dataset for post-processing.  
Vitamin A pearls were placed at the carotid and femoral artery sites where the 
pressure pulse was recorded. These sites were used for distance measurements 
using tape measure. The Vitamin A pearls were identified on the MRI images 
and made it possible to visualize the exact body surface measurement points. 
The exact position was later used for the reconstruction of the real travelled 
aortic path length.  
MRI post-processing was performed using a custom-developed 
Matlab®program (The MathWorks™, Natick, Massachusetts USA). To calculate 
the reference distance for the real travelled aortic path length, centerpoints 
were put manually in each slice. A centerline was reconstructed from those 
manually determined centerpoints. Using this centerline, different distances 
were calculated: the distance between ascending aorta (AA; from aortic valve) 
and the branching-off of the truncus brachiocephalicus (TB), the branching-off 
of TB and carotid artery (CA), the branching-off of TB and the right femoral 
artery (FA). At the time the pulse wave arrives at the carotid artery, this same 
pulse wave is already further down in the aorta. Presuming the same pulse 
wave velocity in the thoracic aorta and the carotid artery, the real travelled 
distance has to be calculated as the AA to FA distance (AA-FA) minus AA to CA 
distance (AA-CA). This distance will further be called “reference distance”. (Fig-
ure 2.3)  
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Figure 2.3 Four examples of cross-sectional MRI images used to trace the reference distance: from 
left to right: carotid artery, truncus brachiocephalicus, aortic bifurcation, femoral artery. The posi-
tion of the vitamin A pearls (body surface measurement points) is indicated by red circles. 
In addition the software program was used to reconstruct the straight distance 
between different anatomical points from the MRI images: carotid artery (Vit-
amin A pearl), suprasternal notch, umbilicus and femoral artery (Vitamin A 
pearl). These distances mimic distances obtained with an anthropometer and 
will further be called “straight MRI measured distances”. 
2.2 Reproducibility of measurements 
Prior to all studies, intra-observer reproducibility tests have been performed for 
cardiac output, AIx, IMT, cf-PWV, femoral and carotid diameter and femoral and 
carotid distension. These tests consisted of two sessions of triplicate measure-
ments, separated in time (>1h), on 10 subjects, yielding intra-and intersession 
coefficients of variation. The results of these tests are tabulated in Table 2.2. 
The measurements in the Asklepios study were carried out by a different opera-
tor (Ernst Rietzschel). The intra-observer reproducibility of IMT measurements 
in Asklepios was tested in 150 subjects (coefficient of variation 5.24%).
138
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Table 2.2 Results of reproducibility tests. 
  Intra-session CV Inter-session CV 
Cardiac output 4.36 % 5.34 % 
Cf-PWV 4.26 % 2.36 % 
Carotid artery   
Augmentation index (tonometry) 3.62 % 3.69 % 
diameter 1.91 % 1.59 % 
distension 8.54 % 4.77 % 
IMT 1.37 % 1.63 % 
Femoral artery   
Diameter 2.01 % 3.18 % 
Distension 8.97 % 9.52 % 
IMT 2.36 % 2.01 % 
Brachial artery  
  
Augmentation index (tonometry) 5.37 % 6.36 % 
CV = coefficient of variation. Cf-PWV = carotid-femoral pulse wave velocity. 
IMT =  Intima-media thickness.  
2.3 Description of the populations 
 Asklepios study participants 2.3.1
A cohort of 2524 apparently healthy, male and female volunteers aged 35 to 55 
years was randomly sampled from the twinned Belgian communities of Erpe-
Mere and Nieuwerkerken. They were all free from overt cardiovascular disease. 
Exclusion criteria were: 1, clinical evidence of atherosclerotic or atherothrom-
botic disease; 2, major concomitant illness; 3, diabetes mellitus type 1 and 2 
with proven clinical macro-vasculopathy or significant renal impairment; 4, 
pregnancy; 5, inability to provide informed consent.
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 Normal-tension glaucoma patients and healthy controls 2.3.2
32 patients diagnosed with NTG were recruited from the University hospital 
ophthalmology department. NTG was defined as neuroretinal rim loss assessed 
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by stereo disc assessment and photography, with a typical visual field defect, 
despite normal intraocular pressure (IOP, < 21 mm Hg). 35 Healthy control sub-
jects, matched for age and sex, were recruited from the local community. Exclu-
sion criteria were: (1) history of cardiovascular disease, (2) modest or severe 
arterial hypertension [i.e. systolic blood pressure (SBP) > 160 and/or diastolic 
blood pressure (DBP) > 100 mmHg], (3) diabetes mellitus, (4) severe hypercho-
lesterolemia (defined as total cholesterol > 290 mg/dl), (5) pregnancy or lacta-
tion. 
 Healthy volunteers eligible for the MRI study 2.3.3
98 Healthy (male and female) volunteers aged 18 to 80 years were recruited 
from the Flemish community. Subjects not eligible for magnetic resonance im-
aging were excluded, yielding the following exclusion criteria: (1) wearing a 
pacemaker, aneurysm clip, cochlear implant, epicardial pacemaker wires or 
neural stimulators, (2) significant claustrophobia, (3) significant obesity, (4) 
large tattoos, (5) pregnancy or breastfeeding. 
 Various other population samples 2.3.4
Chapter 5 and 6 used pooled data from various other population samples (in-
cluding the Asklepios sample) scattered across Europe. These populations are 
listed in tables 5.1 and 6.1 respectively.  
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Chapter 3 Cf-PWV: the influence 
of body side and body contours. 
Adapted from: 
Bossuyt J, Van de Velde S, Azermai M, Vermeersch SJ, De Backer TLM, Devos 
DG, Heyse C, Filipovsky J, Segers P, Van Bortel LM  
Noninvasive assessment of carotid-femoral pulse wave velocity: the influ-
ence of body side and body contours. J Hypertens 2013; 31:946–951. 
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3.1 Abstract 
Background: Recently an expert group advised to measure carotid-femoral 
(cf) pulse wave velocity (PWV) on the right side of the body, and to use a 
sliding caliper when tape measure distance cannot be obtained in a straight 
line. The present study investigates the evidence for these advices by com-
paring the real travelled cf path lengths at both body sides and comparing 
the straight distance (as can be obtained with a sliding caliper) with the tape 
measure distance. 
Methods: Real travelled cf path lengths were measured with Magnetic Res-
onance Imaging (MRI) in 98 subjects (49 men, age 21-76 years). Path lengths 
from the aortic arch to the carotid (AA-CA) and femoral (AA-FA) sites were 
determined. Real travelled cf path lengths was calculated as (AA-FA)-(AA-CA) 
and compared between both sides. Real travelled cf path lengths were com-
pared with 80% of the direct cf distance using a tape measure and the 
straight cf distance obtained from MRI images. 
Results: Real travelled cf path length was slightly longer [11 mm (12), 
p<0.001] at the right side. The 80%-rule overestimated the real travelled cf 
path length with 0.5% at the right and 2.7% at the left side. Straight MRI 
distance tended (p=0.09) to perform slightly better than tape measure dis-
tance. 
Conclusions: The travelled cf path is slightly longer at the right than at the 
left body side and the straight MRI distance tends to perform better than 
tape measure distance. The present study supports the advice of the expert 
consensus group to measure cf-PWV at the right body side using a sliding 
caliper when tape measure distance cannot be obtained in a straight line. 
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3.2 Introduction 
A recent expert consensus document advocates to measure cf-PWV at the 
right side and to use a sliding caliper when no straight tape measure dis-
tance can be obtained.
74
 Although these two advices are likely justified, they 
were based on expert opinion. The present study investigates the evidence 
for these two advices by 1) comparing the travelled distance at right and left 
body side and 2) by investigating whether the distance measured using a 
sliding caliper is more accurate than using a tape measure.  
3.3 Methods 
Ninety-eight apparently healthy subjects underwent body surface meas-
urements and magnetic resonance imaging (MRI), as described in section 
2.1.8 (p35). The carotid and femoral artery sites where the pressure pulse 
was maximally palpable were used as measurement sites for tape meas-
urement of the direct distance. At these sites vitamin A pearls were placed, 
which could be identified on the MRI images and enabled us to calculate the 
straight distance between carotid and femoral measurement points, mim-
icking the distance that would be obtained using a sliding caliper. For calcu-
lation of the real travelled distance, post processing of the MRI images al-
lowed to draw a centerline in the arteries, as previously described.
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The anatomical path travelled by the pulse wave was measured as the dis-
tance from the aortic arch to the femoral artery site (AA-FA) minus the dis-
tance from aortic arch to carotid measurement site (AA-CA). This was calcu-
lated for left- and right-sided carotid and femoral arteries. 
All analyses were done using PASW19® (SPSS inc, Chicago, Illinois USA). 
Distances on left and right body side were compared using a paired samples 
t-test. Pearson's correlation coefficients were determined to assess the 
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association of participants’ characteristics with differences between dis-
tance estimates. Levels of agreement between right and left real travelled 
distances were assessed by constructing scatter plots and Bland–Altman 
plots. Values of p<0.05 are considered significant. Data are reported as 
mean (SD) or frequencies (percentages). 
3.4 Results 
All participants were equally divided across age decade and gender. Subject 
characteristics are summarized in Table 3.1. As the majority of the partici-
pants (95 %) had a Body Mass Index (BMI) < 30 kg/m², we considered this a 
generally non-obese population sample. 
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Table 3.1 Subject characteristics (n=98) 
Men (%) 50 
Age (years, range) 47.8 (21-76)  
Age decade    20-29 (%) 18.4 
                       30-39 (%) 19.4 
                       40-49 (%) 15.3 
                       50-59 (%) 15.3 
                       60-69 (%) 15.3 
                       70-79 (%) 16.3 
Mean Height (cm, range) 171.6 (150-199) 
Mean Weight (kg, range) 72.0 (51-115) 
Mean BMI (kg/m², range) 24.5 (19-35) 
        Normal                  18.5-24.9 (%) 56.3 
        Increased               25.0-29.9 (%)  38.5 
        Obesity                  ≥ 30.0 (%)            5.2 
Mean SBP (mmHg, SD)* 134 (15) 
Mean DBP(mmHg, SD)* 76 (10) 
Mean Heart rate (bpm, SD)* 71 (11) 
*Mean of 3 measurements after 10 minutes of supine rest 
using a validated oscillometric device (OMRON 705 IT, OM-
RON Healthcare, Kyoto, Japan); BMI: Body Mass Index; bpm: 
Beats per minute; DBP: Diastolic Blood Pressure; SBP: Systolic 
Blood Pressure 
 Comparison between right and left real travelled dis-3.4.1
tances 
The results of the MRI based real travelled distances are depicted in Table 
3.2. Scatter plots and Bland-Altman plots of right versus left path lengths are 
presented Figure 3.1. For each arterial segment there was a small but statis-
tically significant length difference between the left and the right path. This 
resulted in a travelled carotid-femoral path being slightly longer [Δ 11 (12) 
mm, p<0.001] at the right side compared to the left. 
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Figure 3.1 Scatterplots and Bland-Altman plots. A: Comparison between the distance of aortic 
arch to right carotid artery (AA-CAright) and aortic arch to left carotid artery (AA-CAleft ), B: com-
parison between the distance of aortic arch to right femoral artery (AA-FAright) and aortic arch to 
left femoral artery (AA-FAleft). C: comparison between right reference distance and left refer-
ence distance. 
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Table 3.2 Travelled path lengths obtained from MRI imaging. 
 
Right (mm) Left (mm) Right – Left (mm) 
(AA-CA) 125 (14) 123 (15) 2 (6)* 
(AA-FA) 632 (46) 618 (47) 13 (11)* 
(AA-FA) - (AA-CA) 506 (42) 496 (41) 11 (12)* 
Data are shown as mean (SD). AA: aortic arch at the branching off of the brachiocephalicus; 
AA-CA: distance between aortic arch and the measurement point at the common carotid 
artery; AA-FA: distance between aortic arch and the measurement point at the common 
femoral artery. * p<0.001 statistical difference between left and right body side 
 
The tape measure distance according to the 80 % rule overestimated the 
real travelled distance at the left side by 2.7%, while this was only 0.5% at 
the right side (Table 3.3).  
 
Table 3.3 Path lengths estimated by tape measure and straight MRI distance using the 80% rule. 
 
Right Left 
Real travelled distance (mm) 506 (42) 496 (41) 
Tape measure distance x 0.8 (mm)  509 (35) 509 (35) 
(Tape measure distance x 0.8 – real travelled distance)/ real 
travelled distance (%) 
0.5 2.7* 
Straight MRI distance x 0.8 (mm) 505 (35) 505 (35) 
(Straight MRI distance x 0.8 – real travelled distance)/ real 
travelled distance (%) 
-0.2 1.9 
Data are shown as mean (SD) or %; Tape measure distances were measured on the right side and 
were considered to be the same on the left side. * p<0.05 statistical difference from real trav-
elled distance 
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 Accuracy of tape measure and straight distances 3.4.2
Straight MRI distances - taken as surrogate for distances measured with a 
sliding caliper - did not differ substantially between left and right body side 
[Δ 0.28 (1.1) mm, p<0.05]. At both body sides the straight MRI distance was 
shorter than the one obtained by tape measure, although no statistical sig-
nificance was reached [right: Δ 4.6 (2.6) mm, p=0.09; left Δ 4.8 (2.6) mm, 
p=0.07]. Straight MRI distances multiplied by 0.8 (80% rule) showed a statis-
tically non-significant (p=0.09) more accurate approximation of the real 
travelled distance, compared with tape measure multiplied by 0.8. (Table 
3.3 and Figure 3.2) 
Linear regression (Table 3.4) revealed that in the present population sample 
the difference in length between straight MRI and tape measure distance 
was only influenced by gender (right: r=0.269, p=0.008; left: r=0.280, 
p=0.005). As gender was the single significant univariate correlate, no multi-
variate analysis was carried out. In men, straight MRI distance did not differ 
from tape measure distance [right: ∆ -2.6 (3.0) mm, p=0.547; left: ∆ -2.4 
(3.0) mm, p=0.793)], while in women, significantly longer distances were 
obtained using a tape measure [right: ∆ 11.7 (1.9) mm, p< 0.001; left: ∆ 12.1 
(1.9) mm, p<0.001]. 
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Figure 3.2 Boxplots: Comparison between tape measure and straight MRI distance, relative to the 
real travelled distance. R = right body side, L = left body side. Top = male, bottom = female. Tape 
measure and straight MRI distances are obtained after application of the 80%-rule (measured 
distance x 0.8). Dashed horizontal lines represent mean right and left real travelled path length 
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Table 3.4 Associations of subject characteristics with the difference between 
tape measure distance and straight MRI distance. 
 Right  Left  
 
r 95% CI r 95% CI 
Age  0.126 -0.07 to 0.33  0.134 -0.07 to 0.33 
Height  -0.141 -0.34 to 0.06  -0.151 -0.35 to 0.05 
Weight  0.050 -0.26 to 0.15  0.051 -0.26 to 0.15 
BMI  0.048 -0.14 to 0.27  0.052 -0.15 to 0.26 
Male  -0.269* -0.47 to -0.07   -0.280* -0.48 to -0.09 
Univariate regression model with the difference between tape measure and 
straight MRI distance as dependent variable, for right and left body side. r = 
regression coefficient. CI = confidence interval. * p<0.05 statistically signifi-
cant correlation. 
3.5 Discussion 
The present study showed a slightly longer travelled path length (11 mm) 
between carotid and femoral arteries at the right side compared to the left 
side. This left-right difference in carotid-femoral travelled path length was 
mainly due to a longer right than left iliac and femoral path (from bifurca-
tion to the measurement point at the common femoral artery; 13 mm), 
while the also slightly longer right arch-to-carotid path (from aortic arch at 
the branching off of the brachiocephalicus to the measurement point at the 
common carotid artery; 2 mm) limited the left-right difference in real trav-
elled carotid-femoral path length. 
The consensus document showed that the 80% rule by tape measurement 
slightly overestimated the travelled right carotid-femoral path length by 
0.5% in the total population sample (all age groups). The present study 
shows that the 80% rule overestimates the travelled left carotid-femoral 
path with 2.7%. It is not clear to what extent this will influence the calcula-
tion of cf-PWV at the left side, as it is not clear to what extent this shorter 
travelled path length also translates into a shorter transit time. Dzeko et al. 
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showed that different PWV values are obtained when switching between 
left and right carotid artery, leaving the femoral measurement site con-
stant.
141
 However, this small difference was comparable with the inter-
observer difference.
142
  So, should we also apply the 80% rule to measure-
ments at the left side? One should realize however that the discrepancy 
definitely still falls within the limits of error of the cf-PWV assessment and 
may therefore be of less importance for single measurements in the clinic 
and that it can be used if measurement at the right side is not possible.  
The present study favors the distance measurement using a sliding caliper 
(although this was demonstrated only indirectly, using MRI measurements 
as a surrogate for caliper measurements), which after application of the 80% 
rule yields the closest approximation of the real travelled distance. In the 
present non-obese population sample, the use of the sliding caliper would 
be particularly important in women, who showed the largest deviation of 
tape measurement distance from the real travelled distance, probably due 
to breast contours. A larger study including obese subjects could show to 
what extent obesity may interfere with the (straight) distance measure-
ment.  
The present study has some limitations. Huybrechts et al. already acknowl-
edged the physical constraints of the MRI scanner, posing a limit on the 
degree of obesity of the subjects (i.e. < 140-150 kg).
140
 This may explain why 
BMI was not a determinant of the difference between tape measure and 
straight MRI distances in the present study. Furthermore, because this study 
was initially not designed to investigate the influence of body side, tape 
measure distances from carotid to femoral artery were only available for the 
right body side, and were considered the same on the left body side. Never-
theless, with respect to the MRI-measured distances, no assumptions had to 
be made, because the entire left path could be constructed using exactly the 
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same MRI images as for the right path. In addition, the same MRI planes at 
carotid and femoral arteries were used to calculate straight MRI distances at 
both sides. Therefore, this is the first study comparing the complete carotid-
to-femoral path length between the two body sides, using an accurate and 
reproducible MRI-based method. Finally, the study was not designed to 
analyze the influence of different cardiovascular risk factors on the path 
lengths. The MRI study showed a mild but acceptable influence of age on 
the accuracy of the measurement at the right body side.
140
 It is not likely 
that this influence would substantially be different at the left body side, but 
this has not been studied yet.     
In conclusion, the present study shows that the travelled carotid-femoral 
path is longer at the right than at the left side, causing the 80% direct dis-
tance rule to be less accurate at the left side, which may influence accuracy 
of cf-PWV. The difference in distance falls within the error of the cf-PWV 
assessment and might be less important for a single measurement, but can 
add to other inaccuracies. The size of error can further be reduced by a 
straight distance measurement as can be obtained with a sliding caliper 
instead of a tape measure. Therefore, the present study supports the advice 
of the consensus document to preferentially measure cf-PWV at the right 
side, measuring the distance in a straight line from carotid to femoral meas-
urement points and to make use of a sliding caliper if a straight line cannot 
be obtained (due to belly or breast size). However, these advices were de-
rived from a relatively small and healthy population. Further validation in 
larger and other populations should be advised. 
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Chapter 4 Left-right prevalence of 
femoral and carotid atherosclerosis  
 
Adapted from:  
Bossuyt J, Van Bortel LM, De Backer TLM, Van de Velde S, Azermai M, Segers 
P, De Buyzere M, Van daele C, Rietzschel E, on behalf of the Asklepios 
Investigators.  
Asymmetry in prevalence of femoral but not carotid atherosclerosis. Journal 
of Hypertension. 2014;32(7):1429–1434. 
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4.1 Abstract 
Objective(s): Atherosclerotic disease is caused by a combination of systemic 
and local factors (e.g. geometry) affecting local flow conditions. In contrast 
to the carotid artery, at the iliac-femoral artery region, a large degree of 
bilateral asymmetry exists. Therefore, we aimed to determine the influence 
of body side on the prevalence of atherosclerosis (i.e. plaque and intima-
media thickening; IMT) at the carotid and femoral arteries.  
Methods: Data were used from the ASKLEPIOS study, including 2524 appar-
ently healthy subjects with a mean age of 46 year (range 35-55). Echograph-
ic images were obtained bilaterally of the carotid and femoral arteries. A 
single observer approach was used for the acquisition and quantification of 
plaques and IMT.  
Results: The carotid artery displays no significant left-right difference in IMT 
values nor plaque prevalence (right: 12.0 % vs. left 13.3 %; p=0.18). In con-
trast, for the femoral artery, the IMT distribution at the right common femo-
ral artery is more skewed (P90 right: 1.11 mm, left 1.01 mm; p<0.001), 
which is mirrored by a significantly higher plaque prevalence (right: 21.9 % 
vs. left: 15.7 %; p<0.001).  
Conclusions: In the present study, atherosclerotic lesions are more preva-
lent at the right than at the left femoral artery. This finding highlights the 
possible role of local arterial geometry in the development of atherosclero-
sis, and underscores the importance of the choice of body side when as-
sessing vascular health. 
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4.2 Introduction 
The link between arterial geometry and atherosclerosis, mediated through 
changes in local hemodynamics and shear stress, has long been recog-
nized.
143
 We hypothesized that if a left-right difference in arterial geometry 
(as demonstrated in Chapter 3) translates into an asymmetric distribution of 
atherosclerosis, then this should reveal itself at the population level. There-
fore, our aim was to compare the prevalence of atherosclerosis (looking at 
both plaques and intima-media thickness, IMT) between the left and right 
carotid and femoral arteries, in a large population sample. 
4.3 Methods 
The ASKLEPIOS study protocol, methodology, and baseline population char-
acteristics have been described elsewhere in detail.
137
  The vascular imaging 
protocol and the study population are described in more detail in sections 
2.1.7. and 2.3.1. respectively. 
 Statistical analyses 4.3.1
For continuous variables, median, 80
th
, 85
th
, 90
th
 and 95
th
 percentiles are 
reported. Distributions were compared between left and right side by per-
forming quantile regression on median and individual percentile values. 
Categorical variables were summarized as absolute values and percentages. 
The influence of body side and (possible) confounding effect of sex was 
tested using logistic regression, adding side, sex and an interaction term 
(body side*sex) as fixed factors into the model. For each test p<0.05 was 
considered statistically significant. Odds ratios (OR) and corresponding 95% 
confidence intervals (CI) were calculated. The OR represents the ratio of the 
odds of finding a plaque at the right side, over the odds of finding a plaque 
at the left side. As a sensitivity analysis we checked whether the results 
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would be maintained when looking at mean IMT (i.e. the average IMT over 
the observed segment) instead of maximal IMT, and when subjects with 
atherosclerosis at two or more locations were excluded (i.e. looking at “sin-
gle-site atherosclerosis”, including only those subjects with a lesion at one 
single site). 
4.4 Results 
Demographics, anthropometric data, lifestyle, and ultrasonographic data are 
provided in Table 4.1. 
 Intima-media thickness (IMT) 4.4.1
Median IMT was not significantly different between left and right carotid 
arteries. Quantile regression also revealed no significant differences for the 
80
th
, 85
th
, 90
th
 and 95
th
 percentiles between right and left side (p>0.05 for all 
percentiles). Median femoral artery IMT was identical for the left and right 
side. Comparison of upper percentiles however, showed increasingly higher 
values at the right femoral artery (p<0.05), indicating a more skewed distri-
bution (Figure 4.1). This effect was also demonstrated by the significantly 
higher number of subjects exceeding the 0.9 mm cut-off value for femoral 
artery IMT on the right side. (Table 4.2) 
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Table 4.1. Baseline characteristics of the ASKLEPIOS Study population. 
Variable Women (n=1301; 51.5%) Men (n=1223; 48.5%) 
Age, y 45.7 (40.8–51.1) 45.9 (41.2–50.9) 
BMI, kg/m2 25.1±4.7 26.5±3.7 
Waist circumference, cm 80.5±11.3 93.8±10.4 
Obesity, BMI ≥30 kg/m² (%)  13.5 17.3 
Abdominal obesity, ATP III (%) 20.7 19.2 
Hemodynamic parameters   
 Systolic BP, mm Hg 123±14 131±13 
 Diastolic BP, mm Hg 78±10 82±10 
 Pulse pressure, mm Hg 45±9 48±7 
 Heart rate, bpm 72±10 68±12 
Biochemical parameters   
 Total cholesterol, mg/dl 214±36 219±38 
 HDL-cholesterol, mg/dl 71±17 56±14 
 LDL-cholesterol, mg/dl 125±33 137±34 
 Diabetes mellitus/IFG, % 1.1/6.9 2.1/14.5 
Lifestyle variables   
 Smoking: Active/Ex, % 17.7/21.8 24.1/34.3 
 Pack-years, of ever smokers 8.1 (2.4–17.7) 11.3 (4.8–22.2) 
 Physical activity: None, % 66.0 53.6 
Ultrasonographic measures   
 Right carotid IMT, mm* 0.67 (0.60–0.76) 0.71 (0.63–0.82) 
 Left carotid IMT, mm* 0.67 (0.60-0.76) 0.73 (0.63–0.83) 
 Right femoral IMT, mm* 0.59 (0.51–0.71) 0.72 (0.60–0.92) 
 Left femoral IMT, mm* 0.59 (0.51–0.70) 0.71 (0.60–0.87) 
Cut-offs for abdominal obesity (Adult Treatment Panel, ATP III) are: waist >88 cm (fe-
males) / >102 cm (males); Impaired fasting glycaemia (IFG): glucose ≥100 mg/dl and 
<126 mg/dl (diabetes). Data are mean±SD or median (interquartile range) where ap-
propriate. *maximum value over the observed segment. 
 Plaque 4.4.2
A total of 303 and 335 plaques were found at the left and right carotid ar-
tery respectively, revealing no significant influence of the body side 
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(p=0.92). In contrast, at the level of the femoral artery, substantially more 
plaques were found on the right side (right: n=552, left: n=396), resulting in 
an odds ratio significantly different from 1 (OR 1.53, 95% CI: 1.28-1.83; 
p<0.001). (Table 4.2) When cases of IMT>1.5 mm but without significant 
protrusion into the lumen (>50% compared to adjacent sites or >0.5 mm) 
were also classified as plaques, these results were maintained (femoral 
artery: right: n=573, left: n=423; OR 1.51, 95% CI: 1.27-1.81; p<0.001; carot-
id artery: right: n=304: left: n=336; OR 1.01, 95% CI: 0.82-1.25; p=0.92). 
 Target organ damage (TOD) 4.4.3
The combined phenotype, “TOD”, exhibits the same pattern as either plaque 
prevalence or intima-medial thickening alone, confirming the symmetrical 
and asymmetrical distributions at the carotid and femoral arteries respec-
tively. (Table 4.2) 
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Figure 4.1 Cumulative distribution of maximal IMT at the carotid (A) and femoral (B) arteries. 
Left and right Carotid IMT distributions largely overlap, while increasingly higher values are 
found at the right femoral artery compared to the left. Statistically significant (p < 0.05) 
differences between individual percentiles are indicated with an asterisk (*). 
62 
 
Table 4.2. Prevalence of preclinical atherosclerosis in men, women and all subjects. 
Carotid artery 
 Men (n=1223) Women (n=1301) All (n=2524)   p-value  
 Left Right Left Right Left Right  Body side Sex Side*sex 
IMT > 0.9 185 (15) 161 (13) 72 (6) 61 (5) 257 (10) 222 (9)  0.164 <0.001 0.952 
Plaque 210 (17) 212 (17) 93 (7) 123 (9) 303 (12) 335 (13)  0.915 <0.001 0.101 
TOD 335 (27) 310 (25) 140 (11) 169 (13) 475 (19) 479 (19)  0.251 <0.001 0.036 
Femoral artery 
 Men (n=1223) Women (n=1301) All (n=2524)   p-value  
 Left Right Left Right Left Right  Body side Sex Side*sex 
IMT > 0.9 241 (20) 292 (24) 113 (9) 137 (14) 354 (14) 429 (17)  0.013 <0.001 0.846 
Plaque 280 (23) 382 (31) 116 (9) 170 (13) 396 (16) 552 (22)  <0.001 <0.001 0.981 
TOD 402 (33) 508 (42) 195 (15) 250 (19) 597 (24) 758 (30)  <0.001 <0.001 0.588 
Vascular target organ damage (TOD) is defined as IMT ≥0.9 mm and/or presence of a plaque. Data are shown as absolute values and percentages, n (%). P-values were obtained 
from logistic regression in all subjects, including body side, sex, and an interaction term (body side*sex) as fixed factors.  
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 The influence of sex 4.4.4
The prevalence of lesions was always higher in men than women (p<0.001). 
However, the modifying effect of sex was limited, since the interaction term 
(body side*sex) was significant only for carotid TOD (p=0.036), because of a 
reversed trend in men (right: n=310, left: n=335) compared to women (right: 
n=169, left: n=140). (Table 4.2)  
 Sensitivity analyses 4.4.5
4.4.5.1 Single-site atherosclerosis 
When only taking into account subjects with atherosclerosis at a single site, 
the same pattern emerges: an almost identical number of lesions at right 
and left carotid arteries (right: n=112, left: n=110; OR 1.02; CI: 0.78-1.33; 
p=0.89), in sharp contrast to the more than twofold difference seen at the 
femoral arteries (right: n=207; left: n=94, OR 2.31, CI: 1.80-2.97; p<0.001).  
(Figure 4.2) This also indicates that by measuring both carotid arteries and 
only right, only left or none of the femoral arteries, 94 (4%), 207 (8%) and 
474 (19%) subjects would be wrongly classified without TOD respectively.  
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Figure 4.2 Distribution of preclinical atherosclerosis in all subjects. Venn-diagram displaying 
all possible combinations of target organ damage distribution (TOD, IMT >0.9 mm or presence 
of a plaque), emphasizing cases of single-site atherosclerosis (bold). 
4.4.5.2 Using mean IMT instead of maximal IMT 
When maximal IMT was replaced with mean IMT, this shifted IMT distribu-
tions towards lower values, reducing the total number of individuals exceed-
ing the 0.9 mm cut-off value. However, this had no impact on our conclu-
sions: P90 percentiles were again divergent for the femoral artery (right: 
0.90 mm, left 0.85 mm; p<0.05), while equal for the carotid artery (right: 
0.75 mm, left 0.75 mm). Left-right distributions of TOD prevalence also re-
mained unchanged when TOD was defined using mean instead of maximum 
IMT (femoral artery: left: n=488, right: n=633; p<0.001; carotid artery: left: 
n=333, right: n=368; p=0.15) adding to the robustness of our findings. 
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4.5 Discussion 
The present study investigated the influence of body side on the prevalence 
of atherosclerosis at the carotid and femoral arteries. Our main finding was 
that atherosclerosis, examined through maximal IMT and the presence of 
plaque, was distributed symmetrically at the carotid artery while asymmet-
rically at the femoral artery. For the carotid artery, these observations are in 
line with results from some previous epidemiological studies, showing 
small
115
 or insignificant
113
 differences between both sides. With regard to 
the femoral artery, data are rather scarce but also tend to confirm our ob-
servations. Plaque thickness
42
 and IMT
119
 tend to be higher when measured 
on the right side. 
The results of this study also mirror anatomical features described in litera-
ture.
144
 The equal distribution of carotid artery atherosclerosis reflects the 
limited amount of morphological asymmetry between left and right side at 
the level of the measurement location, proximal to the bifurcation, while 
the skewed distribution of femoral artery atherosclerosis can be explained 
by more pronounced differences in arterial anatomy. Moreover, the finding 
that the most frequently affected femoral artery is the one lying on the right 
side resonates with the current hemodynamic principles. It is known that 
regions of curvature, bifurcation or branching are associated with low longi-
tudinal or high oscillatory shear stress, creating flow conditions which pro-
mote the development of atherosclerotic lesions.
145–148
 Therefore, the high-
er prevalence of atherosclerosis seen at the right femoral artery may be 
explained by its generally more curved, bended nature. Although the anat-
omy of left and right carotid artery is also not completely comparable, par-
ticularly differing in terms of their origin, we speculate that the impact of 
this anatomical variability on the hemodynamics at the more distal meas-
urement location is buffered by the relatively long straight segment in be-
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tween. Indeed, at the common carotid artery, no bilateral difference is 
found in blood flow characteristics,
149
 including timing and velocity of the 
flow waveform,
150
 and shear stress distributions.
151
 In addition, it can be 
speculated that the difference in vascular wall properties (the more elastic 
carotid and the more muscular femoral arteries), the more bended iliac-
femoral trajectory and the higher pressures at the femoral arteries in stand-
ing position might contribute to a possible difference in sensitivity to local 
atherogenic factors between the common carotid and common femoral 
arteries. However, to provide more conclusive evidence for this hypothesis, 
information on the arterial anatomy on an individual basis is warranted. 
Instead, our assumptions are based on averaged anatomical data found in 
literature, including our own MRI-based research in a different healthy pop-
ulation.
144
 
 Study limitations 4.5.1
As a general remark, we emphasize this study was carried out in an appar-
ently healthy population, exhibiting only preclinical signs of atherosclerosis. 
It remains to be established whether these lesions will actually become 
clinically apparent later in life. Prospective studies are needed to show the 
clinical relevance of the possible difference of atherosclerosis in right and 
left femoral arteries.  
Other limitations of the study include the absence of bilateral diameter and 
flow measurements, and some limitations inherent to the non-invasive as-
sessment of atherosclerosis. Ultrasound imaging provides only a two-
dimensional view of the vessel wall and also fails to distinguish intimal from 
medial thickening.
39
 However, to deal with this latter point, we reported 
maximal (and not mean) IMT values, which may be considered to represent 
more closely the first signs of an atherosclerotic lesion.
152,153
 In our study, 
the difference in maximal IMT values between left and right side was indeed 
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closely mirrored by the difference in plaque prevalence, confirming this 
assumption. 
In addition, this study provides a systematic and robust measurement of 
atherosclerosis at the left and right carotid and femoral arteries, excluding 
any bias due to variations in operator or measurement device. While similar 
experiments have been repeatedly carried out on the carotid artery, this is 
the first study making a rigorous comparison of the prevalence of athero-
sclerosis between left and right femoral artery. 
 Implications 4.5.2
For the carotid artery, our data provide additional support for the current 
consensus advice of not taking into account the body side (on a population 
level). For the femoral artery, guidelines are at present non-existing, leaving 
operators free in their choice on which body side to measure upon. Howev-
er, researchers should be aware of the possibility that femoral artery ather-
osclerosis may more likely affect the right side of the body, as observed in 
this study population. A second implication may relate to the mechanisms 
responsible for the observed differences in atherosclerosis prevalence. 
While unable to provide conclusive evidence for the causal role of anatomi-
cal asymmetries, our data do provide an interesting starting point for further 
research. Characterizing also left-right differences in shear stress and blood 
flow patterns at the same time may yield more insight in the underlying 
processes behind this phenomenon, unraveling the critical anatomical fea-
tures responsible for driving the asymmetrical distribution observed in our 
sample. Follow-up studies (including outcome of patients) could be of help 
to identify the clinical relevance. 
68 
 
 Conclusion 4.5.3
In this healthy, middle-aged population sample, subclinical atherosclerosis is 
equally distributed between right and left carotid arteries. In contrast, the 
right femoral artery is significantly more affected than the left femoral ar-
tery. These results may reflect differences in anatomy between left and right 
side and therefore suggest a causal role for variations in local hemodynam-
ics. 
69 
 
Chapter 5 Reference values for 
carotid artery stiffness. 
 
Engelen L, Bossuyt J, Ferreira I, Van Bortel LM, Boutouyrie P, Laurent S, 
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Reference values for local arterial stiffness. Part A: Carotid artery. (in prepa-
ration) 
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5.1 Abstract 
Aims: Non-invasive measures of common carotid artery properties, such as 
diameter and distension, and pulse pressure, have been widely used to 
determine carotid artery distensibility coefficient (DC), a measure of carotid 
stiffness (stiffness~1/DC). Carotid stiffness has been associated with incident 
cardiovascular disease (CVD) and may therefore be a useful intermediate 
marker for CVD. We aimed to establish age- and sex-specific reference in-
tervals of carotid stiffness. 
Methods and results: We combined data on 22,708 individuals (age range 
15-99; 54% men) from 24 research centres worldwide. Individuals without 
CVD and established cardiovascular risk factors (CV-RFs) constituted a 
healthy subpopulation (n=3,601, 48% men) and were used to establish sex-
specific equations for percentiles of carotid DC across age. In the subpopula-
tion without CVD and treatment (n=12,906, 52% men), carotid DC Z-scores 
based on these percentile equations were independently and negatively 
associated, in men and women respectively, with diabetes [-0.28 (95% CI: -
0.41; -0.15) and -0.27 (-0.43; -0.12)], mean arterial pressure [-0.26 (-0.29; -
0.24) and -0.32 (-0.35; -0.29)], total-to-HDL cholesterol ratio [-0.05 (-0.09; -
0.02) and -0.05 (-0.011; 0.01)] and body mass index [-0.06 (-0.09; -0.04) and 
-0.05 (-0.08; -0.02)], whereas these were positively associated with smoking 
[0.30 (0.24; 0.36) and 0.24 (0.18; 0.31)]. 
Conclusion: We estimated age- and sex-specific percentiles of carotid stiff-
ness in a healthy population and assessed the association between CV-RFs 
and carotid DC Z-scores, which enables comparison of carotid stiffness val-
ues between (patient) groups with different cardiovascular risk profiles, 
helping interpretation of such measures. 
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5.2 Introduction 
As described in Chapter 1, carotid artery stiffness (or its inverse, the carotid 
artery distensibility coefficient, DCcar) carries added predictive value for all-
cause and cardiovascular mortality.
87
 However, the interpretation of DCcar 
values measured across different age, sex and risk groups has been ham-
pered by the absence of reference values. In view of these considerations, 
we aimed 1) to establish age- and sex-specific normal values using percen-
tiles of local DCcar obtained in individuals without prior CVD, treatment and 
established cardiovascular risk factors (CV-RFs) and 2) to investigate associa-
tions between known CV-RFs and these DCcar percentiles in individuals with 
or without CV-RFs, treatment and prior CVD. 
5.3 Methods 
 Study population  5.3.1
With a systematic literature review all cohort studies using echotracking for 
DCcar measurement were identified. Next, the principal investigators of the 
cohorts (n=57) were personally contacted to inform them about the project 
and inviting them to participate. Finally, subject-level data was compiled 
from 24 research centres/research groups – corresponding to 30 distinct 
cohorts – distributed across 13 countries worldwide (Table 5.1).
109
 A total of 
23,007 individuals with data on carotid artery diameter and distension ob-
tained using echotracking systems, blood pressure (BP), age (range 5-99 
years), sex (12,390 men/10,617 women), CVD status, and important CV-RFs 
were available for analysis. For the present study we excluded 299 (54% 
girls) individuals who were aged <15 years because their data lacked suffi-
cient variability with age (primarily concentrated at the age of five
154
) leav-
ing 22,708 (46% women) individuals for analyses. 
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To generate age- and sex-specific normative tables for DCcar, we selected a 
healthy sub-population composed of individuals who did not meet any of 
the following criteria: 1) history of CVD; 2) use of BP-, lipid- and/or glucose-
lowering medication; 3) hypertension [i.e. SBP ≥140 mm Hg and/or diastolic 
blood pressure (DBP) ≥90 mm Hg];
10
 4) current smoking; 5) diabetes (de-
fined as self-reported diabetes and/or fasting plasma glucose ≥7.0 mmol/L 
(if available) and/or postload plasma glucose ≥11.0 mmol/L (if available)];
155
 
6) total cholesterol >6.2 mmol/L;
156
 7) HDL cholesterol <1.17 mmol/L (for 
men) and <1.30 (for women); 
156
  and 8) BMI ≥30 kg/m
2
.
157
 This healthy sub-
population consisted of 3,601 (52% women) individuals, who originated 
from 19 out of the 24 research centres (Table 5.1). The cut-off values used 
to define the healthy sub-population were chosen, whenever possible, to be 
similar to those used to indicate increased risk in current guidelines (or risk 
algorithms) to enable optimal comparison with other studies.  
To investigate the relation of CV-RFs with individuals’ levels of DCcar percen-
tiles we stratified the total population according to history of CVD and, in 
individuals without prior CVD only, by use of BP-, lipid- and/or glucose-
lowering medication. This resulted in three reference sub-populations con-
sisting of: 1) 12,906 (48% women) individuals without prior CVD and without 
use of BP-, lipid- and/or glucose-lowering medication; 2) 5,137 (52% wom-
en) individuals without prior CVD and who used BP-, lipid- and/or glucose-
lowering medication; and 3) 4.665 individuals (34% women) with prior CVD 
irrespective of medication use. A ﬂowchart describing the selection of the 
healthy and reference sub-populations and exact numbers per sex is pre-
sented in Figure 5.1. 
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Figure 5.1 Study flowchart describing the selection and categorization of individuals from the 
total carotid stiffness (CS) to the reference and healthy sub-populations.  
aBP-, lipid-, and/or glucose-lowering medication. bRisk factors considered were hypertension 
(systolic blood pressure/diastolic blood pressure ≥140/90 mmHg), current smoking, diabetes 
[self-reported diabetes and/or fasting plasma glucose ≥7.0 mmol/L and/or post-load plasma 
glucose ≥11.0 mmol/L (if available)], total cholesterol >6.2 mmol/L, HDL cholesterol <1.17 
mmol/L (for men) and <1.30 mmol/L (for women), and body mass index ≥30 kg/m2. 
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Table 5.1 Contributing centres (in order of decreasing number of participating individuals) and respective carotid artery measurement techniques used. 
Total  
n 
Healthy sub- 
population n 
Centre Study name/ 
acronym 
Echotracking  
system 
Anatomical  
location* 
(Local) PP measure-
ment 
MAP calculation for 
local PP  
4,892 -  Rotterdam (NL) Rotterdam Study WTS 1 cm Brachial PP - 
4,772 1,059 810 
201 
48 
Paris-HEGP (F) PPS3 (n=3,762) 
HEGP studies (n=622) 
CASHMERE (n=388) 
ART.LABa 
WTSb 
WTS 
1 cm 
2 cm 
2 cm 
Distension waveforms 
Carotid tonometry/ 
brachial PP (277/304) 
Carotid tonometry 
Distension waveforms 
Radial tonometry 
Radial tonometry 
3,423   14 14 
- 
Utrecht (NL)  SMART (n=3,296) 
Whistler Cardio (n=127) 
WTS 
ART.LAB 
2 cm 
1 cm 
Brachial PP 
Brachial PP 
- 
- 
2,027 742  Ghent (BE) ASKLEPIOS Echopac 1-2 cm Carotid tonometry Brachial tonometry 
1,597 279 45 
192 
42 
Maastricht/  
Amsterdam (NL) 
Hoorn study (n=717) 
AGAHLS (n=406) 
CODAM 1 (n=474) 
WTS 
WTS 
WTS 
1 cm 
1 cm 
1-2 cm 
Distension waveforms 
Distension waveforms 
Brachial PP 
Distension waveforms 
Distension waveforms 
- 
1,367 338  Leuven (BE) FLEMENGHO WTS 2 cm Carotid tonometry Maximal oscillometry 
854 398  Shanghai (CN) Ningbo Working place ART.LAB 0-1 cm Radial tonometryf Constant 
664 158            
 
37 
121 
Pisa (I) CATOD (n=369) 
Other (n=295)  
Carotid  
Studioe 
1 cm Carotid tonometry 
/Radial tonometry 
(241/54) 
Brachial tonometry 
Brachial tonometry/ 
Constant (241/54) 
570 74  Mannheim (D) MIPH Industrial Cohort Study ART.LAB 1 cm Brachial PP - 
472 83  Vilnius (LT) LitHir ART.LAB 1 cm Carotid tonometry/ 
brachial PP (249/223) 
Radial tonometry 
359 11  Antwerp (BE)  WTS 2 cm Brachial PP - 
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307 65  São Paulo (BR) CHEST-BR, GeneHy WTS 1 cm Brachial PP - 
300 32  Nancy (F) ARTEOS study WTS 2 cm Brachial PP - 
248 71  Bern (CH)  ART.LAB 1 cm Carotid tonometry Brachial tonometry 
223 29  Milano/Monza (I)  ART.LAB 2 cm Radial tonometry Constant 
222 43  Maastricht-VitaK (NL)  ART.LAB 2 cm Brachial PP - 
176 127  Budapest (H)  ART.LAB 1 cm Carotid tonometry Radial tonometry 
136 36  Rouen (F)  ART.LAB 1 cm Carotid tonometry Radial tonometry 
121 2  Paris-Foch (F)  ART.LAB 1 cm Carotid tonometry Maximal oscillometry 
85 -  Gdansk (PL) CareNorth ART.LAB 1 cm Carotid tonometry Constant (0.33) 
43 -  Pilsen (CZ) SAS study ART.LAB 1 cm Brachial PP - 
32 -  Québec (CDN)  ART.LAB 1 cm Carotid tonometry Radial tonometry 
21 -  Montreal (CDN)  ART.LAB 1 cm Carotid tonometry Brachial tonometry 
*Anatomical location of the measurement is expressed as distance (in cm) proximal to the carotid bifurcation; aART.LAB echotracking system (ESAOTE, Maastricht, 
the Netherlands); bWall Track System [WTS (former version of ART.LAB), ESAOTE, Maastricht, the Netherlands]; cVivid-7 US system (GE Vingmed Ultrasound, Horten, 
Norway) with Echopac post-processing; dAloka SSD-650 US system (Aloka, Tokyo, Japan) with post-processing in dedicated software (M’ATHS, Metris, France); eCarot-
id Studio (Institute of Clinical Physiology, National Research Council, Pisa, Italy); fRadial tonometry plus transfer function (Sphygmocor, Atcor Medical, Australia).
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 Estimation of carotid artery stiffness: preliminary 5.3.2
methodological considerations  
Level of carotid artery stiffness was expressed by the distensibility coeffi-
cient (DCcar), calculated as described earlier (section 1.3.2.1).  
Estimates of local carotid PP were only available in a subsample of 50% 
(n=11,458) of the total study population. Among them, the correlation be-
tween brachial and estimated local PP was strong both in men (r=0.73, 
p<0.001) and women (r=0.80, p<0.001), though strongest for those in the 
oldest tertile (youngest: r=0.57, middle: r=0.79, oldest: r=0.82). This indi-
cates that the rank between individuals within the study population will not 
change much when DCcar will be estimated using one or the other PP. There-
fore, we chose to use DCcar as estimated with brachial PP to preserve the 
largest population sample, though we acknowledge that such values would 
expectedly be slightly higher than when using local PP in the calculation due 
to the amplification in PP between central and peripheral arterial sites. Nev-
ertheless, and for completeness, we have also estimated the reference in-
tervals for DCcar calculated with local carotid PP, though these data were 
confined to 3,123 individuals out of the 3,601 individuals meeting the crite-
ria for a healthy sub-population, i.e., free from CV-RFs, prior CVD and not on 
medication.  
5.3.2.1 Measurement of diameter and distension  
Only external (diastolic) carotid diameter and distension data obtained by 
means of echotracking was included (either pure echotracking or related 
techniques).  
Different types of ultrasound systems were used across centres:  
77 
 
(1) the ART.LAB system (n=6,841; advanced version of WTS; ESAO-
TE, Maastricht, The Netherlands); 
(2) the Wall Track System (n=13,176; WTS, ESAOTE, Maastricht, 
The Netherlands
158
); 
(3) the Vivid-7 US system, with Echopac post-processing, which 
has been validated against the WTS.
159
 (n=2,027; GE Vingmed 
Ultrasound, Horten, Norway) 
(4) Carotid Studio (n=664; Institute of Clinical Physiology, National 
Research Council, Pisa, Italy).
20
  
The exact anatomical location of the measurement of carotid artery diame-
ter and distension differed across centres:  
(1) 0-1 cm proximal to the carotid artery bifurcation (n=854); 
(2) 1 cm proximal to the carotid artery bifurcation (n=12,528); 
(3) at 1-2 cm proximal to the carotid artery bifurcation (n=2,601)  
(4) at 2 cm proximal to the carotid artery bifurcation (n=6,725)  
Therefore, prior to the calculation of DC, all carotid diameter and distension 
values obtained with different echotracking systems and anatomical loca-
tion were standardized. To this aim, original carotid diameter and distension 
values were rescaled to the same metric of the most recent system and the 
mostly used anatomical location, i.e. measurements with the ART.LAB sys-
tem and centred at 1 cm proximal to the carotid bifurcation (Table 5.2). 
5.3.2.2 Measurement of local pulse pressure  
Different methods to determine local carotid PP were used. First, carotid 
distension waveforms were obtained and rescaled using brachial distension 
waveforms (n=4,807). Second, carotid tonometry was performed and the 
obtained pressures were rescaled with brachial MAP calculated using bra-
chial tonometry (n=2,940), radial tonometry (n=1,247), maximal oscillometry 
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(n=1,384) or the equation MAP=DBP+1/3*PP (n=71). Third, radial tonometry 
was performed to obtain carotid pressures using a transfer function 
(Sphygmocor, Atcor Medical, Australia; n=1,009) (Table 5.3). Similar to the 
calibration analyses for diameter and distension, multiple linear regression 
analyses with included dummy variables for each method (with carotid dis-
tension waveforms + brachial distension waveforms as reference) was used 
to obtain  ‘calibration factors’ to rescale individual carotid PP values to the 
reference technique (Table 5.3). We used these rescaled carotid PP values in 
all further analyses. 
 Statistical analyses 5.3.3
Statistical analyses were performed using the Statistical Package for Social 
Sciences, version 20 (SPSS, Inc, Chicago, IL, USA) unless specified otherwise. 
5.3.3.1 Multiple imputation of missing values  
A total of 3,165 individuals (14% of the total reference population) had miss-
ing values for one (n=3,044) or more (n=121) of the co-variables of interest. 
The percentage missing values per variable varied from 0.3% (BMI) to 13% 
(total cholesterol). We used multiple imputation chained equations to im-
pute those values rather than perform complete case analyses in order to 
decrease bias and increase the power of the analyses.
160,161
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Table 5.2 Calibration factors for carotid diameter and distension values as obtained with different measurement devices and locations  
 Carotid diameter  Carotid distension 
 β 95% CI p  β 95% CI p 
Echotracking system [reference=ART.LAB* (n=6,841)] 
     Wall Track system (n=13,176) 0.220 0.191; 0.250 <0.001  0.019 0.014; 0.024 <0.001 
     Vivid-7 (n=2,027) 0.191 0.109; 0.273 <0.001  0.185 0.172; 0.198 <0.001 
     Carotid studio (n=664) -0.082 -0.149; -0.015 0.016  0.113 0.102; 0.123 <0.001 
Anatomical location [reference=centered at 1 cm** (n=12,528)] 
     0-1 cm (n=854) 0.910 0.849; 0.970 <0.001  -0.015 -0.024; -0.005 0.002 
     1-2 cm (n=2,601) -0.068 -0.139; 0.003 0.062  -0.115 -0.126; -0.103 <0.001 
     2 cm (n=6,725) -0.125 -0.155; -0.095 <0.001  0.004 -0.001; 0.009 0.105 
Regression coefficients β represent the mean difference in carotid artery diameter (in mm) or distension (in mm) when using each of the echotracking systems, 
and/or anatomical locations vs. the reference one (as indicated above) at mean levels of age, sex, MAP, total-HDL cholesterol ratio, smoking, diabetes, BMI, 
history of CVD, and use of BP- and/or lipid-lowering medication in the total reference population (n=22,812).  
*In contrast to the Wall Track system, Vivid-7 and Carotid Studio, which select a single M-line, ART.LAB takes measures over an arterial width of >10 mm, com-
prising multiple M-lines, which may yield considerably more precise measurements. 
**Anatomical location is expressed as distance (in cm) proximal to the carotid bifurcation. 
On the basis of this equation, to rescale diameter values obtained by, for instance, the Wall Track System (WTS) to values of ART.LAB, 0.220 mm needs to be 
subtracted from the original WTS values. In addition, the appendix (p203) contains reference tables calibrated to each specific device. 
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5.3.3.2 Standardization of carotid artery diameter and distension 
measurements 
We performed multiple linear regression analyses that included dummy vari-
ables for each echotracking system (with ART.LAB as reference) and anatomi-
cal location of the measurement (with measurements centred at 1 cm proxi-
mal to the carotid bifurcation as reference) as independent determinants of 
carotid diameter and distension. These analyses were conducted in the total 
population (n=22,708) and included adjustments for all CV-RFs, history of CVD 
and use of BP- and/or lipid-lowering medication. The regression coefficients 
(β) for the dummy variables hereby obtained were used as ‘calibration fac-
tors’ to rescale individual carotid diameter and distension values to the refer-
Table 5.3 Calibration factors for local carotid artery pulse pressure values as obtained with 
different methods  
  Carotid artery pulse pressure 
  β 95% CI p 
Reference method   - - - 
Carotid tonometry + brachial tonometry  0.8 0.0; 1.5 0.049 
Carotid tonometry + radial tonometry  1.9 1.2; 2.7 <0.001 
Carotid tonometry + maximal oscillometry  -0.9 -3.7; 1.8 0.505 
Carotid tonometry + constant  -5.7 -6.5; -4.9 <0.001 
Radial tonometry + transfer function  5.4 4.7; 6.0 <0.001 
Regression coefficients β represent the mean difference in local carotid pulse pressure (in mm 
Hg) when using each of the local PP measurement techniques vs. the reference one (carotid 
distension waveforms + brachial distension waveforms) at mean levels of age, sex, MAP, heart 
rate, total-HDL cholesterol ratio, BMI, history of CVD, and use of BP- and/or lipid-lowering 
medication only in individuals in whom a measure of local carotid PP was performed 
(n=11,558). 
On the basis of this equation, to rescale local carotid PP values obtained by for instance radial 
tonometry + transfer function to values of carotid distension waveforms + brachial distension 
waveforms (i.e. to the values presented in Table 5.10), to the original radial tonometry + trans-
fer function values 5.6 mm Hg needs to be added.  
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ence technique (for details, see Table 5.2). We used these rescaled carotid 
diameter and distension values in all further analyses. 
5.3.3.3 Definition of age- and sex-specific reference intervals of DCcar 
Calculation of age-specific reference intervals for DCcar [and additionally for 
the individual components of the DCcar (i.e., carotid diameter, carotid disten-
sion and brachial PP)] was conducted in the healthy sub-population (n=3,601), 
and in men and women separately. To this aim we used a parametric regres-
sion method based on fractional polynomials (FPs) as described by Royston 
and Wright and implemented in STATA software (version 11.0 Stata Corp., 
College Station, TX, USA).
162–164
 Briefly, carotid DC data were assumed to be 
normally distributed, conditional on age. With the STATA command xrigls, the 
best fitting FPs for the age-specific mean and standard deviation (SD) regres-
sion curves were defined using an iterative procedure (generalised least 
squares - GLS). Results of these analyses enable estimation of the age-specific 
mean and SD of DCcar as meanDC = a + b*age
p
 + c*age
q
 + …, where a, b, c, … 
are the coefficients, and p, q, … are the powers with numbers selected from 
the set [-2, -1, -0.5, 0, 0.5, 1, 2, 3] estimated from the regression for the me-
anDC curve and, likewise, from the regression for the SDDC curve. For example, 
FPs with powers [1 2], that is, with p=1 and q=2, illustrate an equation with 
the form a + b*age + c*age
2
. Estimated mean, SD and Z-scores [i.e., (ob-
servedDC – meanDC)/SDDC] were all stored in the dataset. The Z-scores were 
used to assess the model fit, which was deemed appropriate if these were 
normally distributed with a mean of 0 and an SD of 1, and randomly scattered 
above and below 0 when plotted against age. Finally, age-specific 2.5
th
, 10
th
, 
25
th
, 50
th
, 75
th
, 90
th
, and 97.5
th
 percentile curves were calculated as meanDC + 
Zp* SD, where Zp assumed the values of -1.96, -1.28, -0.67, 0, 0.67, 1.28, and 
1.96, respectively. 
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5.3.3.4 Association with risk factors 
Based on the equations estimated as described above, we computed ex-
pected ‘normal’ mean DCcar (and additionally carotid diameter, carotid disten-
sion an brachial PP) values for each individual in the reference sub-
populations (i.e. those with and without CVD and/or medication) and calcu-
lated age- and sex-specific DCcar Z-scores as (observedDC – ex-
pectedDC)/SDexpectedDC; this allows for a standardized comparison between 
observed DC values vs. those from healthy individuals of the same age and 
sex, expressed by the number of SDs that an individual measurement lies 
above or below the healthy population median (i.e., 50
th
 percentile).  
The associations between known CV-RFs and the DCcar Z-scores were then 
investigated in the different reference sub-populations to enable interpreta-
tion of DCcar values across different risk groups. We performed (multiple) 
linear regression analyses, unadjusted (model 1), adjusted for mean arterial 
pressure (MAP; model 2) and additionally adjusted for the other CV-RFs 
(model 3) to assess to which extent the associations between the individual 
CV-RFs and DCcar Z-scores were independent of MAP and the other CV-RFs.  
The fully adjusted analyses were additionally performed for Z-scores of the 
individual components of DCcar (i.e., of carotid diameter, carotid distension 
and brachial PP). In these analyses, we estimated standardized regression 
coefficients to enable comparison of the magnitude of the associations and 
interpretation of the association between CV-RFs and DCcar Z-scores in view of 
the associations between CV-RFs and the individual components, i.e., to ena-
ble understanding of the driving forces behind the associations between CV-
RFs and DCcar Z-scores.  
In addition, we added interaction terms between sex and each of the CV-RFs 
to the models to assess potential effect modification.  
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 Table 5.4 Risk factors and clinical characteristics of the total, healthy and reference sub-populations in men. 
 
Total Refer-
ence 
population 
Healthy 
sub-
population 
Sub-population without CVD Sub-
population 
with CVD 
without 
treatmenta 
with 
treatmenta 
N 12,253 1,724 6,703 2,467 3,083 
Carotid diameter (mm) 7.6 ± 1.0 7.0 ± 0.7 7.3 ± 0.9 7.7 ± 1.0  8.0 ± 1.2 
Carotid distension (mm) 0.42 ± 0.17 0.49 ± 0.19 0.45 ± 0.17 0.40 ± 0.15 0.38 ± 0.14 
PP (mm Hg) 56 ± 14 51 ± 9 54 ± 12 59 ± 15 60 ± 15 
DCcar (10
-3 kPa-1) 16.6 ± 8.5 22.1 ± 9.8 18.9 ± 9.2 14.4 ± 6.7 13.3 ± 6.4 
Age [years (range)] 56 (15-99) 45 (15-81) 51 (15-99) 58 (16-98) 63 (23-97) 
Body mass index (kg/m2) 26.2 ± 3.7 23.9 ± 2.7 25.6 ± 3.5 27.5 ± 3.9 26.4 ± 3.4 
SBP (mm Hg) 135 ± 19 122 ± 10 131 ± 17 142 ± 19 140 ± 20 
DBP (mm Hg) 79 ± 11 73 ± 8 78 ± 11 82 ± 12 80 ± 10 
MAP (mm Hg) 102 ± 13 92 ± 8 99 ± 12 106 ± 13 104 ± 13 
Hypertension [n (%)] 6,363  (52) - 1,920 (29) 2,032 (83) 2,410 (78) 
Total cholesterol (mmol/L) 5.4 ± 1.1 5.0 ± 0.8 5.5 ± 1.1 5.4 ± 1.1 5.3 ± 1.1 
LDL cholesterol (mmol/L) 3.4 ± 1.0 3.0 ± 0.7 3.5 ± 1.0 3.4 ± 1.0 3.4 ± 1.0 
HDL cholesterol (mmol/L) 1.3 ± 0.4 1.5 ± 0.3 1.3 ± 0.4 1.2 ± 0.4 1.2 ± 0.3 
Total-to-HDL cholesterol 4.6 ± 2.1 3.3 ± 0.7 4.4 ± 1.6 4.7 ± 2.7 4.9 ± 2.3 
Triglycerides (mmol/L) 1.4 (1.0-2.0) 0.9 (0.7-1.3) 1.2 (0.9-1.8) 1.5 (1.1-2.1)       1.5 (1.1-2.1) 
Fasting glucose (mmol/L) 5.9 ± 1.7 5.1 ± 0.7 5.4 ± 1.1 6.4 ± 2.3 6.3 ± 1.9 
Diabetes [n (%)] 1,442 (12) - 253 (4) 580 (24) 609 (20) 
Current smoking [n (%)] 2,952 (24) - 1,518 (23) 509 (21) 924 (30) 
BP-lowering drugs [n (%)] 3,646 (30) - - 1,810 (74) 1,836 (60) 
Lipid-lowering drugs [n (%)] 2,221 (18) - - 988 (40) 1,233 (40) 
Glucose-lowering drugs [n (%)] 689 (6) - - 404 (16) 285 (9) 
History of CVD [n (%)] 3,083 (25) - - - 3,083 (100) 
Data are presented as means ± SD, medians [interquartile ranges] or numbers (percentages), as appropriate. aBP-, lipid- 
and/or glucose-lowering treatment.  
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Table 5.5 Risk factors and clinical characteristics of the total, healthy and reference sub-populations in women. 
 
Total Refer-
ence 
population 
Healthy 
sub-
population 
Sub-population without CVD Sub-
population 
with CVD 
without 
treatmenta 
with 
treatmenta 
N 10,455 1,877 6,203 2,670 1,582 
Carotid diameter (mm) 6.9 ± 0.9 6.4 ± 0.7 6.7 ± 0.8 7.2 ± 0.9 7.2 ± 0.9 
Carotid distension (mm) 0.37 ± 0.14 0.44 ± 0.16 0.39 ± 0.15 0.34 ± 0.13 0.35 ± 0.13 
PP (mm Hg) 56 ± 15 48 ± 9 52 ± 13 61 ± 16 64 ± 17 
DCcar (10
-3 kPa-1) 16.4 ± 9.4 23.8 ± 11.3 18.7 ± 10.1 13.0 ± 6.7 13.0 ± 6.9 
Age [years (range)] 57 (15-95) 44 (15-85) 53 (15-95) 62 (17-93) 63 (20-95) 
Body mass index (kg/m2) 25.7 ± 4.6 22.7 ± 2.7 24.6 ± 4.1 27.6 ± 4.9 26.4 ± 4.5 
SBP (mm Hg) 132 ± 21 116 ± 11 127 ± 19 141 ± 21 140 ± 21 
DBP (mm Hg) 76 ± 11 71 ± 8 74 ± 10 79 ± 12 77 ± 11 
MAP (mm Hg) 99 ± 13 89 ± 9 95 ± 12 104 ± 14 102 ± 13 
Hypertension [n (%)] 4,862 (47) - 1,467 (24) 2,306 (87) 1,089 (69) 
Total cholesterol (mmol/L) 5.8 ± 1.1 5.1 ± 0.7 5.7 ± 1.1 5.9 ± 1.2 5.8 ± 1.1 
LDL cholesterol (mmol/L) 3.6 ± 1.0 2.8 ± 0.7 3.5 ± 1.0 3.7 ± 1.1 3.6 ± 1.0 
HDL cholesterol (mmol/L) 1.6 ± 0.4 1.9 ± 0.4 1.7 ± 0.4 1.5 ± 0.4 1.5 ± 0.4 
Total-to-HDL cholesterol 3.9 ± 1.5 2.8 ± 0.6 3.6 ± 1.2 4.2 ± 1.9 4.2 ± 1.5 
Triglycerides (mmol/L) 1.2 (0.9-1.7) 0.8 (0.7-1.1) 1.1 (0.8-1.5) 1.4 (1.0-2.0)       1.4 (1.0-1.9) 
Fasting glucose (mmol/L) 5.6 ± 1.6 4.9 ± 0.6 5.2 ± 0.9 6.1 ± 2.0 6.1 ± 1.9 
Diabetes [n (%)] 976 (9) - 182 (3) 498 (19) 296 (19) 
Current smoking [n (%)] 1,861 (18) - 1,090 (18) 402 (15) 369 (23) 
BP-lowering drugs [n (%)] 2,902 (28) - - 2,118 (79) 785 (50) 
Lipid-lowering drugs [n (%)] 1,327 (13) - - 875 (33) 452 (28) 
Glucose-lowering drugs [n (%)] 412 (4) - - 285 (11) 127 (8) 
History of CVD [n (%)] 1,582 (15) - - - 1,582 (100) 
Data are presented as means ± SD, medians [interquartile ranges] or numbers (percentages), as appropriate. aBP-, lipid- 
and/or glucose-lowering treatment.  
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5.4 Results 
Table 5.4 and Table 5.5 show the participants’ characteristics of the total, 
healthy and reference sub-populations, in men and women, respectively. In 
the total reference population, women had, on average, a slightly more favor-
able cardiovascular risk profile than men. Values for CV-RFs were more unfa-
vorable for men and women from the sub-populations with treatment and/or 
with prior CVD compared to those from the population without treatment and 
CVD (p-values for trend were 0.001 for all comparisons). 
 Age- and sex-specific reference intervals for DCcar in 5.4.1
the healthy sub-population  
The best fitting FPs’ powers (p, q…) for the meanDC curves were p=-0.5 for 
men and p=-2 q=-2 for women and for the SDDC curves were p=-1 for men and 
p=-0.5 for women, indicating non-linear negative relations between age and 
DCcar in both men and women. Accordingly, the equations derived on the basis 
of the estimated coefficients were, for men:   
 MeanDC (in 10
-3
 kPa
-1
) = -12.85 + 70.85 x (age/10)
-0.5
    
 SDDC (in 10
-3 
kPa
-1
) = 2.510 + 15.43 x (age/10)
-1
   
and, for women:  
 MeanDC (in 10
-3 
kPa
-1
) = 4.958 + 1.399 x (age/10)
-2
 + 218.2 x (age/10)
-2
 x 
ln(age/10) 
 SDDC (in 10
-3 
kPa
-1
) = -3.664 + 21.55 x (age/10)
-0.5 
 
The estimated Z-scores had a mean value of 0 and an SD of 1 and, when plot-
ted against age, were randomly distributed above and below 0 (Figure 5.2), 
indicating good model fit and no residual dependency on age. 
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Figure 5.2 Scatter plot of DCcar Z-scores by age, showing the mean (horizontal line) and +/- 1.96 SD 
(dotted lines), from the fitted model for DCcar data for men (A) and women (B) 
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Sex-specific percentile lines superimposed on the raw data are shown in Fig-
ure 5.3 and the respective levels by age category are presented in Table 5.6.  
In addition, the appendix (p203) contains reference tables (Table 0.1-0.3) 
calibrated to devices other than the reference method (Art.lab) 
Table 5.6 Age- and sex-specific percentiles of DCcar (in 10
-3 kPa-1) in the healthy sub-population. 
   percentiles 
  Age (years) 2.5th 10th 25th 50th 75th 90th 97.5th 
Men (n=1,724) 20 17.2 24.2 30.3 37.2 44.2 50.3 57.3 
 30 13.1 18.3 22.9 28.1 33.2 37.9 43.1 
 40 10.1 14.4 18.3 22.6 26.9 30.7 35.1 
 50 7.9 11.7 15.1 18.8 22.6 26.0 29.8 
 60 6.1 9.6 12.6 16.1 19.5 22.6 26.0 
 70 4.7 7.9 10.7 13.9 17.1 20.0 23.2 
         
Women (n=1,877) 20 20.4 28.3 35.3 43.1 50.9 57.9 65.8 
 30 14.5 20.5 25.8 31.7 37.7 43.0 49.0 
 40 10.0 14.8 19.2 24.0 28.8 33.1 37.9 
 50 7.4 11.4 15.0 19.1 23.1 26.7 30.8 
 60 5.8 9.3 12.4 15.9 19.3 22.4 25.9 
 70 4.9 7.9 10.6 13.7 16.7 19.4 22.4 
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Figure 5.3 Age-specific percentiles of DCcar in the healthy sub-population. A, 
men; B, women. 
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 Age- and sex-specific reference intervals for carotid 5.4.2
PWV in the healthy sub-population  
To enable comparison with carotid-femoral PWV metrics, DCcar was converted 
to local carotid PWV (in m/s) through the Bramwell-Hill equation.
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The best fitting FPs’ powers (p, q, …) for the meanPWV curves were p=1 for 
both men and women and for the SDPWV curves were p=1 for men and p=2 
women. Accordingly, the equations derived on the basis of the estimated 
coefficients were, for men:   
 MeanPWV (in m/s) = 4.011 + 0.071 x age    
 SDPWV (in m/s) = 0.325 + 0.017 x age     
and, for women:  
 MeanPWV (in m/s) = 3.391 + 0.082 x age  
 SDPWV (in m/s) = 0.640 + 0.022 x (age/10)
2 
 
Sex-specific percentile lines superimposed on the raw data are shown in Fig-
ure 5.4 and the respective levels of DCcar by age category are presented in 
Table 5.7.  
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Table 5.7 Age- and sex-specific percentiles of carotid PWV (in m/s) in the healthy sub-population.  
    percentiles 
  Age (years) 2.5th 10th 25th 50th 75th 90th 97.5th 
Men (n=1,724) 20 4.1 4.6 5.0 5.4 5.9 6.3 6.7 
 30 4.5 5.1 5.6 6.1 6.7 7.2 7.8 
 40 4.8 5.5 6.2 6.8 7.5 8.1 8.8 
 50 5.2 6.0 6.7 7.5 8.3 9.1 9.9 
 60 5.6 6.5 7.3 8.3 9.2 10.0 10.9 
 70 5.9 7.0 7.9 9.0 10.0 10.9 12.0 
         
Women (n=1,877) 20 3.6 4.1 4.5 5.0 5.5 6.0 6.5 
 30 4.2 4.8 5.3 5.8 6.4 6.9 7.5 
 40 4.7 5.4 6.0 6.7 7.3 7.9 8.6 
 50 5.2 6.0 6.7 7.5 8.3 9.0 9.8 
 60 5.5 6.5 7.3 8.3 9.3 10.1 11.1 
 70 5.8 6.9 8.0 9.1 10.3 11.3 12.5 
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Figure 5.4 Age-specific percentiles of carotid PWV in the healthy sub-population. A, men; B, women. 
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 Associations of cardiovascular risk factors with DCcar 5.4.3
percentiles derived from the healthy sub-population 
In the sub-population without prior CVD and treatment, and both in men and 
women, diabetes and higher MAP, total-to-HDL-cholesterol ratio and BMI 
were significantly associated with lower DCcar Z-scores (i.e. negative deviation 
from the healthy population median), whereas smoking was associated with 
higher DCcar Z-scores (Table 5.8 and Table 5.9, Figure 5.5). Although the posi-
tive association between smoking (yes vs. no) and DCcar Z-scores was stronger 
in younger individuals, it was positive and significant in the youngest [in the 
fully adjusted model: 0.36 SD (95%CI: 0.28; 0.44)], middle [0.25 (0.17; 0.32)], 
and oldest tertiles of age [0.15 (0.08; 0.23)] (data not shown in tables).  
Similar results were found in the treated sub-population without CVD alt-
hough not significantly so for smoking (in men) and total-to-HDL-cholesterol 
ratio (both in men and women) (Table 5.8 and Table 5.9, Figure 5.6). In the 
sub-population with prior CVD, smoking was again no longer associated with 
DCcar Z-scores in men and total-to-HDL-cholesterol ratio and additionally use 
of BP- and/or glucose-lowering medication was not associated with DCcar Z-
scores in both men and women. However, after full adjustment, the use of 
lipid-lowering medication was positively associated with DCcar Z-scores (Table 
5.8 and Table 5.9, Figure 5.7). 
Comparisons by sex showed that the associations between CV-RFs and DCcar Z-
scores were similar in direction and magnitude in men and women (P-values 
for interaction were all >0.01).  
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Table 5.8 Relation between known cardiovascular risk factors and DCcar Z-scores in the reference sub-populations in men 
  Sub-population without CVD  Sub-population with CVD (n =3,083) 
  without  treatmenta  (n =6,703)  with treatmenta (n =2,467)   
Risk factor Model ß 95%CI P-value  ß 95%CI P-value  ß 95%CI P-value 
Mean arterial pressure (10 mmHg) 1 -0.250 -0.271; -0.229 <0.001  -0.285 -0.314; -0.256 <0.001  -0.362 -0.388; -0.336 <0.001 
2 - - -  - - -  - - - 
3 -0.222 -0.244; -0.200 <0.001  -0.271 -0.300; -0.241 <0.001  -0.346 -0.372; -0.320 <0.001 
Current smoking (yes) 1 0.284 0.222; 0.346 <0.001  0.135 0.033; 0.236 0.009  0.084 0.003; 0.165 0.043 
2 0.285 0.225; 0.345 <0.001  0.078 -0.018; 0.173 0.111  0.047 -0.026; 0.120 0.204 
3 0.298 0.238; 0.358 <0.001  0.089 -0.007; 0.184 0.068  0.050 -0.025; 0.124 0.190 
Diabetes (yes) 1 -0.484 -0.620; -0.347 <0.001  -0.171 -0.267; -0.074 0.001  -0.386 -0.479; -0.294 <0.001 
 2 -0.328 -0.460; -0.196 <0.001  -0.188 -0.278; -0.098 <0.001  -0.263 -0.346; -0.179 <0.001 
 3 -0.279 -0.411; -0.147 <0.001  -0.162 -0.252; -0.071 <0.001  -0.220 -0.331; -0.108 <0.001 
Total-to-HDL cholesterol ratio (unit) 1 -0.070 -0.094; -0.046 <0.001  -0.022 -0.066; 0.022 0.270  -0.026 -0.061; 0.009 0.129 
2 -0.042 -0.063; -0.021 <0.001  -0.013 -0.046; 0.019 0.358  -0.013 -0.040; 0.014 0.309 
 3 -0.037 -0.059; -0.014 0.002  -0.011 -0.042; 0.020 0.418  -0.007 -0.034; 0.020 0.587 
Body mass index (kg/m2) 1 -0.047 -0.054; -0.040 <0.001  -0.043 -0.053; -0.033 <0.001  -0.032 -0.043; -0.021 <0.001 
 2 -0.024 -0.031; -0.016 <0.001  -0.030 -0.040; -0.020 <0.001  -0.019 -0.029; -0.009 0.001 
 3 -0.018 -0.026; -0.010 <0.001  -0.027 -0.037; -0.017 <0.001  -0.014 -0.024; -0.004 0.006 
Use of BP-lowering medication (yes) 1 - - -  - - -  -0.092 -0.168; -0.017 0.017 
2 - - -  - - -  -0.045 -0.113; 0.023 0.195 
 3 - - -  - - -  -0.031 -0.102; 0.040 0.393 
Use of lipid-lowering medication (yes) 1 - - -  - - -  0.129 0.054; 0.205 0.001 
2 - - -  - - -  0.068 0.000; 0.136 0.050 
 3 - - -  - - -  0.097 0.025; 0.170 0.009 
Use of glucose-lowering medication 
(yes) 
1 - - -  - - -  -0.341 -0.470; -0.213 <0.001 
2 - - -  - - -  -0.253 -0.369; -0.138 <0.001 
 3 - - -  - - -  -0.043 -0.193; 0.108 0.579 
The regression coefficient ß represents the change in DCcar (in SD from the healthy population mean among individuals of the same age and sex) per unit increase in each 
risk factor. Model 1: unadjusted. Model 2: adjusted for MAP. Model 3: adjusted for MAP and all other risk factors. aBP-, lipid- and glucose-lowering treatment 
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Table 5.9 Relation between known cardiovascular risk factors and DCcar Z-scores in the reference sub-populations in women 
  Sub-population without CVD  Sub-population with CVD (n =1,582) 
  without  treatmenta  (n =6,203)  with treatmenta (n =2,670)   
Risk factor Model ß 95%CI P-value  ß 95%CI P-value  ß 95%CI P-value 
Mean arterial pressure (10 mmHg) 1 -0.288 -0.308; -0.268 <0.001  -0.260 -0.287; -0.232 <0.001  -0.343 -0.380; -0.307 <0.001 
2 - - -  - - -  - - - 
3 -0.258 -0.279; -0.236 <0.001  -0.247 -0.275; -0.220 <0.001  -0.312 -0.349; -0.275 <0.001 
Current smoking (yes) 1 0.282 0.214; 0.351 <0.001  0.203 0.089; 0.317 <0.001  0.218 0.094; 0.342 0.001 
2 0.238 0.174; 0.303 <0.001  0.147 0.040; 0.254 0.007  0.208 0.095; 0.320 <0.001 
3 0.244 0.178; 0.309 <0.001  0.133 0.026; 0.240 0.014  0.188 0.075; 0.302 0.001 
Diabetes (yes) 1 -0.632 -0.800; -0.464 <0.001  -0.222 -0.323; -0.122 <0.001  -0.629 -0.760; -0.497 <0.001 
 2 -0.345 -0.499; -0.191 <0.001  -0.210 -0.305; -0.116 <0.001  -0.436 -0.558; -0.313 <0.001 
 3 -0.274 -0.432; -0.116 0.001  -0.166 -0.262; -0.070 0.001  -0.352 -0.511; -0.193 <0.001 
Total-to-HDL cholesterol ratio (unit) 1 -0.102 -0.166; -0.038 0.009  -0.046 -0.070; -0.023 <0.001  -0.065 -0.106; -0.025 0.002 
2 -0.052 -0.105; 0.002 0.054  -0.031 -0.053; -0.008 0.008  -0.048 -0.085; -0.010 0.012 
 3 -0.042 -0.095; 0.011 0.103  -0.021 -0.042; 0.001 0.061  -0.028 -0.067; 0.010 0.144 
Body mass index (kg/m2) 1 -0.045 -0.051; -0.038 <0.001  -0.029 -0.037; -0.022 <0.001  -0.041 -0.053; -0.030 <0.001 
 2 -0.019 -0.025; -0.012 <0.001  -0.020 -0.028; -0.013 <0.001  -0.024 -0.034; -0.013 <0.001 
 3 -0.013 -0.020; -0.005 0.001  -0.016 -0.023; -0.008 <0.001  -0.010 -0.021; 0.001 0.084 
Use of BP-lowering medication (yes) 1 - - -  - - -  -0.290 -0.394; -0.185 <0.001 
2 - - -  - - -  -0.159 -0.256; -0.063 0.001 
 3 - - -  - - -  -0.105 -0.207; -0.002 0.045 
Use of lipid-lowering medication (yes) 1 - - -  - - -  0.015 -0.103; 0.132 0.809 
2 - - -  - - -  0.073 -0.033; 0.179 0.176 
 3 - - -  - - -  0.115 0.005; 0.225 0.041 
Use of glucose-lowering medication 
(yes) 
1 - - -  - - -  -0.576 -0.769; -0.382 <0.001 
2 - - -  - - -  -0.393 -0.570; -0.216 <0.001 
 3 - - -  - - -  -0.024 -0.247; 0.199 0.834 
The regression coefficient ß represents the change in DCcar (in SD from the healthy population mean among individuals of the same age and sex) per unit increase in each 
risk factor. Model 1: unadjusted. Model 2: adjusted for MAP. Model 3: adjusted for MAP and all other risk factors. aBP-, lipid- and glucose-lowering treatment 
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Figure 5.5 Associations between CV-RFs and DCcar (A), carotid diameter (B), carotid distension (C) 
and brachial PP (D) Z-scores: reference sub-population without CVD or treatment. Point estimates 
and 95% confidence intervals represent the increase in the Z-scores (in SD from the healthy 
population mean) per SD increase (or for presence vs. absence) in risk factor resulting from a 
multivariable regression model including all risk factors, stratified by sex (male (M) and female (F), 
respectively). BMI, body mass index; MAP, mean arterial pressure.  SDs in men and women, 
respectively, were 12 and 12 mm Hg for MAP, 1.6 and 1.5 for total-to-HDL cholesterol ratio, and 3.5 
and 4.1 kg/m2 for BMI. The SD equations in men and women, respectively, were 
2.510+15.43*(age/10)-1 and -3.664+21.55*(age/10)-0.5 for DCcar (in 10-3*kPa-1), 
0.514+0.001*(age/10)3 and 0.555+0.001*(age/10)3 for carotid diameter (in mm), 
0.118+0.221*(age/10)-2 and 0.089+0.114*(age/10)-1 for carotid distension (in mm), and 9.940-
0.035*age and 6.266+0.052*age for brachial PP (in mm Hg). 
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Figure 5.6 Associations between CV-RFs and DCcar (A), carotid diameter (B), carotid distension (C) 
and brachial PP (D) Z-scores: reference sub-population without CVD with BP-, lipid- and/or glucose-
lowering treatment. Point estimates and 95% confidence intervals represent the increase in the Z-
scores (in SD from the healthy population mean) per SD increase (or for presence vs. absence) in 
risk factor resulting from a multivariable regression model including all risk factors, stratified by sex 
(male (M) and female (F), respectively). BMI, body mass index; MAP, mean arterial pressure. SDs in 
men and women, respectively, were 13 and 14 mm Hg for MAP, 2.6 and 1.9 for total-to-HDL 
cholesterol ratio, and 3.9 and 4.9 kg/m2 for BMI. The SD equations in men and women, respectively, 
were 2.510+15.43*(age/10)-1 and -3.664+21.55*(age/10)-0.5 for DCcar (in 10
-3*kPa-1), 
0.514+0.001*(age/10)3 and 0.555+0.001*(age/10)3 for carotid diameter (in mm), 
0.118+0.221*(age/10)-2 and 0.089+0.114*(age/10)-1 for carotid distension (in mm), and 9.940-
0.035*age and 6.266+0.052*age for brachial PP (in mm Hg). 
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Figure 5.7 Associations between CV-RFs and DCcar (A), carotid diameter (B), carotid distension (C) 
and brachial PP (D) Z-scores: reference sub-population with CVD. Point estimates and 95% confi-
dence intervals represent the increase in the Z-scores (in SD from the healthy population mean) 
per SD increase (or for presence vs. absence) in risk factor resulting from a multivariable regres-
sion model including all risk factors, stratified by sex (male (M) and female (F), respectively). BMI, 
body mass index; BP, blood pressure; med, medication; MAP, mean arterial pressure. SDs in men 
and women, respectively, were 13 and 13 mm Hg for MAP, 2.3 and 1.5 for total-to-HDL cholester-
ol ratio, and 3.4 and 4.5 kg/m2 for BMI. The SD equations in men and women, respectively, were 
2.249+16.79*(age/10)-1 and -2.894+19.73*(age/10)-0.5 for DCcar in 10
-3*kPa-1), 
0.603+0.001*(age/10)3 and 0.361+1.253*(age/10)-1 for carotid diameter (in mm), 
0.117+0.291*(age/10)-2 and 0.089+0.102*(age/10)-1 for carotid distension (in mm), and 9.820-
0.033*age and 5.961+0.056*age for brachial PP (in mm Hg). 
 
 Additional analyses 5.4.4
5.4.4.1 Reference intervals for carotid artery diameter, distension, 
and brachial PP 
The equations derived from FP analyses on the individual components of 
DCcar, i.e. carotid diameter, carotid distension and brachial PP and the sex-
specific percentile lines according to age superimposed on the raw data are 
provided in Figure 5.8, Figure 5.9 and Figure 5.10 for diameter, distension 
and PP, respectively. Carotid diameter values increased and carotid disten-
sion values decreased non-linearly with age. In men, brachial PP showed a 
slight decrease with age until the age of 50 after which PP started to in-
crease. In women, brachial PP showed a decrease with age until the age of 
25, increasing thereafter in a fairly linear fashion. Of these three compo-
nents of DCcar, carotid distension seemed to be the major driver behind the 
reduction in DCcar with age. 
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Figure 5.8 Age-specific percentiles of carotid diameter in the healthy sub-population. A, men; B, women. 
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Figure 5.9 Age-specific percentiles of carotid distension in the healthy sub-population. A, men; B, women. 
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Figure 5.10 Age-specific percentiles of brachial pulse pressure in the healthy sub-population. A, men; B, 
women. 
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Age- and sex-specific reference intervals for carotid diameter in the healthy 
sub-population 
The best fitting FPs’ powers (p, q, …) for the meandiameter curves were p=-2 
q=-2 for men and p=0.5 for women and for the SDdiameter curves were p=3 for 
men and p=3 women. Accordingly, the equations derived on the basis of the 
estimated coefficients were, for men:   
 Meandiameter (in mm) = 7.661 + 0.087 x (age/10)
-2
 - 8.250 x (age/10)
-2 
x 
ln(age/10)   
 SDdiameter (in mm) = 0.514 + 0.001 x (age/10)
3
    
and, for women:  
 Meandiameter (in mm) = 4.783 + 0.780 x (age/10)
0.5
   
 SDdiameter (in mm) = 0.555 + 0.001 x (age/10)
3
  
Age- and sex-specific reference intervals for carotid distension in the healthy 
sub-population 
The best fitting FPs’ powers (p, q…) for the meandistension curves were p=0 for 
men and p=-0.5 for women and for the SDdistension curves were p=-2 for men 
and p=-1 women. Accordingly, the equations derived on the basis of the 
estimated coefficients were, for men:   
 Meandistension (mm) = 0.962 - 0.326 x ln(age/10) 
 SDdistension (in mm) = 0.118 + 0.221 x (age/10)
-2
  
and, for women:  
 Meandistension (in mm) = -0.137 + 1.163 x (age/10)
-0.5
 
 SDdistension (in mm) = 0.089 + 0.114 x (age/10)
-1  
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Age- and sex-specific reference intervals for brachial PP in the healthy sub-
population 
The best fitting FPs’ powers (p, q…) for the meanPP curves were p=3 q=3 for 
men and p=-2 q=-0.5 for women and for the SDPP curves were p=1 for men 
and p=1 women. Accordingly, the equations derived on the basis of the 
estimated coefficients were, for men:   
 MeanPP (in mm Hg) = 53.64 - 0.133*(age/10)
3
 + 0.067*(age/10)
3
 x 
ln(age/10) 
 SDPP (in mm Hg) = 9.940 - 0.035 x age     
and, for women:  
 MeanPP (in mm Hg) = 72.83 + 55.88 x (age/10)
-2
 - 59.22 x (age/10)
-0.5
 
 SDPP (in mm Hg) = 6.266 + 0.052 x age 
5.4.4.2 Associations of cardiovascular risk factors with percentiles 
of components of DCcar (i.e. diameter, distension, PP)  
The associations between CV-RFs and the individual components of the DCcar 
are shown in Figure 5.5, Figure 5.6 and Figure 5.7 for the sub-population 
without prior CVD and treatment, the treated sub-population without prior 
CVD and the sub-population with CVD, respectively. The negative associa-
tion between MAP and diabetes and the DCcar Z-scores seemed to be mainly 
driven by the strong positive association between both MAP and diabetes on 
the one hand and brachial PP and carotid diameter on the other. The nega-
tive association between BMI and the DCcar Z-scores seemed to be mainly 
driven by the positive association between BMI and carotid diameter. The 
negative association between the total-to-HDL cholesterol ratio and the 
DCcar Z-scores seemed to be mainly driven by the negative association be-
tween the total-to-HDL cholesterol ratio and carotid distension. Smoking 
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was positively associated with carotid diameter and distension and negative-
ly associated with brachial PP (although the latter not significantly so in the 
treated sub-population without CVD and the sub-population with CVD), 
resulting in the positive association between smoking and the DCcar Z-scores. 
5.4.4.3 Reference intervals for DCcar calculated with local carotid 
artery PP and the association with CV-RFs 
Prior to calculating reference intervals for DCcar using local carotid artery PP, 
we calibrated local carotid PP values obtained with different techniques 
towards values obtained using the reference method (i.e. calibration using 
carotid and brachial distension waveforms, for details see Table 5.3). 
Absolute values for the 50
th
 percentile of DCcar were higher when DCcar was 
calculated using local carotid PP than when using brachial PP. These differ-
ences were smaller with increasing age, though. In men, the associations 
between CV-RFs and DCcar Z-scores when calculated using local carotid PP 
(Table 5.11) were generally somewhat weaker than when brachial PP was 
used (Table 5.8). Furthermore, in the sub-population without treatment and 
prior CVD, the association between diabetes and the DCcar Z-score was not 
significant (and positive) when local carotid PP was used, whereas this asso-
ciation was strongly negative when brachial PP was used. In women, the 
associations between CV-RFs and DCcar Z-scores were similar when calculat-
ed using local carotid PP (Table 5.12) or using brachial PP (Table 5.9).   
Reference intervals were additionally established for DCcar calculated with 
local carotid PP. The best fitting FPs’ powers (p, q …) for the meanDC curves 
were p=-0.5 for men and p=-2 q=-2 for women and for the SDDC curves were 
p=-2 for both men and women. Accordingly, the equations derived on the 
basis of the estimated coefficients were,  
for men:   
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 MeanDC (in 10
-3 
kPa
-1
) =-17.93 + 90.78 x (age/10)
-0.5
   
 SDDC (in 10
-3 
kPa
-1
) = 5.304 + 39.85 x (age/10)
-2
     
and, for women:  
 MeanDC (in 10
-3 
kPa
-1
) = 8.707 + 117.7 x (age/10)
-2
 + 138.7 x (age/10)
-2
 x 
ln(age/10)  
 SDDC (in 10
-3 
kPa
-1
) = 3.536 + 87.51 x (age/10)
-2 
 
Sex-specific percentile lines according to age superimposed on the raw data 
are shown in Figure 5.11, the respective levels of DCcar by age category in 
Table 5.10 and the associations with CV-RFs in Table 5.11 and Table 5.12.  
Table 5.10 Age- and sex-specific percentiles of DCcar (in 10
-3 kPa-1) calculated using local PP in 
the healthy sub-population. 
   percentiles 
  Age (years) 2.5th 10th 25th 50th 75th 90th 97.5th 
Men (n=1,532) 20 16.3 26.7 36.0 46.3 56.6 65.8 76.2 
 30 15.4 22.0 27.9 34.5 41.1 46.9 53.6 
 40 12.2 17.5 22.2 27.5 32.7 37.4 42.7 
 50 9.1 13.8 18.0 22.7 27.3 31.5 36.2 
 60 6.6 10.9 14.8 19.1 23.5 27.3 31.7 
 70 4.4 8.6 12.3 16.4 20.5 24.2 28.4 
         
Women (n=1,591) 20 12.4 29.6 45.0 62.2 79.3 94.7 112.0 
 30 12.7 21.7 29.8 38.7 47.7 55.7 64.7 
 40 10.4 16.6 22.0 28.1 34.2 39.6 45.7 
 50 8.6 13.3 17.6 22.3 27.1 31.4 36.1 
 60 7.2 11.2 14.9 18.9 22.9 26.5 30.6 
 70 6.2 9.8 13.0 16.6 20.2 23.4 27.0 
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Figure 5.11 Sex-specific percentiles of DCcar calculated using local PP according to age in the healthy sub-
population. A, men; B, women. 
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Table 5.11 Relation between known cardiovascular risk factors and DCcar Z-scores calculated using local pulse pressure in the reference sub-populations in men 
  Sub-population without CVD  Sub-population with CVD (n =596) 
  without  treatmenta  (n =4,458)  with treatmenta (n =1,117)   
Risk factor Model ß 95%CI P-value  ß 95%CI P-value  ß 95%CI P-value 
Mean arterial pressure (10 mmHg) 1 -0.270 -0.298; -0.242 <0.001  -0.349 -0.401; -0.297 <0.001  -0.295 -0.356; -0.235 <0.001 
2 - - -  - - -  - - - 
3 -0.228 -0.257; -0.199 <0.001  -0.330 -0.383; -0.277 <0.001  -0.257 -0.320; -0.194 <0.001 
Current smoking (yes) 1 0.002 -0.079; 0.083 0.960  -0.027 -0.201; 0.147 0.763  -0.065 -0.286; 0.156 0.566 
2 0.001 -0.077; 0.079 0.979  -0.043 -0.205; 0.119 0.600  -0.056 -0.263; 0.150 0.592 
3 0.010 -0.069; 0.089 0.808  -0.026 -0.188; 0.137 0.755  -0.019 -0.225; 0.186 0.853 
Diabetes (yes) 1 -0.422 -0.665; -0.178 0.001  -0.197 -0.363; -0.032 0.019  -0.618 -0.834; -0.403 <0.001 
 2 -0.249 -0.484; -0.013 0.038  -0.127 -0.281; 0.028 0.108  -0.448 -0.655; -0.242 <0.001 
 3 -0.188 -0.422; 0.047 0.117  -0.102 -0.259; 0.054 0.200  -0.469 -0.735; -0.204 0.001 
Total-to-HDL cholesterol ratio (unit) 1 -0.092 -0.130; -0.053 <0.001  -0.050 -0.135; 0.035 0.197  -0.142 -0.209; -0.075 <0.001 
2 -0.059 -0.099; -0.019 0.007  -0.036 -0.098; 0.026 0.212  -0.114 -0.175; -0.053 <0.001 
 3 -0.034 -0.079; 0.010 0.113  -0.032 -0.087; 0.023 0.221  -0.102 -0.166; -0.039 0.002 
Body mass index (kg/m2) 1 -0.063 -0.073; -0.054 <0.001  -0.042 -0.058; -0.025 <0.001  -0.037 -0.060; -0.015 0.001 
 2 -0.038 -0.047; -0.028 <0.001  -0.023 -0.038; -0.007 0.004  -0.018 -0.040; 0.004 0.102 
 3 -0.033 -0.044; -0.022 <0.001  -0.019 -0.035; -0.002 0.026  -0.003 -0.026; 0.020 0.799 
Use of BP-lowering medication (yes) 1 - - -  - - -  -0.185 -0.349; -0.021 0.027 
2 - - -  - - -  -0.055 -0.211; 0.101 0.489 
 3 - - -  - - -  -0.005 -0.169; 0.159 0.953 
Use of lipid-lowering medication (yes) 1 - - -  - - -  0.062 -0.118; 0.243 0.498 
2 - - -  - - -  0.003 -0.164; 0.171 0.969 
 3 - - -  - - -  0.039 -0.139; 0.216 0.670 
Use of glucose-lowering medication (yes) 1 - - -  - - -  -0.394 -0.719; -0.070 0.017 
2 - - -  - - -  -0.310 -0.614; -0.007 0.045 
 3 - - -  - - -  0.102 -0.279; 0.482 0.600 
The regression coefficient ß represents the change in DCcar (in SD from the healthy population mean among individuals of the same age and sex) per unit increase in each risk factor. Model 1: unadjusted. Model 2: adjusted 
for MAP. Model 3: adjusted for MAP and all other risk factors. aBP-, lipid- and glucose-lowering treatment 
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Table 5.12 Relation between known cardiovascular risk factors and DCcar Z-scores calculated using local pulse pressure in the reference sub-populations in women 
  Sub-population without CVD  Sub-population with CVD (n =630) 
  without  treatmenta  (n =3,716)  with treatmenta (n =941)   
Risk factor Model ß 95%CI P-value  ß 95%CI P-value  ß 95%CI P-value 
Mean arterial pressure (10 mmHg) 1 -0.290 -0.319; -0.261 <0.001  -0.358 -0.413; -0.302 <0.001  -0.438 -0.509; -0.366 <0.001 
2 - - -  - - -  - - - 
3 -0.271 -0.302; -0.240 <0.001  -0.337 -0.394; -0.281 <0.001  -0.356 -0.431; -0.281 <0.001 
Current smoking (yes) 1 0.106 0.010; 0.203 0.031  0.219 -0.007; 0.444 0.058  0.523 0.217; 0.828 0.001 
2 0.066 -0.026; 0.158 0.159  0.080 -0.130; 0.291 0.453  0.429 0.152; 0.707 0.002 
3 0.069 -0.024; 0.161 0.145  0.070 -0.140; 0.280 0.513  0.376 0.103; 0.650 0.007 
Diabetes (yes) 1 -0.420 -0.932; 0.092 0.102  -0.266 -0.468; -0.063 0.010  -1.037 -1.319; -0.756 <0.001 
 2 -0.137 -0.571; 0.298 0.525  -0.195 -0.383; -0.007 0.042  -0.678 -0.946; -0.410 <0.001 
 3 -0.061 -0.498; 0.377 0.778  -0.146 -0.337; 0.045 0.135  -0.682 -1.006; -0.358 <0.001 
Total-to-HDL cholesterol ratio (unit) 1 -0.092 -0.134; -0.050 <0.001  -0.083 -0.146; -0.020 0.010  -0.035 -0.123; 0.052 0.431 
2 -0.043 -0.085; -0.001 0.045  -0.036 -0.095; 0.023 0.227  -0.010 -0.090; 0.069 0.797 
 3 -0.032 -0.077; 0.013 0.157  -0.008 -0.072; 0.055 0.793  0.051 -0.032; 0.135 0.226 
Body mass index (kg/m2) 1 -0.042 -0.051; -0.033 <0.001  -0.039 -0.053; -0.024 <0.001  -0.076 -0.099; -0.052 <0.001 
 2 -0.016 -0.025; -0.006 0.001  -0.023 -0.037; -0.009 0.002  -0.040 -0.063; -0.018 <0.001 
 3 -0.013 -0.023; -0.002 0.015  -0.020 -0.035; -0.004 0.012  -0.031 -0.055; -0.007 0.012 
Use of BP-lowering medication (yes) 1 - - -  - - -  -0.565 -0.778; -0.351 <0.001 
2 - - -  - - -  -0.301 -0.502; -0.100 0.003 
 3 - - -  - - -  -0.132 -0.346; 0.082 0.226 
Use of lipid-lowering medication (yes) 1 - - -  - - -  -0.180 -0.464; 0.105 0.215 
2 - - -  - - -  -0.033 -0.292; 0.226 0.802 
 3 - - -  - - -  0.031 -0.232; 0.294 0.816 
Use of glucose-lowering medication (yes) 1 - - -  - - -  -0.617 -1.129; -0.105 0.018 
2 - - -  - - -  -0.293 -0.761; 0.174 0.219 
 3 - - -  - - -  0.427 -0.105; 0.960 0.116 
The regression coefficient ß represents the change in DCcar (in SD from the healthy population mean among individuals of the same age and sex) per unit increase in each risk factor. Model 1: unadjusted. Model 2: adjusted for 
MAP. Model 3: adjusted for MAP and all other risk factors. aBP-, lipid- and glucose-lowering treatment 
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5.5 Discussion 
In the present study we estimated age- and sex-specific percentiles of DCcar 
in healthy individuals aged 15-85 years, based on a large population ob-
tained by combining data at the individual level from 24 research centres 
worldwide. We additionally assessed the associations between CV-RFs and 
these DCcar percentiles to enable comparison of DCcar values across (patient) 
groups with different cardiovascular risk profiles with those from a healthy 
population. 
Recently, associations between greater levels of carotid stiffness and in-
creased risk of incident stroke, but not coronary heart disease, have been 
shown in a large sample (>10,000) of middle-aged individuals free from prior 
CVD (the ARIC study)
86
 and associations between greater carotid stiffness 
and incident CV events and all-cause mortality have been shown in a popu-
lation-based study among the elderly (the Hoorn study).
87
 Importantly, 
these associations were independent of CV-RFs
86
 and carotid-femoral 
PWV.
87
 Earlier studies have also shown carotid stiffness to be associated 
with incident CVD and/or mortality among patients with chronic kidney 
disease
88,90,92
 and who had received a renal transplant,
89
 elderly individuals 
with and without prior CVD,
93
 and healthy individuals.
91
 These findings were 
not corroborated by other studies, however,
94–97
 which may be explained, at 
least in part, by differences in sample size and duration of follow-up, devices 
and techniques used to process ultrasound signals, the cardiovascular out-
comes considered, and the characteristics of the study populations (e.g., old 
vs. middle aged, diseased vs. apparently healthy). Further studies (e.g., me-
ta-analysis) will determine the predictive association between carotid stiff-
ness and incident CV events and CV mortality. Nevertheless, a major ad-
vantage of local stiffness estimation by means of echotracking is that it can 
be directly determined from changes in pressure driving the change in arte-
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rial volume without using any model from the circulation.
85
 Moreover, it 
enables characterization of the arterial structural and functional changes 
underlying the loss of the elastic properties of the arteries and thus a better 
understanding of the etiological mechanisms of arterial stiffening in re-
sponse to risk factor exposure and lifestyle and/or pharmacological inter-
ventions.
85
 In this line, many studies have now incorporated measures of 
local stiffness into their vascular characterization protocols. The reference 
intervals for DCcar as currently presented may be helpful in the interpreta-
tion of the results on carotid stiffness levels obtained in those studies.       
The reference intervals in the healthy sub-population showed a non-linear 
and negative relation between age and DCcar, which was somewhat steeper 
in women than in men. In contrast, reference values for carotid-femoral 
PWV did not differ between men and women.
106
  
In the sub-population without prior CVD and treatment, we found that dia-
betes (yes vs. no) and higher MAP, total-to-HDL cholesterol ratio and BMI 
were significant determinants of lower DCcar in men and women, an obser-
vation that is largely in line with previous studies.
165,166
 Remarkably, smoking 
(yes vs. no) was a significant determinant of higher DCcar in men and women, 
which has previously been shown in The cardiovascular risk in Young Finns 
study
167
 and in the two smaller case-control studies (although not signifi-
cantly so for all comparisons).
168,169
 A priori, a negative association between 
smoking and DCcar was hypothesized, as smoking may lead to vascular dys-
function (e.g., arterial stiffness) through inflammation, endothelial dysfunc-
tion and oxidative stress.
170,171
 Such a negative association has also been 
described previously, although only in two smaller studies on smoking and 
stiffness index and DCcar.
172,173
 However, it is possible that the chronic effects 
of current smoking were outweighed by the acute effects of withdrawal 
from smoking, which has an immediate impact on the sympathetic nervous 
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system activity.
174
 Indeed, all measurement protocols of the studies included 
here institute abstinence from smoking at the time of measurement, at least 
three hours in advance, which may have confounded the results. In addition, 
exposure to smoking was cross-sectionally assessed with a yes/no question 
including the quitters (who may be unhealthier) in the non-smokers group 
and residual confounding (e.g., by physical activity, alcohol intake) could not 
be taken into account. Therefore, ideally, the chronic effect of smoking (or 
quitting smoking) on DCcar should still be evaluated in intervention studies 
that control for these factors. 
In addition, in the sub-population with prior CVD regardless of medication, 
we found that the use of lipid-lowering medication was positively associated 
with DCcar in men and women, which seemed to be driven mainly by its 
positive association with carotid distension. We assume these lipid-lowering 
drugs to be mainly statins, but we cannot be sure as specific information 
regarding the type of drugs is lacking for most included studies. The current 
findings may reflect the beneficial effects of statin treatment on carotid 
stiffness that have previously been shown in intervention studies on fluvas-
tatin
175
 and atorvastatin.
176–178
  
We calculated DCcar values both using brachial and local carotid PP. We 
found that absolute percentile values were lower when DCcar was calculated 
using brachial PP (Table 5.6) than when using local carotid PP (Table 5.10). 
This may be explained by the principle of PP amplification due to wave re-
flection at bifurcations resulting in higher PP in peripheral than central arter-
ies.
179
 PP amplification decreases with increasing age, showing a plateau 
from the age of 40 (women) or 50 (men) years onwards in healthy individu-
als.
180
 This is also in line with the current findings of decreasing differences 
between DCcar calculated using brachial vs. local carotid PP with increasing 
age, similarly showing plateaus (in these differences) from the age of 50 
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onwards. In men, associations between CV-RFs and DCcar were weaker when 
local carotid PP was used than when brachial PP was used, which may be 
due to more difficult and/or less precise measurements in the former com-
pared to the latter method. Also, with the use of local carotid PP for the 
calculation of DCcar an additional calibration step was needed to align differ-
ent techniques to determine local carotid PP, possibly introducing additional 
error. However, in women, associations between CV-RFs and DCcar were 
similar when either local carotid or brachial PP was used. The difference 
(found in men) may thus be explained differently. 
 Limitations 5.5.1
This study has some limitations. First, given the cross-sectional design, the 
‘increases’ of carotid stiffness with age need to be interpreted with caution, 
because these may misestimate the longitudinal rates of change within 
individuals. Second, we standardized differences in techniques between 
studies/centres by first adjusting carotid diameter and distension (and local 
carotid PP) for all potential physiological/pathological factors supposed to 
influence these variables, assuming that the residual differences were of 
methodological origin. However, this calibration may still have been sub-
optimal because hidden confounders might have been missed.  
 Conclusion 5.5.2
In conclusion, we estimated age- and sex-specific percentiles of DCcar in a 
healthy population and assessed the association between CV-RFs and DCcar 
Z-scores, which enables comparison of DCcar values for (patient) groups with 
different cardiovascular risk profiles, helping interpretation of such 
measures obtained both in research and clinical settings. 
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Chapter 6 Reference values for 
femoral artery stiffness. 
Bossuyt J, Engelen L, Ferreira I, Stehouwer CDA, Boutouyrie P, Laurent S, 
Segers P, Reesink K, Van Bortel LM  
Reference values for local arterial stiffness. Part B: Femoral artery. (in prepa-
ration) 
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6.1 Abstract 
Aims: Carotid-femoral pulse wave velocity (PWV) is considered the gold 
standard measure of arterial stiffness, representing mainly aortic stiffness. 
As compared to the elastic carotid and aorta, the more muscular femoral 
artery may be differently associated with cardiovascular risk factors (CV-
RFs), or, as shown in a recent study, provide additional predictive infor-
mation beyond carotid-femoral PWV. Still, clinical application is hampered 
by the absence of reference values. Therefore, our aim was (1) to establish 
age- and sex-specific reference values for femoral stiffness in healthy sub-
jects and (2) to investigate the associations with CV-RFs.  
Methods and results: femoral distensibility coefficient (DC), the inverse of 
stiffness, was calculated as the ratio of relative diastolic-systolic distension 
(obtained from ultrasound echo-tracking) and pulse pressure among 5,069 
individuals (49.5% men, age range: 15-87 year). Individuals without cardio-
vascular disease (CVD), CV-RFs and medication use (n=1,489; 43% men) 
constituted a healthy sub-population used to establish sex-specific equations 
for percentiles of femoral DC across age. In the total population, femoral DC 
Z-scores were independently associated with body mass index (BMI), mean 
arterial pressure (MAP), and total-to-HDL cholesterol ratio. Standardized βs, 
in men and women respectively, were -0.18 (95% CI: -0.23;-0.13) and -0.19 (-
0.23; -0.14) for BMI; -0.13 (-0.18; -0.08) and -0.05 (-0.10; -0.01) for MAP; and 
-0.07 (-0.11; -0.02) and -0.16 (-0.20; -0.11) for total-to-HDL cholesterol ratio.  
Conclusion: In young and middle-aged men and women, normal femoral 
stiffness does not change substantially with age up to the 6
th
 decade. CV-RFs 
related to metabolic disease are associated with femoral stiffness. 
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6.2 Introduction 
As described in Chapter 1, femoral artery stiffness (or its inverse, the femo-
ral artery distensibility coefficient, DCfem) carries added predictive value for 
all-cause and cardiovascular mortality,
87
 and can be specifically altered in 
certain sub-populations.
98,99
 In addition, some drugs have been shown to 
operate exclusively on muscular arteries, providing a window for monitoring 
pharmacological interventions.
181
  
However, the interpretation of DCfem values measured across different age, 
sex and risk groups is hampered by the absence of reference values. In view 
of these considerations, we aimed 1) to establish age- and sex-specific nor-
mal values using percentiles of local DCfem obtained in individuals without 
prior CVD, treatment and established cardiovascular risk factors (CV-RFs) 
and 2) to investigate associations between known CV-RFs and these DCfem 
percentiles in individuals with or without CV-RFs, treatment and prior CVD. 
6.3 Methods 
Methods used for data collection, stratification of the population, standardi-
zation of methodology and statistical analyses were similar to those used in 
Chapter 5, analysing carotid artery stiffness. For a more detailed description, 
we therefore refer to Chapter 5.  Differences are outlined below.  
 Study population  6.3.1
Of the 31 cohorts included in Chapter 5, only 7 contained data on the femo-
ral artery as well. One cohort [Psicofirb, Monza (ITA)] was unique to Chapter 
6 (Table 6.1). A total of 5,069 individuals constituted the femoral artery 
reference values database, including data on femoral diameter and disten-
sion obtained using echotracking systems, blood pressure (BP), age (range 
15-87 years), sex (2,510 men/2,559 women), CVD status, and important 
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cardiovascular risk factors (CV-RFs). The healthy sub-population, meeting 
the same criteria as outlined in Chapter 5, consisted of 1,489 (43% men) 
individuals. A ﬂowchart describing the selection of the healthy and refer-
ence sub-populations and exact numbers per sex is presented in Figure 6.1 
 
Figure 6.1 Study flowchart describing the selection and categorization of individuals from the 
total femoral stiffness (FS) to the reference and healthy sub-populations.  
aBP-, lipid-, and/or glucose-lowering medication. bRisk factors considered were hypertension 
(systolic blood pressure/diastolic blood pressure ≥140/90 mmHg), current smoking, diabetes 
[self-reported diabetes and/or fasting plasma glucose ≥7.0 mmol/L and/or post-load plasma 
glucose ≥11.0 mmol/L (if available)], total cholesterol >6.2 mmol/L, HDL cholesterol <1.17 
mmol/L (for men) and <1.30 mmol/L (for women), and body mass index ≥30 kg/m2.  
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Table 6.1 Contributing centres (in order of decreasing number of participating individuals) and respective femoral artery measurement techniques used. 
Total 
n 
Healthy sub- 
Population n 
Centre Study name/ acronym Included in  
Chapter 5 
Echotracking  
system 
Anatomical  
location* 
(Local) PP meas-
urement 
MAP calculation  
for local PP 
2,026 684  Ghent (BE) Asklepios Yes Echopacc 1-2 cm Tonometry Tonometry 
1,486  274  Amsterdam (NL) 
/Maastricht (NL) 
 
Hoorn study (n=664) Yes WTSa 2 cm distension curves distension curves 
  CODAM 2* (n=414) Yes Art.Labb 2 cm distension curves distension curves 
  AGAHLS** (n=408)  Yes, all WTSa 2 cm distension curves distension curves 
1,405 458  Leuven (BE) FLEMENGHO (n=1,305) Yes WTSa 1 cm Tonometry Maximal oscillometry 
    Migraine study (n=100) No WTSa 1-2 cm Tonometry Tonometry 
100 56  Maastricht (NL) Migraine No WTSa 1-2 cm Tonometry Tonometry 
52 11  Monza (ITA) Psicofirb No Art.Labb 2 cm distension curves MAP=SBP+1/3.PP 
*Anatomical location of the measurement is expressed as distance (in cm) proximal to the femoral artery bifurcation.  aWall Track System (WTS (former version of 
ART.LAB), ESAOTE, Maastricht, the Netherlands); bART.LAB echotracking system (ESAOTE, Maastricht, the Netherlands); cVivid-7 US system (GE Vingmed Ultrasound, 
Horten, Norway) with Echopac post-processing; 
**in contrast to Chapter 5 which included CODAM 1 data (baseline examination), data included here are that from CODAM 2 (i.e. 1st follow-up examination), when 
characteristics of the femoral artery were measured for the first time in this cohort;  ***includes independent data from individuals ever measured in this cohort, 
specifically, n=377 measured for the first time in the 2000 round (at the mean age of 36) + n=31 measured for the first time in the measured round of 2006 (at the 
mean age of 42); 
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 Estimation of femoral artery stiffness: preliminary 6.3.2
methodological considerations  
Level of femoral stiffness was expressed by the distensibility coefficient 
(DCfem), calculated as described earlier (section 1.3.2.1). 
Estimates of local PP were available in 85% of all subjects (n=4,347). Correla-
tion between brachial and femoral artery PP was strong both in men 
(r=0.82, p<0.001) and women (r=0.89, p<0.001), though strongest for those 
in the oldest tertile (youngest: r=0.75, middle: r=0.83, oldest: r=0.85). For 
the same reasons as outlined in Chapter 5, and for uniformity, brachial PP 
was used in all our main analyses. Nevertheless, and for completeness, we 
have also estimated the reference intervals for DCfem calculated with local 
femoral PP. (Table 6.10 and Figure 6.11) 
Measurement of diameter and distension  
Only external (diastolic) femoral diameter and distension data obtained by 
means of echotracking was included (either pure echotracking or related 
techniques).  
Different types of ultrasound systems were used across centres:  
(1) the ART.LAB system (n=466; advanced version of WTS; ESAOTE, 
Maastricht, The Netherlands); 
(2) the Wall Track System (n=2,577; WTS, ESAOTE, Maastricht, The 
Netherlands
158
); 
(3) the Vivid-7 US system, with Echopac post-processing, which 
has been validated against the WTS.
159
 (n=2,026; GE Vingmed 
Ultrasound, Horten, Norway) 
The exact anatomical location of the measurement of femoral artery diame-
ter and distension differed across centres:  
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(1) 1 cm proximal to the femoral artery bifurcation (n=1,305); 
(2) between 1 and 2 cm proximal to the femoral artery bifurcation 
(n=2,226); 
(3) 2 cm proximal to the femoral artery bifurcation (n=1,538)  
Therefore, prior to the calculation of DCfem, we standardized all femoral 
artery diameter and distension values obtained with different echotracking 
systems and anatomical locations (Table 6.2). To this aim, original femoral 
artery diameter and distension values were rescaled to the same metric as 
used in Chapter 5  (for uniformity reasons), i.e. with the ART.LAB system and 
centred at 1 cm proximal to the femoral bifurcation.  
Measurement of local pulse pressure  
Different techniques to estimate local pulse pressure include:  
(1) femoral artery tonometry calibrated using brachial DBP and MAP 
obtained through: 
 (1a) maximal oscillometry, or  
 (1b) the area under the curve (AUC) of brachial artery tonome-
try waveforms.  
(2) femoral artery distension calibrated using brachial DBP and MAP 
obtained through:  
 (2a) the 40%-rule, i.e. MAP = DBP + 0.4.(SBP-DBP), or  
 (2b) the area under the curve (AUC) of brachial artery disten-
sion waveforms.127  
Similar to the calibration of diameter and distension values, original femoral 
PP values were calibrated to the reference technique. (Table 6.3) 
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Table 6.2 Calibration factors for femoral diameter and distension values as obtained with different measurement devices and locations. 
 Femoral diameter  Femoral distension 
 β 95% CI p  β 95% CI p 
Echotracking system (Reference=Art.Lab*) (n=466) - - -  - - - 
Wall Track system (n=2,577) 1.666 1.531; 1.801 <0.001  0.070 0.056; 0.084 <0.001 
Vivid-7 (n=2,026) 0.599 0.457; 0.741 <0.001  0.187 0.172; 0.202 <0.001 
Anatomical location (reference= 1 cm**) (n=1,305) - - -  - - - 
1-2  cm (n=2,226) -1.795 -2.005; -1.585 <0.001  0.012 -0.009; 0.033 0.256 
2 cm (n=1,538) -0.995 -1.226; -.0.764 <0.001  0.047 0.024; 0.070 <0.001 
Regression coefficients β represent the mean difference in femoral artery diameter (in mm) or distension (in mm) when using each of the echotrack-
ing systems and/or anatomical locations vs. the reference (as indicated above) at mean levels of age, sex, MAP, total-HDL cholesterol ratio, BMI, 
smoking, diabetes, history of CVD, and use of BP- and/or lipid-lowering medication in the total reference population (n =5,069).  
* In contrast to the Wall-track system and Vivid-7, which select a single M-line, ART.LAB takes measures over an arterial width of > 10mm, comprising 
multiple M-lines, which may yield considerably more precise results. 
**Anatomical location is expressed as distance (in cm) proximal to the femoral bifurcation. 
These regression coefficients can be used to rescale diameter (by subtracting 1.666 or 0.599 mm) and distension (by subtracting 0.070 or 0.187 mm) 
values obtained by, respectively, the Wall Track System (WTS) or the Vivid-7 systems, to those as obtained by the ART.LAB system (i.e. the values 
presented in the paper). In addition, the appendix (p203) contains reference tables calibrated to each specific device. 
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 Statistical analyses 6.3.1
6.3.1.1 Multiple imputation of missing values  
A total of 124 individuals (2.4% of the total reference population) had missing 
values for one (2.2%) or more (0.2%) of the variables of interest. The percent-
age of missing values per variable varied from 0.02% (current smoking) to 2.2% 
(HDL cholesterol). We used multiple imputation chained equations to impute 
those values rather than perform complete case analyses. 
6.3.1.2 Data analyses  
Methods used to define age-and sex-specific reference intervals for DCfem and 
to examine the association with risk factors were identical to those described in 
detail in Chapter 5. 
Table 6.3 Calibration factors for local femoral pulse pressure values as obtained with different 
methods  
  Femoral artery pulse pressure 
  β 95% CI p 
Reference method   - - - 
Femoral distension +  40%-rule  -11.6 -13.9; -9.3 <0.001 
Femoral tonometry + brachial tonometry  1.1 0.4; 1.8 0.003 
Femoral tonometry + maximal oscillometry  0.8 0.0; 1.5 0.046 
Regression coefficients β represent the mean difference in local femoral pulse pressure (in mm 
Hg) when this was calculated by each of techniques listed vs. the reference one (i.e. femoral 
distension + brachial distension), at the mean levels of age, sex, MAP, heart rate, total-HDL 
cholesterol ratio, BMI, smoking, diabetes history of CVD, and use of BP- and/or lipid-lowering 
medication in the total reference population (n=5,069). On the basis of these regression coeffi-
cients femoral PP values obtained by, for instance, femoral tonometry + brachial tonometry 
can be re-scaled to values as obtained by femoral distension + brachial distension by subtract-
ing 1.1 mm Hg.  
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 Table 6.4 Risk factors and clinical characteristics of the total, healthy and reference sub-populations in men. 
 
Total Refer-
ence 
population 
Healthy 
sub-
population 
Sub-population without CVD Sub-
population 
with CVD 
without  
treatmenta 
with  
treatmenta 
n 2,510 634 1,803 391 316 
Femoral diameter (mm) 8.8 ± 1.4 8.8 ± 1.3 8.8 ± 1.3 8.9 ± 1.5 8.5 ± 1.8 
Femoral distension (mm) 0.20 ± 0.11 0.24 ± 0.11 0.23 ± 0.11 0.16 ± 0.11 0.10 ± 0.05 
PP (mm Hg) 55.0 ± 11.6 50.6 ± 7.9 53.0 ± 9.7 58.4 ± 13.0 62.4 ± 15.3 
DCfem (10
-3 kPa-1) 6.8 ± 4.3 8.4 ± 4.2 7.7 ± 4.2 5.2 ± 3.9 3.1 ± 2.3 
Age [years (range)] 50 (39-60) 42 (36-49) 45 (37-52) 56 (48-66) 67 (63-73) 
Body mass index (kg/m2) 26.1 ± 3.7 24.0 ± 2.7 25.5 ± 3.5 28.1 ± 3.6 27.4 ± 3.6 
SBP (mm Hg) 131.1 ± 16.7 120.6 ± 10.7 127.7 ± 14.8 139 ± 16.9 140.9 ± 19.3 
DBP (mm Hg) 76.1 ± 10.6 69.9 ± 8.5 74.6 ± 10.5 80.7 ± 9.7 78.5 ± 10 
MAP (mm Hg) 98.1 ± 12.1 90.1 ± 8.6 95.8 ± 11.5 104 ± 11.4 103.5 ± 12.4 
Hypertension [n (%)] 760 (30) - 391 (22) 199 (51) 170 (54) 
Total cholesterol (mmol/L) 5.4 ± 1.0 5.0 ± 0.7 5.4 ± 1.0 5.5 ± 0.9 5.3 ± 1.0 
LDL cholesterol (mmol/L) 3.4 ± 0.9 3.0 ± 0.7 3.4 ± 0.9 3.3 ± 0.9 3.3 ± 0.8 
HDL cholesterol (mmol/L) 1.4 ± 0.4 1.6 ± 0.3 1.4 ± 0.4 1.2 ± 0.3 1.2 ± 0.3 
Total-to-HDL cholesterol 4.3 ± 1.5 3.3 ± 0.7 4.1 ± 1.3 4.7 ± 1.3 4.8 ± 2.3 
Triglycerides (mmol/L) 1.7 (0.9-1.9) 1.2 (0.7-1.4) 1.6 (0.9-1.8) 2 (1.2-2.3) 1.7 (1.1-2) 
Fasting glucose (mmol/L) 5.5 ± 1.1 5.1 ± 0.5 5.3 ± 0.8 5.6 ± 1.3 6.6 ± 1.6 
Diabetes [n (%)] 304 (12) - 62 (3) 81 (21) 161 (51) 
Current smoking [n (%)] 538 (21) - 442 (25) 71 (18) 25 (8) 
BP-lowering drugs [n (%)] 492 (20) - - 296 (76) 196 (62) 
Lipid-lowering drugs [n (%)] 288 (11) - - 168 (43) 120 (38) 
Glucose-lowering drugs [n (%)] 104 (4) - - 51 (13) 53 (17) 
History of CVD [n (%)] 316 (13) - - - 316 (100) 
Data are presented as means ± SD, medians [interquartile ranges] or numbers (percentages), as appropriate. aBP-, lipid- 
and/or glucose-lowering treatment. P-values were obtained from a one-way ANOVA on the last three sub-populations. 
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Table 6.5 Risk factors and clinical characteristics of the total, healthy and reference sub-populations in women. 
 
Total Refer-
ence 
population 
Healthy 
sub-
population 
Sub-population without CVD Sub-
population 
with CVD 
without  
treatmenta 
with  
treatmenta 
n 2,559 855 1,948 384 227 
Femoral diameter (mm) 7.5 ± 1.6 7.4 ± 1.6 7.5 ± 1.6 7.4 ± 1.3 7.7 ± 1.3 
Femoral distension (mm) 0.20 ± 0.11 0.23 ± 0.11 0.22 ± 0.11 0.17 ± 0.10 0.10 ± 0.05 
PP (mm Hg) 53.7 ± 13.6 47.8 ± 8.0 50.5 ± 10.9 60.6 ± 14.7 70.0 ± 16.4 
DCfem (10
-3 kPa-1) 8.6 ± 5.6 11.0 ± 6.0 9.8 ± 5.6 6.2 ± 4.3 3.3 ± 2.2 
Age [years (range)] 48 (38-56) 41 (36-48) 44 (37-51) 57 (49-66) 68 (63-73) 
Body mass index (kg/m2) 25.2 ± 4.2 23.1 ± 2.8 24.5 ± 3.9 27.4 ± 4.4 27.4 ± 4 
SBP (mm Hg) 127.6 ± 19 118 ± 10.6 123.1 ± 15.9 138.7 ± 19.8 147.3 ± 21.9 
DBP (mm Hg) 73.9 ± 10.4 70.2 ± 8.4 72.6 ± 10 78.1 ± 11.1 77.3 ± 9.6 
MAP (mm Hg) 95.4 ± 12.8 89.3 ± 8.5 92.8 ± 11.5 102.4 ± 13.4 105.3 ± 13.5 
Hypertension [n (%)] 606 (24) - 290 (15) 176 (46) 140 (62) 
Total cholesterol (mmol/L) 5.5 ± 1.0 5.0 ± 0.7 5.4 ± 1.0 5.8 ± 1.0 5.9 ± 1.1 
LDL cholesterol (mmol/L) 3.3 ± 1.0 2.7 ± 0.7 3.1 ± 0.9 3.5 ± 0.9 3.7 ± 1.0 
HDL cholesterol (mmol/L) 1.7 ± 0.4 1.8 ± 0.4 1.7 ± 0.4 1.6 ± 0.4 1.5 ± 0.4 
Total-to-HDL cholesterol 3.5 ± 1.2 2.8 ± 0.6 3.4 ± 1.1 3.9 ± 1.2 4.1 ± 1.4 
Triglycerides (mmol/L) 1.3 (0.8-1.6) 1.0 (0.6-1.2) 1.2 (0.7-1.4) 1.6 (1-2) 1.6 (1-1.9) 
Fasting glucose (mmol/L) 5.2 ± 1 4.8 ± 0.5 5.0 ± 0.7 5.6 ± 1.3 6.5 ± 1.7 
Diabetes [n (%)] 215 (8) - 33 (2) 72 (19) 110 (48) 
Current smoking [n (%)] 463 (18) - 392 (20) 56 (15) 15 (7) 
BP-lowering drugs [n (%)] 418 (16) - - 311 (81) 107 (47) 
Lipid-lowering drugs [n (%)] 176 (7) - - 123 (32) 53 (23) 
Glucose-lowering drugs [n (%)] 58 (2) - - 37 (10) 21 (9) 
History of CVD [n (%)] 227 (9) - - - 227 (100) 
Data are presented as means ± SD, medians [interquartile ranges] or numbers (percentages), as appropriate. aBP-, lipid- 
and/or glucose-lowering treatment. P-values were obtained from a one-way ANOVA on the last three sub-populations. 
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6.4 Results 
Table 6.4 and Table 6.5 show the participants’ characteristics of the healthy and 
reference sub-populations, in men and women, respectively. In the total refer-
ence population, women had on average a more favourable CV-RF profile than 
men, which was reflected by a higher fraction of women allocated to the 
‘healthy’ subpopulation (men: 25%, women: 33%). In addition, both in men and 
women, CV-RFs were more unfavourable from the sub-populations with treat-
ment and/or with prior CVD compared to those from the population without 
treatment and CVD (p-values for trend were <0.001 for all comparisons). 
 Age- and sex-specific reference intervals for DCfem in the 6.4.1
healthy sub-population  
The best fitting fractional polynomial (FP) powers (p, q) for the mean DCfem 
curves were p=2 q=2 for men and p=3 q=3 for women and for the standard 
deviation (SD) DCfem curves were p=-1 and p=3 for men and women. According-
ly, the equations derived on the basis of the estimated coefficients were,  
for men:   
 Mean DCfem (in 10
-3
.kPa
-1
) =5.604 + 0.779 x (age/10)²-0.411 x (age/10)² x ln 
(age/10)  
 SD DCfem (in 10
-3
.kPa
-1
) = 2.829 + 3.677 x (age/10)
-1
   
and, for women:  
 Mean DCfem (in 10
-3
.kPa
-1
)= 9.44 + 0.163 x (age/10)³ - 0.092 x (age/10)³ x 
ln(age/10)  
 SD DCfem (in 10
-3
.kPa
-1
) = 5.984 - 0.005 x (age/10)³  
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The estimated Z-scores had a mean value of 0 and a SD of 1 and, when plotted 
against age, were randomly distributed above and below 0 (Figure 6.2), indicat-
ing good model fit and no residual dependency on age.  
 
 
 
Figure 6.2 Scatter plot of DCfem Z-scores by age, showing the mean (horizontal line) and +/- 1.96 SD 
(dotted lines), from the fitted model for DCfem data for men (A) and women (B) 
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Sex-specific percentile lines superimposed on the raw data are shown in Figure 
6.3 and the respective levels of DCfem by age category are presented in Table 
6.6.  
Table 6.6 Age- and sex-specific percentiles of DCfem (in 10
-3.kPa-1) in the healthy sub-population. 
   percentiles 
  Age (years) 2.5th 10th 25th 50th 75th 90th 97.5th 
Men (n=634) 20 -1.6* 1.6 4.5 7.6 10.7 13.6 16.7 
 30 0.6 3.4 5.8 8.6 11.3 13.7 16.5 
 40 1.6 4.2 6.5 9.0 11.5 13.8 16.3 
 50 1.6 4.0 6.2 8.6 11.0 13.1 15.5 
 60 0.4 2.8 4.9 7.2 9.5 11.6 13.9 
 70 -1.9* 0.3 2.4 4.6 6.9 8.9 11.2 
         
Women (n=855) 20 -1.4* 2.6 6.3 10.2 14.2 17.9 21.9 
 30 -0.4* 3.6 7.2 11.1 15.0 18.6 22.6 
 40 0.6 4.4 7.9 11.7 15.5 19.0 22.9 
 50 0.7 4.4 7.7 11.3 14.9 18.2 21.9 
 60 -0.8* 2.6 5.7 9.0 12.4 15.4 18.8 
 70 -4.8* -1.8* 0.9 3.9 6.9 9.6 12.6 
*Negative values of DCfem estimated for the 2.5
th percentile are not realistic, but are likely artefacts 
derived from a model accounting for high variability across age categories. 
In addition, the appendix (p203) contains reference tables (Table 0.4-0.5) cali-
brated to devices other than the reference method (Art.lab) 
Mean values of DCfem were slightly lower in men than in women at any age 
(p<0.001). The relationship with age was also different between sexes, with 
DCfem levels in women plateauing until the age of 50, when they exhibited a 
sudden steep drop from the age of 60 onwards, in contrast to the more gradual 
decrease in men, starting at the age of 50. However, both in ‘healthy’ men and 
women, DCfem levels were only weakly dependent on age, as illustrated by the 
fact that the most optimal equation based on FPs explained only 8.1% (women) 
to 8.6% (men) of the variation in DCfem across age.  
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Figure 6.3 Age-specific percentiles of DCfem in the healthy sub-population. A, 
men; B, women. 
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 Age sex-specific reference intervals for femoral PWV in 6.4.2
the healthy sub-population 
To enable comparison with carotid-femoral PWV metrics, DCfem was converted 
to femoral PWV (in m/s) through the Bramwell-Hill equation.
69
  
The best fitting FPs’ powers (p, q …) for the meanPWV curves were p=3 q=3 for 
both men and women and for the SDPWV curves p=3 for both men and women. 
Accordingly, the equations derived on the basis of the estimated coefficients 
were,  
for men:   
 MeanPWV (in m/s) = 12.58  – 0.100 x (age/10)³ + 0.057 x (age/10)³ x 
ln(age/10) 
 SDPWV (in m/s) = 2.48 + 0.004 x (age/10)³  
and, for women:  
 MeanPWV (in m/s) = 11.55 – 0.125 x (age/10)³ + 0.072 x (age/10)³ x 
ln(age/10) 
 SDPWV (in m/s) = 2.55 + 0.004 x (age/10)³ 
Sex-specific percentile lines superimposed on the raw data are shown in Figure 
6.4 and the respective levels of femoral PWV by age category are presented in 
Table 6.7. 
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Table 6.7 Age- and sex-specific percentiles of femoral PWV (in m/s) in the healthy sub-population. 
   percentiles 
  Age (years) 2.5th 10th 25th 50th 75th 90th 97.5th 
Men (n=634) 20  7.2   8.9   10.4   12.1   13.8   15.3   17.0  
 30  6.5   8.3   9.8   11.6   13.3   14.9   16.6  
 40  5.9   7.7   9.4   11.2   13.1   14.7   16.6  
 50  5.7   7.7   9.6   11.5   13.5   15.4   17.4  
 60  6.5   8.8   10.8   13.0   15.3   17.3   19.6  
 70  8.8   11.4   13.7   16.3   18.9   21.3   23.9  
         
Women (n=855) 20  5.9   7.6   9.2   10.9   12.7   14.3   16.0  
 30  5.1   6.9   8.5   10.3   12.1   13.7   15.5  
 40  4.4   6.3   8.1   9.9   11.8   13.5   15.4  
 50  4.4   6.5   8.4   10.4   12.5   14.3   16.4  
 60  5.7   8.0   10.1   12.4   14.7   16.8   19.1  
 70  9.0   11.7   14.1   16.7   19.4   21.8   24.4  
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Figure 6.4 Age-specific percentiles of femoral PWV in the healthy sub-population. A, men; B, wom-
en. 
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 Associations of cardiovascular risk factors with DCfem 6.4.3
percentiles derived from the healthy sub-population 
In the sub-population without prior CVD and treatment (Table 6.8 and Table 
6.9, Figure 6.5), and both in men and women, lower DCfem Z-scores (i.e. negative 
deviation from the healthy population mean) were strongly associated with 
BMI, followed by total-to-HDL cholesterol ratio and MAP. Diabetes was also 
negatively associated with DCfem Z-scores, in men only, and smoking even 
showed a positive association (in men). The seemingly favorable effect of smok-
ing was true for all 3 age tertiles, not exhibiting any age-dependency [standard-
ized betas in men, for T1: 0.11 (p=0.002); for T2:  0.05 (p=0.13); for T3: 0.10 
(p=0.06)] (data not in table). In the sub-population without prior CVD but under 
BP-, lipid- and/or glucose-lowering treatment (Table 6.8 and Table 6.9, Figure 
6.6), BMI, MAP and total-to-HDL cholesterol ratio showed a significant (nega-
tive) association in men. In the sub-population with prior CVD (Table 6.8 and 
Table 6.9, Figure 6.7), the associations with BMI and MAP were maintained (in 
men only), also showing an association with lipid-lowering medication.  
Comparisons by sex showed that in the sub-population without prior CVD and 
treatment (Figure 6.5) MAP was more negatively associated with DCfem Z-scores 
in men compared to women. Furthermore, the effects of smoking (positively 
related only in men), diabetes (negatively related only in men), and total-to-HDL 
cholesterol ratio (less negatively related in men) also differed between sexes. 
However, in the other subpopulations (Figure 6.6 and Figure 6.7), only the in-
fluence of MAP remained significantly different between men and women. 
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Table 6.8 Relation between known cardiovascular risk factors and DCfem Z-scores in the reference sub-populations in men 
  Sub-population without CVD  Sub-population with CVD (n =316) 
  without  treatmenta  (n =1,803)  with treatmenta (n =391)   
Risk factor Model ß 95%CI P-value  ß 95%CI P-value  ß 95%CI P-value 
Mean arterial pressure (10 mmHg) 1 -0.209 -0.251; -0.167 <0.001  -0.159 -0.244; -0.074 <0.001  -0.152 -0.225; -0.080 <0.001 
2 - - -  - - -  - - - 
3 -0.118 -0.163; -0.074 <0.001  -0.092 -0.176; -0.007 0.033  -0.141 -0.210; -0.072 <0.001 
Current smoking (yes) 1 0.240 0.125; 0.355 <0.001  0.043 -0.213; 0.299 0.741  -0.270 -0.609; 0.068 0.117 
2 0.220 0.108; 0.332 <0.001  0.031 -0.220; 0.283 0.807  -0.343 -0.674; -0.012 0.042 
3 0.217 0.107; 0.327 <0.001  0.000 -0.238; 0.238 0.998  -0.257 -0.574; 0.059 0.110 
Diabetes (yes) 1 -0.701 -0.972; -0.43 <0.001  -0.478 -0.717; -0.24 <0.001  -0.218 -0.400; -0.036 0.019 
 2 -0.548 -0.815; -0.282 <0.001  -0.413 -0.653; -0.174 <0.001  -0.202 -0.380; -0.025 0.026 
 3 -0.426 -0.687; -0.165 0.001  -0.108 -0.405; 0.190 0.478  -0.099 -0.291; 0.094 0.313 
Total-to-HDL cholesterol ratio (unit) 1 -0.132 -0.171; -0.094 <0.001  -0.138 -0.211; -0.065 <0.001  -0.024 -0.064; 0.017 0.246 
2 -0.092 -0.130; -0.053 <0.001  -0.137 -0.209; -0.065 <0.001  -0.023 -0.063; 0.016 0.242 
 3 -0.054 -0.094; -0.014 0.008  -0.111 -0.181; -0.041 0.002  -0.013 -0.051; 0.026 0.518 
Body mass index (kg/m2) 1 -0.081 -0.095; -0.068 <0.001  -0.062 -0.089; -0.036 <0.001  -0.075 -0.099; -0.052 <0.001 
 2 -0.065 -0.079; -0.050 <0.001  -0.055 -0.082; -0.028 <0.001  -0.070 -0.093; -0.046 <0.001 
 3 -0.056 -0.071; -0.041 <0.001  -0.036 -0.062; -0.010 0.008  -0.059 -0.083; -0.034 <0.001 
Use of BP-lowering medication (yes) 1 - - -  - - -  -0.181 -0.369; 0.007 0.059 
2 - - -  - - -  -0.160 -0.344; 0.023 0.087 
 3 - - -  - - -  0.027 -0.164; 0.217 0.782 
Use of lipid-lowering medication (yes) 1 - - -  - - -  -0.352 -0.537; -0.167 <0.001 
2 - - -  - - -  -0.373 -0.553; -0.193 <0.001 
 3 - - -  - - -  -0.323 -0.518; -0.128 0.001 
Use of glucose-lowering medication (yes) 1 - - -  - - -  -0.271 -0.514; -0.027 0.030 
2 - - -  - - -  -0.243 -0.481; -0.005 0.045 
 3 - - -  - - -  0.076 -0.187; 0.339 0.570 
The regression coefficient ß represents the change in DCfem (in SD from the healthy population mean among individuals of the same age and sex) per unit increase in each risk factor. Model 1: unadjusted. Model 2: adjusted for 
MAP. Model 3: adjusted for MAP and all other risk factors. aBP-, lipid- and glucose-lowering treatment 
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Table 6.9 Relation between known cardiovascular risk factors and DCfem Z-scores in the reference sub-populations in women 
  Sub-population without CVD  Sub-population with CVD (n =316) 
  without  treatmenta  (n =1,803)  with treatmenta (n =391)   
Risk factor Model ß 95%CI P-value  ß 95%CI P-value  ß 95%CI P-value 
Mean arterial pressure (10 mmHg) 1 -0.100 -0.137; -0.062 <0.001  -0.050 -0.116; 0.015 0.132  0.069 -0.048; 0.185 0.246 
2 - - -  - - -  - - - 
3 -0.043 -0.081; -0.005 0.026  -0.034 -0.101; 0.034 0.327  0.076 -0.044; 0.197 0.212 
Current smoking (yes) 1 -0.009 -0.116; 0.099 0.873  -0.027 -0.277; 0.222 0.830  -0.757 -1.384; -0.130 0.018 
2 -0.043 -0.150; 0.065 0.435  -0.059 -0.311; 0.193 0.647  -0.717 -1.352; -0.083 0.027 
3 -0.013 -0.118; 0.092 0.804  -0.079 -0.329; 0.171 0.534  -0.646 -1.295; 0.004 0.051 
Diabetes (yes) 1 -0.264 -0.597; 0.07 0.122  0.128 -0.097; 0.353 0.265  -0.167 -0.481; 0.148 0.298 
 2 -0.188 -0.521; 0.145 0.268  0.153 -0.074; 0.380 0.185  -0.206 -0.525; 0.113 0.205 
 3 0.022 -0.301; 0.344 0.895  0.276 0.001; 0.551 0.049  -0.081 -0.429; 0.267 0.647 
Total-to-HDL cholesterol ratio (unit) 1 -0.192 -0.23; -0.155 <0.001  -0.054 -0.126; 0.017 0.135  -0.103 -0.214; 0.009 0.071 
2 -0.187 -0.224; -0.149 <0.001  -0.054 -0.125; 0.017 0.137  -0.107 -0.219; 0.004 0.060 
 3 -0.135 -0.174; -0.096 <0.001  -0.027 -0.101; 0.047 0.475  -0.074 -0.191; 0.043 0.215 
Body mass index (kg/m2) 1 -0.063 -0.073; -0.052 <0.001  -0.027 -0.047; -0.007 0.008  -0.032 -0.071; 0.007 0.108 
 2 -0.059 -0.071; -0.048 <0.001  -0.025 -0.045; -0.005 0.015  -0.037 -0.077; 0.002 0.063 
 3 -0.046 -0.058; -0.034 <0.001  -0.020 -0.041; 0.001 0.062  -0.029 -0.071; 0.014 0.186 
Use of BP-lowering medication (yes) 1 - - -  - - -  -0.199 -0.514; 0.116 0.215 
2 - - -  - - -  -0.221 -0.537; 0.096 0.171 
 3 - - -  - - -  -0.018 -0.368; 0.332 0.920 
Use of lipid-lowering medication (yes) 1 - - -  - - -  -0.298 -0.669; 0.072 0.114 
2 - - -  - - -  -0.293 -0.664; 0.077 0.120 
 3 - - -  - - -  -0.282 -0.675; 0.110 0.158 
Use of glucose-lowering medication (yes) 1 - - -  - - -  -0.261 -0.804; 0.283 0.345 
2 - - -  - - -  -0.301 -0.847; 0.245 0.279 
 3 - - -  - - -  -0.012 -0.611; 0.588 0.970 
The regression coefficient ß represents the change in DCfem (in SD from the healthy population mean among individuals of the same age and sex) per unit increase in each risk factor. Model 1: unadjusted. Model 2: adjusted for 
MAP. Model 3: adjusted for MAP and all other risk factors. aBP-, lipid- and glucose-lowering treatment 
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Figure 6.5 Associations between CV-RFs and DCfem (A), femoral diameter (B), femoral distension 
(C) and brachial PP (D) Z-scores: reference sub-population without CVD or treatment. Point 
estimates and 95% confidence intervals represent the increase in the Z-scores (in SD from the 
healthy population mean) per SD increase (or for presence vs. absence) in risk factor resulting 
from a multivariable regression model including all risk factors, stratified by sex (male (M) and 
female (F), respectively). BMI, body mass index. ; MAP, mean arterial pressure. SD’s in men and 
women respectively: 3.5 and 3.9 kg/m² for BMI, 11.5 and 11.5 mm Hg for MAP, 1.3 and 1.1 for 
total-to-HDL cholesterol ratio. The SD equations in men and women, respectively, were 2.829 + 
3.677 x (age/10)-1 and 5.984 - 0.005 x (age/10)³  for DCfem (in 10
-3*kPa-1), 1.018 + 0.002 x 
(Age/10)3 and 3.502 - 1.492 x ln(Age/10) for femoral diameter (in mm), 0.137 - 0.001 x Age and 
0.110 - 0.001 x (Age/10)³ for femoral distension (in mm), and 7.566 + 3.309 x (Age/10)-2 and 
5.835 - 0.046 x Age for brachial PP (in mm Hg). 
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Figure 6.6 Associations between CV-RFs and DCfem (A), femoral diameter (B), femoral distension 
(C) and brachial PP (D) Z-scores: reference sub-population without CVD with BP-, lipid- and/or 
glucose-lowering treatment. Point estimates and 95% confidence intervals represent the 
increase in the Z-scores (in SD from the healthy population mean) per SD increase (or for pres-
ence vs. absence) in risk factor resulting from a multivariable regression model including all risk 
factors, stratified by sex (male (M) and female (F), respectively). BMI, body mass index; MAP, 
mean arterial pressure. SD’s in men and women respectively: 3.6 and 4.4 kg/m² for BMI, 11.4 
and 13.4 mm Hg for MAP, 1.3 and 1.2 for total-to-HDL cholesterol ratio. The SD equations in 
men and women, respectively, were 2.829 + 3.677 x (age/10)-1 and 5.984 - 0.005 x (age/10)³  for 
DCfem (in 10
-3*kPa-1), 1.018 + 0.002 x (Age/10)3 and 3.502 - 1.492 x ln(Age/10) for femoral diame-
ter (in mm), 0.137 - 0.001 x Age and 0.110 - 0.001 x (Age/10)³ for femoral distension (in mm), 
and 7.566 + 3.309 x (Age/10)-2 and 5.835 - 0.046 x Age for brachial PP (in mm Hg). 
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Figure 6.7 Associations between CV-RFs and DCfem (A), femoral diameter (B), femoral distension 
(C) and brachial PP (D) Z-scores: reference sub-population with CVD. Point estimates and 95% 
confidence intervals represent the increase in the Z-scores (in SD from the healthy population 
mean) per SD increase (or for presence vs. absence) in risk factor resulting from a multivariable 
regression model including all risk factors, stratified by sex (male (M) and female (F), respective-
ly). BMI, body mass index; BP, blood pressure; med, medication; MAP, mean arterial pressure. 
SD’s in men and women respectively: 3.6 and 3.9 kg/m² for BMI, 12.4 and 11.5 mm Hg for MAP, 
2.3 and 1.4 for total-to-HDL cholesterol ratio. The SD equations in men and women, respective-
ly, were 2.829 + 3.677 x (age/10)-1 and 5.984 - 0.005 x (age/10)³  for DCfem (in 10
-3*kPa-1), 1.018 + 
0.002 x (Age/10)3 and 3.502 - 1.492 x ln(Age/10) for femoral diameter (in mm), 0.137 - 0.001 x 
Age and 0.110 - 0.001 x (Age/10)³ for femoral distension (in mm), and 7.566 + 3.309 x (Age/10)-2 
and 5.835 - 0.046 x Age for brachial PP (in mm Hg). 
 
 Additional analyses 6.4.4
6.4.4.1 Reference intervals for femoral artery diameter, distension, 
and brachial PP 
The equations derived from FP analyses on the individual components of 
DCfem, i.e. femoral artery diameter, femoral artery distension and brachial PP 
and the sex-specific percentile lines according to age superimposed on the 
raw data are provided (Figure 6.8, Figure 6.9 and Figure 6.10 for diameter, 
distension and PP, respectively). In the healthy sub-population, the age-
related decrease in DCfem reflected a drop in distension, no change in diame-
ter, and a rise in PP. Of these three components, distension seemed to be 
the major driver behind the reduction in DCfem, while the effect of PP was 
limited. 
Age- and sex-specific reference intervals for femoral diameter in the healthy 
sub-population 
The best fitting FPs’ powers (p, q) for the meandiameter curves were p=-2 
q=0.5 for men and p=2 q=2 for women and for the SDdiameter curves were p=3 
for men and p=0 women. Accordingly, the equations derived on the basis of 
the estimated coefficients were, for men:   
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 Meandiameter (in mm) = 8.319 - 2.892 x (Age/10)
-2 
+ 0.370 x (Age/10)
0.5 
                   
 SDdiameter (in mm) = 1.018 + 0.002 x (Age/10)
3 
    
and, for women:  
 Meandiameter (in mm) = 8.79 - 0.28 x (Age/10)² + 0.14 x (Age/10)² x ln(Age/10)  
 SDdiameter (in mm) = 3.502 - 1.492 x ln(Age/10) 
Age- and sex-specific reference intervals for femoral distension in the healthy 
sub-population 
The best fitting FPs’ powers (p,q) for the meandistension curves were p=2, q=3 
for men and p=3 q=3 for women and for the SDdistension curves were p=1 for 
men and p=3 women. Accordingly, the equations derived on the basis of the 
estimated coefficients were, for men:   
 Meandistension (mm) =   0.184 + 0.012 x (Age/10)² - 0.002 x (Age/10)³  
 SDdistension (in mm) = 0.137 - 0.001 x Age    
and, for women:  
 Meandistension (in mm) = 0.197 + 0.004 x (Age/10)³ - 0.002 x (Age/10)³ x 
ln(Age/10) 
 SDdistension (in mm) = 0.110 - 0.001 x (Age/10)³  
Age- and sex-specific reference intervals for brachial PP in the healthy sub-
population 
The best fitting FPs’ powers (p) for the meanPP curves were p=1 q=2 for men 
and p=-1 q=-0.5 for women and for the SDPP curves were p=-2 for men and 
p=1 women. Accordingly, the equations derived on the basis of the estimat-
ed coefficients were, for men:   
 MeanPP (in mm Hg) = 62.626 - 7.124 x (Age/10) + 0.027 x (Age/10)²      
 SDPP (in mm Hg) = 7.566 + 3.309 x (Age/10)
-2
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and, for women:  
 MeanPP (in mm Hg) = 89.136 + 97.779 x (Age/10)
-1 
- 132.336 x (Age/10)
-0.5
 
 SDPP (in mm Hg) = 5.835 - 0.046 x Age 
 
Figure 6.8 Age-specific percentiles of femoral diameter in the healthy sub-population. A, men; 
B, women. 
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Figure 6.9 Age-specific percentiles of femoral distension in the healthy sub-population. A, men; B, women. 
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Figure 6.10 Age-specific percentiles of brachial pulse pressure in the healthy sub-population. A, men; B, women. 
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6.4.4.2 Associations of cardiovascular risk factors with percentiles 
of components of DCfem (i.e. diameter, distension, PP)  
In the sub-population without prior CVD and treatment (Figure 6.5), the 
negative association between MAP and DCfem Z-score seemed to be mainly 
driven by the strong positive association of MAP and brachial PP. The nega-
tive association of both BMI and total-to-HDL ratio with DCfem Z-score could 
be explained by a negative association with femoral artery distension, and 
the positive association of BMI with femoral artery diameter. The seemingly 
favorable effect of smoking in men (positive association with DCfem) was 
driven by a negative association between smoking and femoral artery diam-
eter while distension remained unaltered. This effect, however, is not ob-
served in subjects on medication (Figure 6.6) or with a history of CVD. (Fig-
ure 6.7) 
6.4.4.3 Reference intervals for DCfem calculated with local femoral 
artery PP and the association with CV-RFs 
Reference intervals were additionally established for DCfem calculated with 
local femoral artery PP. Accordingly, the equations derived on the basis of the 
estimated coefficients were, for men:   
 Mean DCfem (in 10
-3
.kPa
-1
) = 7.506 + 0.411 x (age/10)² - 0.246 x (age/10)² x 
ln (age/10)   
 SD DCfem (in 10
-3
.kPa
-1
) = 0.232 + 6.884 x (age/10)
-0,5
 
or, women:  
 Mean DCfem (in 10
-3
.kPa
-1
) = 9.325 + 0.119 x (age/10)
³
 - 0.070 x (age/10)³ x 
ln(age/10)  
 SD DCfem (in 10
-3
.kPa
-1
) = 3.931 + 5.114 x (age/10)
-1  
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Sex-specific percentile lines according to age superimposed on the raw data 
(Figure 6.11), the respective levels of DCfem by age category (Table 6.10) and 
the associations with CV-RFs (Table 6.11 and Table 6.12).  
Since local femoral artery PP was on average higher than brachial PP (P50 
men: 56.4 mmHg vs. 54 mmHg; P50 women: 54.5 mmHg vs. 52 mmHg), 
calculating DCfem using local femoral artery PP resulted in slightly lower abso-
lute values of DCfem (P50 men: 5.7 vs. 6.1 10
-3
.kPa
-1
; P50 women: 6.7 vs. 7.6 
10
-3
.kPa
-1
).  
 
Table 6.10 Age- and sex-specific percentiles of DCfem (in 10
-3.kPa-1) calculated using local PP in 
the healthy sub-population. 
   Percentiles 
  Age (years) 2.5th 10th 25th 50th 75th 90th 97.5th 
Men (n=588) 20 -1.5* 2.0 5.1 8.5 11.9 15.0 18.5 
 30 0.5 3.4 6.0 8.8 11.6 14.2 17.0 
 40 1.4 3.9 6.1 8.6 11.1 13.3 15.8 
 50 1.3 3.6 5.6 7.8 10.0 12.1 14.3 
 60 0.4 2.4 4.3 6.3 8.4 10.2 12.3 
 70 -1.5* 0.4 2.1 4.0 5.9 7.7 9.6 
Women (n=721) 20 -2.8* 1.6 5.5 9.9 14.2 18.2 22.6 
 30 -0.6* 3.3 6.7 10.5 14.2 17.7 21.5 
 40 0.5 4.1 7.2 10.7 14.2 17.4 20.9 
 50 0.4 3.8 6.8 10.1 13.4 16.4 19.8 
 60 -1.5* 1.8 4.7 7.9 11.1 14.0 17.3 
 70 -5.8* -2.6* 0.2 3.3 6.5 9.3 12.5 
*Negative values of DCfem estimated for the 2.5
th percentile are not realistic, but are likely 
artefacts resulting from a model accounting for high variability across age categories. 
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Figure 6.11 Sex-specific percentiles of DCfem calculated using local PP according to age in the 
healthy sub-population. A, men; B, women. 
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Table 6.11 Relation between known cardiovascular risk factors and DCfem Z-scores in the reference sub-populations in men 
  Sub-population without CVD  Sub-population with CVD (n =316) 
  without  treatmenta  (n =1,803)  with treatmenta (n =391)   
Risk factor Model ß 95%CI P-value  ß 95%CI P-value  ß 95%CI P-value 
Mean arterial pressure (10 mmHg) 1 -0.209 -0.251; -0.167 <0.001  -0.159 -0.244; -0.074 <0.001  -0.152 -0.225; -0.080 <0.001 
2 - - -  - - -  - - - 
3 -0.118 -0.163; -0.074 <0.001  -0.092 -0.176; -0.007 0.033  -0.141 -0.210; -0.072 <0.001 
Current smoking (yes) 1 0.240 0.125; 0.355 <0.001  0.043 -0.213; 0.299 0.741  -0.270 -0.609; 0.068 0.117 
2 0.220 0.108; 0.332 <0.001  0.031 -0.220; 0.283 0.807  -0.343 -0.674; -0.012 0.042 
3 0.217 0.107; 0.327 <0.001  0.000 -0.238; 0.238 0.998  -0.257 -0.574; 0.059 0.110 
Diabetes (yes) 1 -0.701 -0.972; -0.43 <0.001  -0.478 -0.717; -0.24 <0.001  -0.218 -0.400; -0.036 0.019 
 2 -0.548 -0.815; -0.282 <0.001  -0.413 -0.653; -0.174 <0.001  -0.202 -0.380; -0.025 0.026 
 3 -0.426 -0.687; -0.165 0.001  -0.108 -0.405; 0.190 0.478  -0.099 -0.291; 0.094 0.313 
Total-to-HDL cholesterol ratio (unit) 1 -0.132 -0.171; -0.094 <0.001  -0.138 -0.211; -0.065 <0.001  -0.024 -0.064; 0.017 0.246 
2 -0.092 -0.130; -0.053 <0.001  -0.137 -0.209; -0.065 <0.001  -0.023 -0.063; 0.016 0.242 
 3 -0.054 -0.094; -0.014 0.008  -0.111 -0.181; -0.041 0.002  -0.013 -0.051; 0.026 0.518 
Body mass index (kg/m2) 1 -0.081 -0.095; -0.068 <0.001  -0.062 -0.089; -0.036 <0.001  -0.075 -0.099; -0.052 <0.001 
 2 -0.065 -0.079; -0.050 <0.001  -0.055 -0.082; -0.028 <0.001  -0.070 -0.093; -0.046 <0.001 
 3 -0.056 -0.071; -0.041 <0.001  -0.036 -0.062; -0.010 0.008  -0.059 -0.083; -0.034 <0.001 
Use of BP-lowering medication (yes) 1 - - -  - - -  -0.181 -0.369; 0.007 0.059 
2 - - -  - - -  -0.160 -0.344; 0.023 0.087 
 3 - - -  - - -  0.027 -0.164; 0.217 0.782 
Use of lipid-lowering medication (yes) 1 - - -  - - -  -0.352 -0.537; -0.167 <0.001 
2 - - -  - - -  -0.373 -0.553; -0.193 <0.001 
 3 - - -  - - -  -0.323 -0.518; -0.128 0.001 
Use of glucose-lowering medication (yes) 1 - - -  - - -  -0.271 -0.514; -0.027 0.030 
2 - - -  - - -  -0.243 -0.481; -0.005 0.045 
 3 - - -  - - -  0.076 -0.187; 0.339 0.570 
The regression coefficient ß represents the change in DCfem (in SD from the healthy population mean among individuals of the same age and sex) per unit increase in each risk factor. Model 1: unadjusted. Model 2: adjusted 
for MAP. Model 3: adjusted for MAP and all other risk factors. aBP-, lipid- and glucose-lowering treatment 
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Table 6.12 Relation between known cardiovascular risk factors and DCfem Z-scores in the reference sub-populations in women 
  Sub-population without CVD  Sub-population with CVD (n =316) 
  without  treatmenta  (n =1,803)  with treatmenta (n =391)   
Risk factor Model ß 95%CI P-value  ß 95%CI P-value  ß 95%CI P-value 
Mean arterial pressure (10 mmHg) 1 -0.100 -0.137; -0.062 <0.001  -0.050 -0.116; 0.015 0.132  0.069 -0.048; 0.185 0.246 
2 - - -  - - -  - - - 
3 -0.043 -0.081; -0.005 0.026  -0.034 -0.101; 0.034 0.327  0.076 -0.044; 0.197 0.212 
Current smoking (yes) 1 -0.009 -0.116; 0.099 0.873  -0.027 -0.277; 0.222 0.830  -0.757 -1.384; -0.130 0.018 
2 -0.043 -0.150; 0.065 0.435  -0.059 -0.311; 0.193 0.647  -0.717 -1.352; -0.083 0.027 
3 -0.013 -0.118; 0.092 0.804  -0.079 -0.329; 0.171 0.534  -0.646 -1.295; 0.004 0.051 
Diabetes (yes) 1 -0.264 -0.597; 0.07 0.122  0.128 -0.097; 0.353 0.265  -0.167 -0.481; 0.148 0.298 
 2 -0.188 -0.521; 0.145 0.268  0.153 -0.074; 0.380 0.185  -0.206 -0.525; 0.113 0.205 
 3 0.022 -0.301; 0.344 0.895  0.276 0.001; 0.551 0.049  -0.081 -0.429; 0.267 0.647 
Total-to-HDL cholesterol ratio (unit) 1 -0.192 -0.23; -0.155 <0.001  -0.054 -0.126; 0.017 0.135  -0.103 -0.214; 0.009 0.071 
2 -0.187 -0.224; -0.149 <0.001  -0.054 -0.125; 0.017 0.137  -0.107 -0.219; 0.004 0.060 
 3 -0.135 -0.174; -0.096 <0.001  -0.027 -0.101; 0.047 0.475  -0.074 -0.191; 0.043 0.215 
Body mass index (kg/m2) 1 -0.063 -0.073; -0.052 <0.001  -0.027 -0.047; -0.007 0.008  -0.032 -0.071; 0.007 0.108 
 2 -0.059 -0.071; -0.048 <0.001  -0.025 -0.045; -0.005 0.015  -0.037 -0.077; 0.002 0.063 
 3 -0.046 -0.058; -0.034 <0.001  -0.020 -0.041; 0.001 0.062  -0.029 -0.071; 0.014 0.186 
Use of BP-lowering medication (yes) 1 - - -  - - -  -0.199 -0.514; 0.116 0.215 
2 - - -  - - -  -0.221 -0.537; 0.096 0.171 
 3 - - -  - - -  -0.018 -0.368; 0.332 0.920 
Use of lipid-lowering medication (yes) 1 - - -  - - -  -0.298 -0.669; 0.072 0.114 
2 - - -  - - -  -0.293 -0.664; 0.077 0.120 
 3 - - -  - - -  -0.282 -0.675; 0.110 0.158 
Use of glucose-lowering medication (yes) 1 - - -  - - -  -0.261 -0.804; 0.283 0.345 
2 - - -  - - -  -0.301 -0.847; 0.245 0.279 
 3 - - -  - - -  -0.012 -0.611; 0.588 0.970 
The regression coefficient ß represents the change in DCfem (in SD from the healthy population mean among individuals of the same age and sex) per unit increase in each risk factor. Model 1: unadjusted. Model 2: 
adjusted for MAP. Model 3: adjusted for MAP and all other risk factors. aBP-, lipid- and glucose-lowering treatment 
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6.5 Discussion 
In the present study, we estimated age- and sex-specific percentiles of fem-
oral artery stiffness, based on individual-level data obtained through 
echotracking from 1,489 healthy individuals not exhibiting any of the classi-
cal CV-RFs. As such, we have provided a framework for “healthy femoral 
artery ageing”, indicating what normal changes in stiffness may be expected 
when a person ages. In addition, we also examined the association of CV-RFs 
with deviations from these normal curves, helping interpretation of femoral 
artery stiffness values obtained both in research and clinical settings. 
Epidemiological studies on femoral artery stiffness are limited in number 
and often restricted to specific subpopulations. However, those few studies 
reporting normal values do show consistent results. In the FLEMENGHO
182
 
cohort, femoral artery functional properties (i.e. stiffness and buffering 
capacity) changed very little with age, despite a wide age range. This was 
also seen in the middle-aged healthy subjects from the ASKLEPIOS study
183
, 
and is further supported by a lack of change in brachial artery stiffness over 
time, as described earlier.
60
 In (sub-)populations at increased cardiovascular 
risk, such as the (pre-) diabetic subjects of the Hoorn study or obese partici-
pants of AGHALS
184,111
 and FLEMENGHO
185
, femoral artery stiffness was 
increased compared to normal subjects.    
Largely drawing on the same datasets, this study confirms the findings of the 
previously described epidemiological studies, i.e., in healthy individuals, 
femoral artery stiffness remains constant over many years, only to increase 
significantly between the 6
th
 and 8
th
 decade, in both men and women.  
CV-RFs related with metabolic syndrome (BMI, MAP and dyslipidaemia) 
show associations with greater femoral artery stiffness. However, we cannot 
exclude the possibility that compression by perivascular fat tissue (or excep-
155 
 
tionally, by the operator) is the main driver behind the strong association 
between femoral stiffness and BMI. Smoking showed a paradoxically nega-
tive relationship with femoral stiffness in men. However, it is possible that 
the chronic effects of current smoking were outweighed by the acute effects 
of withdrawal from smoking, which has an immediate impact on the sympa-
thetic nervous system activity.
174
 Indeed, all protocols institute abstinence 
from smoking at the time of measurement, ranging in time from at least 
3h
182
 till 6h
183,186
 in advance. In addition, the cross-sectional assessment of 
smoking (i.e. a yes/no question, not taking into account the quitters) may 
have further confounded these results.  
To illustrate the absolute impact of the negative relationships between the 
other CV-RFs and DCfem, the change in CV-RF level associated with a theoret-
ical drop in DCfem of 2.36 10
-3
.kPa
-1
 (which predicted incident cardiovascular 
events in the Hoorn Study
87
) was calculated. For BMI, this equates to a rise 
of about 7 points (+6.9 kg/m² in men, +6.7 kg/m² in women). For MAP, a rise 
of 27 mmHg (in men) or 42 mmHg (in women) would be needed, and for 
total-HDL cholesterol ratio this means a rise of 4.3 (in men) or 2.2 (in wom-
en). In terms of percentiles of DCfem, such a decrease (-2.36 10
-3
.kPa
-1
) corre-
sponds with going from P50 to P25 (in men, age 50) or from P50 to P33 (in 
women, age 50). However, we must be cautious when interpreting such 
effects, since we are dealing with different populations here. Longitudinal 
data will be necessary to show what percentile levels are unfavourable and 
eligible to serve as thresholds for intervention.  
 Comparison between carotid and femoral artery 6.5.1
stiffness 
Percentile curves reveal a different relationship with ageing between femo-
ral and carotid artery stiffness. In contrast to the long plateau phase and 
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steep rise at old age for femoral artery stiffness, carotid artery stiffness 
increases rapidly in early adulthood, followed by a slower rise later in life 
(Chapter 5). Associations with CV-RFs were more similar. However, MAP was 
a stronger determinant for carotid artery stiffness, while BMI was the most 
important factor for femoral artery stiffness. Smoking showed a similar 
favorable effect at both locations, although the mechanism may be different 
(i.e. for the carotid artery: through increased distension, for the femoral 
artery: through a reduced diameter). Diabetes was linked with carotid artery 
stiffness in men and women, while only in men it showed a relationship with 
femoral artery stiffness.  
Comparing determinants of carotid and femoral artery diameter, a clear 
(positive) influence of MAP was seen on the carotid, but not on femoral 
artery diameter. Both carotid and femoral artery diameters strongly corre-
lated with BMI, while the relationship with smoking was opposite (positive 
for carotid artery, negative for femoral artery diameter)   
Although we cannot exclude the possibility that these discrepancies are 
caused by differences in study population between Chapter 5 (carotid ar-
tery) and Chapter 6 (femoral artery), results of carotid artery stiffness did 
not materially change when restricted to subjects also available in Chapter 
6. 
 Limitations 6.5.2
This study has several limitations, the most important of which is its cross-
sectional design and noise introduced by calibration between centres. In 
addition, femoral artery reference values show huge scatter, with models in 
men and women only explaining a marginal proportion of the variation. A 
possible contributor to this large variability on the population level is the 
seemingly random variability in the same individual over time. Indeed, Hof-
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stra et al,
187
 performing serial measurements on the same individual, ob-
served large variation in femoral artery distension throughout the meas-
urement period, which could not be explained by changes in diastolic or 
pulse pressure. Femoral artery stiffness also shows no linear dependency on 
diastolic pressure
188
 (in contrast to carotid artery stiffness), suggesting a 
more autonomous, spontaneous behaviour. A possible explanation is that 
elastic properties of a muscular artery are under the influence of vasoactive 
substances (e.g. angiotensin, noradrenaline, atrial natriuretic factor), and 
the central nervous system, producing a permanently changing vascular 
tone. In addition, both intra-
188
 and inter-observer
111
 variability are always 
larger for the femoral compared to the carotid artery,
189
 although this may 
also reflect the difficulty to obtain high quality images of the anatomically 
more curved femoral artery. To illustrate, of all data sent to us 521 subjects 
could not be included in the total database because of missing femoral ar-
tery diameter/distension data. Since this sample of excluded subjects was 
significantly more obese (BMI 28.0 kg/m² vs 25.7 kg/m²), had a higher MAP 
(103.9 mmHg vs 96.7 mmHg), had a worse lipid profile (total-to-HDL ratio of 
4.4 vs 3.9), contained relatively more diabetic individuals (17.3% vs 10.2%) 
and slightly more smokers (20.7% vs 19.7%), it is likely that the impact of 
these CV-RFs on DCfem is underestimated in the present study. 
 Conclusion 6.5.3
Reference values for femoral artery stiffness have been established. In 
young and middle-aged men and women, normal femoral artery stiffness 
does not change substantially with increasing age up to the 6
th
 decade. Our 
data confirm that CV-RFs related to early metabolic disease are associated 
with increased femoral artery stiffness. 
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Chapter 7 Macro- and microcirculation 
in normal-tension glaucoma 
Adapted from: 
Bossuyt J, Vandekerckhove G, Van de Velde S, De Backer TLM, Azermai M, Stevens 
A, Kestelyn P, Raemdonck T, Segers P, Vanmolkot F, Van Bortel LM.  
Vascular dysregulation in normal-tension glaucoma is not reflected by alterations in 
the micro- or macrocirculation at rest. A case-control study. (Submitted to the 
Journal of Glaucoma) 
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7.1 Abstract 
Aims: In normal-tension glaucoma (NTG), optic nerve damage occurs despite a 
normal intraocular pressure. Studies implicating arterial stiffness in the pathophys-
iology of NTG have produced conflicting results. Our aim was to investigate wheth-
er NTG is associated with alterations in arterial structure or function. 
Methods: Cardiovascular measurements included peripheral (Omron M6) and 
central (Sphygmocor) blood pressures, wave reflection, arterial stiffness measures 
[Pulse wave velocity (PWV), Sphygmocor and Esaote AU5 Wall track system], Inti-
ma-media thickness (IMT), cardiac output (Esaote AU5) and total peripheral re-
sistance index (TPRI). Symptoms of vascular dysregulation were assessed using a 
questionnaire. 
Results: 30 patients with NTG (mean age 65y, range 46-79) and 33 healthy subjects 
(mean age 67y, range 42-79) matched for age and sex were recruited. There were 
no statistically significant differences in arterial structure and function, for any of 
the measured arterial segments; for NTG versus controls, respectively: blood pres-
sure 126±15 / 77±8 mmHg vs. 127±16 / 76±7 mmHg, p=0.81; aortic PWV 9.8±2.1 
m/s vs. 10.1±1.9 m/s, p=0.60; TPRI 1833±609 vs. 1779±602 dyne.s/cm5/m², p=0.79; 
carotid IMT 0.65±0.14 mm vs. 0.68±0.13 mm; p=0.39. Questionnaire reports re-
vealed an increased prevalence of cold extremities in the NTG group (73% vs. 21%, 
p<0.001) suggesting vascular dysregulation is present in most NTG patients 
Conclusion: NTG is not associated with altered arterial stiffness, IMT, TPRI, cardiac 
output, peripheral or central hemodynamics. Although the majority of NTG pa-
tients do exhibit symptoms of vascular dysregulation, in the present study this did 
not translate into alterations in the micro- or macrocirculation at rest. 
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7.2 Introduction 
As described in Chapter 1, Normal-tension glaucoma (NTG) is associated with vas-
cular dysregulation, although the exact role of this alteration in the pathophysiolo-
gy of NTG remains to be identified.
124
 Historically, NTG has been linked with low 
arterial blood pressure, either diurnally
190,191
, or at night only
192,193
. Many studies, 
however, did not find an association between NTG and low blood pressure
194–203
 or 
did not show overdipping
97, 105–107
.  Focusing on more integrative measures of vas-
cular health did not solve these discrepancies. Augmentation index (a measure of 
wave reflections) in NTG patients was found increased by Mroczkowska et al,
200
 but 
unaltered by Graham et al
202
. Pulse wave velocity (a measure of arterial stiffness) in 
NTG was found increased in one study
207
 while not different from controls in other 
studies.
197,208
  
Still, not all hemodynamic variables have been investigated in NTG, such as muscu-
lar artery properties and total peripheral resistance. However, compliance of a 
muscular (the brachial) artery was found decreased in migraine patients,
186
 whose 
condition might share a common etiology with NTG.
209
 Similarly, total peripheral 
resistance may be an interesting parameter to examine in NTG, as it can be altered 
in case of systemic microvascular abnormalities.
210
 
Since many of the proposed systemic factors are treatable, it is of clinical im-
portance that they are identified and described. Therefore, the aim of this study 
was to gain more insight into the function of the systemic micro- and macrocircula-
tion in NTG, by comparing NTG patients with healthy age- and sex-matched con-
trols. To this aim, non-invasive measurements of arterial structure and function 
were performed: diameter, intima media thickness and stiffness of elastic (carotid) 
and more muscular (femoral) arteries; aortic stiffness (carotid-to-femoral pulse 
wave velocity); total peripheral resistance and peripheral and central hemodynam-
ics. 
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7.3 Materials and Methods 
A description of the methods (hemodynamic measurements) and study population 
characteristics is provided in chapter 2. Since the ophthalmic investigations were 
only included in the study to confirm or exclude the diagnosis of NTG, they were 
not discussed in the methods section of this thesis (Chapter 2).   
 Study design 7.3.1
Control and NTG subjects underwent the following ophthalmic examinations: (1) 
Visual acuity assessment; (2) Slit-lamp examination; (3) Goldmann applanation 
tonometry; (4) Fundoscopy; (5) Haag-Streit Octopus perimeter (30.2); (6) Spectral 
Domain Optical Coherence Tomography: nerve fiber layer thickness and (7) Central 
corneal thickness measurement. Following ophthalmic examination, all participants 
underwent a screening visit and a study visit. At screening, a fasted blood sample 
was drawn [to determine total cholesterol, low-density lipoproteins (LDL), high 
density lipoproteins (HDL), creatinine, glucose and triglycerides], brachial blood 
pressure was measured and a questionnaire was completed (medical history, life-
style habits, medication use, signs of vascular dysregulation, Table 7.2). The study 
visit included all hemodynamic measurements. Subjects who were on vasoactive 
drugs were asked to stop treatment 3 days before study visit.  
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Table 7.1 Baseline characteristics of the study population. 
Variable NTG (n=30) Control (n=33) p-value 
Age, y 65 ± 8 67 ± 8 0.46 
Male, n (%) 7 (23) 8 (24) 0.93 
BMI, kg/m2 25.8 ± 3.5 26.3 ± 3.6 0.59 
Biochemical parameters    
 Total cholesterol, mg/dl 201 ± 34 215 ± 30 0.08 
 HDL-cholesterol, mg/dl 69 ± 16 75 ± 21 0.18 
 LDL-cholesterol, mg/dl 111 ± 28 120 ± 32 0.25 
 Triglycerides, mg/dl 94 ± 31 98 ± 40 0.72 
    Creatinin, mg/dl 0.82 ± 0.13 0.85 ± 0.19 0.61 
 Glucose, mg/dl 94 ± 12 92 ± 10 0.51 
Lifestyle variables    
 Active smoking, n (%) 0 (0) 1 (3) 0.84 
    Regular alcohol use, n (%) 8 (27) 9 (27) 0.23 
Medication use    
   Lipid-lowering drugs, n (%) 8 (27) 7 (21) 0.62 
   Antihypertensive drugs, n (%) 12 (40) 14 (42) 0.85 
Data are mean±SD or frequency (percentage). 
  
 164 
7.4 Results 
Of all screened NTG subjects (n=32), two participants were excluded because of 
type II diabetes mellitus and history of CVD, respectively. Baseline characteristics of 
subjects are summarized in Table 7.1. There were no significant differences be-
tween NTG and control subjects for age, sex, BMI, lifestyle habits or any of the 
biochemical variables. Survey data (Table 7.2) revealed that significantly more NTG 
patients suffered from cold hand and/or feet (73% vs. 27%, p<0.001). There were 
also trends towards an increased prevalence of migraine (p=0.17), fibromyalgia 
(p=0.14), and sleep apnea (p=0.26) in the NTG group. None of the cardiovascular 
parameters were different between NTG and control subjects (Table 7.3). Femoral 
IMT was borderline significant (p=0.05), and lower in the NTG subjects. However, 
when this parameter (IMT) was corrected for differences in arterial diameter, this 
near statistical significance disappeared (CSWA, p=0.21). 
Table 7.2 Results of the study questionnaire. 
Variable NTG (n=30) Control (n=33) p-value 
Co-morbidities    
  History of hypertension (n, %) 8 (27) 10 (30) 0.75 
  Respiratory disease (n, %) 3 (10) 2 (6) 0.57 
  Hypothyroidism (n, %) 2 (7) 2 (6) 0.92 
  Hyperthyroidism (n, %) 1 (3) 1 (3) 1.00 
  Rheumatoid arthritis (n, %) 1 (3) 3 (9) 0.36 
  Sleep apnea (n, %) 3 (10) 1 (3) 0.26 
  Fibromyalgia (n, %) 2 (7) 0 (0) 0.14 
  Allergy (n, %) 9 (30) 6 (18) 0.28 
Symptoms of vascular dysregulation 
  History of hypotension (n, %) 4 (13) 2 (6) 0.33 
  History of migraine (n, %) 10 (33) 6 (18) 0.17 
  Cold extremities (n, %) 22 (73) 9 (27) <0.001 
  Reduced thirst sensation (n, %) 5 (17) 5 (15) 0.87 
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Table 7.3 Hemodynamic measurements 
Variable NTG (n=30) Control (n=33) p-value 
Hemodynamics      
  Peripheral      
 SBP, mm Hg 126 ± 15 127 ± 16 0.81 
 DBP, mm Hg 77 ± 8 76 ± 7 0.60 
 PP, mm Hg 49 ± 9 51 ± 11 0.49 
    MAP, mm Hg 96 ± 10 96 ± 10 0.98 
  Central       
    cSBP, mm Hg 122 ± 16 125 ± 17 0.49 
    PP amplification 1.11 ± 0.17 1.06 ± 0.14 0.19 
    RM, % 69 ± 6 71 ± 7 0.41 
    AIx, % 128 ± 20 130 ± 18 0.55 
  Cardiac       
    HR, beats/min 63 ± 8 65 ± 8 0.32 
    SI, ml/m² 41 ± 9 39 ± 10 0.62 
    CI, l/min/m² 2.4 ± 0.6 2.4 ± 0.6 1.00 
    TPRI, dyne.s/cm5/m² 1833 ± 609 1779 ± 602 0.79 
        
Vascular properties       
  Femoral artery       
    Diameter, mm 8.61 ± 1.45 8.44 ± 1.00 0.59 
    IMT, mm 0.71 ± 0.18 0.83 ± 0.26 0.05 
    CSWA, mm² 17.9 ± 5.4 19.8 ± 6.3 0.21 
 CC, mm²/kPa 0.99 ± 0.49 0.97 ± 0.68 0.90 
 DC, 10-3/kPa 17.6 ± 9.3 18.3 ± 14.1 0.84 
  Carotid artery       
    Diameter, mm 6.92 ± 0.64 7.16 ± 0.85 0.21 
    IMT, mm 0.65 ± 0.14 0.68 ± 0.13 0.39 
    CSWA, mm² 12.8 ± 3.3 13.9 ± 3.7 0.26 
 CC, mm²/kPa 0.78 ± 0.26 0.80 ± 0.34 0.78 
 DC, 10-3/kPa 21.3 ± 8.7 20.5 ± 9.3 0.74 
  Aorta       
    PWV, m/s 9.8 ± 2.1 10.1 ± 1.9 0.60 
Data are mean±SD; IMT = intima-media thickness; WCSA = Wall Cross-Sectional 
Area; CC = cross-sectional compliance coefficient; DC = distensibility coefficient; 
SBP = systolic blood pressure; DBP = diastolic blood pressure; MAP = mean arteri-
al pressure; PP = pulse pressure; PWV = pulse wave velocity; AIx = augmentation 
index; RM = reflection magnitude; HR = heart rate; CI = cardiac index; SVI = stroke 
volume index; TPRI = total peripheral resistance index. 
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7.5 Discussion 
A comprehensive assessment of the macro- and microcirculation at rest did not 
reveal any difference between NTG patients and age- and sex-matched healthy 
controls. This finding confirms those of others who observed no difference in blood 
pressure and/or waveform parameters, and pulse wave velocity.
202, 208
 In addition, 
we showed that muscular artery stiffness, reflection magnitude and total peripher-
al resistance, which to our knowledge constitute a blind spot in NTG research, were 
also not different from the controls. However, questionnaire reports do suggest 
vascular dysregulation is present in the majority of NTG patients, and is not re-
stricted to the eye. To summarize, despite arguments for a systemic involvement, 
no systemic differences in cardiovascular structure and function were found at rest.  
There are several possible explanations for this paradox:  
(1) Vascular dysregulation represents a defective response to a certain stressor, 
while all cardiovascular parameters were measured at rest. As symptoms of vascu-
lar dysregulation occur only episodically (e.g. at night, after cold exposure, etc.), 
provocative tests may be needed to unmask alterations in cardiovascular function. 
Indeed, Su et al. observed no differences in brachial artery blood flow at baseline, 
but an impaired response following ischemia in NTG patients.
211
 Similarly, Nicolela 
et al. found no difference in plasma endothelin-1 levels at baseline, but a signifi-
cantly higher endothelin-1 concentration in glaucoma patients after cold expo-
sure.
212
 
 (2) Although it is evident to consider improper cardiovascular function as a direct 
cause of inadequate ocular blood flow, the pathophysiology of NTG may involve 
defects in other organ systems as well. Indeed, glaucoma is a multi-factorial dis-
ease, having an immunological, endocrine and neurological component, which may 
make it difficult to isolate a single (cardiovascular) profile.
120,213–216 
 (3) This is a cross-sectional study. Therefore, we cannot exclude the possibility that 
cardiovascular alterations were present long before diagnosis, but were in the 
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meantime influenced by other factors, such as lifestyle changes, medication, course 
of disease, etc. To illustrate, glaucoma patients often recall having low blood pres-
sure in youth,
217
 but this effect may disappear with ageing. 
Table 7.4. Associations with NTG tested in literature and/or in this study 
      
  Literature   
 
  
Association 
with NTG 
No association 
with NTG 
  This study 
  Primary vascular dysregulation         
       Female sex   218–221    + + 
       Cold extremities   212,222–224    + + 
       History of Migraine   225,226 227  +  
       Reduced thirst sensation  NA NA   - 
  Alterations in the macrocirculation 
       Carotid intima-media thickening 
 
200    - 
       Increased augmentation index 200  202  - 
       Increased reflection magnitude  NA NA  - 
       Elastic artery stiffening 
 
 
197 
 
- 
       Muscular artery stiffening  NA NA  - 
       Increased central pressure   202  - 
  Alterations in the microcirculation      
       Total peripheral resistance  NA NA  - 
References are shown for associations described in literature between NTG and symptoms of PVD, and 
alterations in macro-or microcirculation (p<0.05).  ‘NA’ indicates not described in literature. Associa-
tions with NTG in the present study are indicated with symbols:  + + significant association with NTG 
(p<0.05); + trend (p>0.05); - no association.  
Table 7.4 provides an overview of literature data and associations with NTG tested 
in the present study. From this Table, it is clear that the vast majority of studies 
associated NTG with signs of vascular dysregulation, but not consistently with vas-
cular alterations at rest, while no literature data exists on muscular artery stiffness, 
total peripheral resistance and reflection magnitude.  
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 Strengths and limitations 7.5.1
The strength of this study is that the influence of confounders is limited by match-
ing subjects for age and gender, which was successful and resulted in similar levels 
of biochemical (e.g. cholesterol, fasting glucose, etc.) and physical (e.g. height, 
weight, etc.) variables between the case and control group. However, this study 
also has some limitations. First, as already mentioned, this study suffers from its 
cross-sectional design. Second, due to low prevalence of NTG, the sample size was 
small. However, to detect a difference in cross-sectional compliance of 20%, as was 
found in migraine patients,
186
 this sample size was deemed adequate (power 80%, 
α=0.05).  
 Conclusion 7.5.2
To conclude, our data show no alterations of the micro- or macrocirculation in NTG 
at rest, despite a history of clinical symptoms of systemic vascular dysregulation. In 
particular, vascular dysregulation did not lead to statistically significant alterations 
in vascular tone as evidenced by no differences in function of the muscular femoral 
artery, total peripheral resistance, mean arterial pressure and measures of wave 
reflection. Provocative tests may be needed to reveal alterations in cardiovascular 
function in NTG patients. 
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Chapter 8 Conclusion 
8.1 Main findings 
The main findings of this thesis will be approached from the perspective of the five 
study objectives (Table 1.5), which will be answered or commented on. 
Study objective n°1 
= to investigate the impact of body side and size on carotid-femoral PWV. 
The main finding was that the human body is not symmetrical at the level of the 
arteries. In particular, a significant difference in length exists between the left vs. 
right aortic-femoral path (the latter being longer). This difference is in part, but not 
fully compensated by the also slightly longer right vs. left aortic-carotid path. As a 
result, the total travelled path between carotid and femoral is slightly longer on the 
right side of the body. The total difference, however, still falls within the margins of 
error of cf-PWV assessment and might be less important for a single measurement, 
but can add to other inaccuracies. In addition, the distance between carotid and 
femoral artery as measured with a tape may be significantly affected by body con-
tours.  
Since all sources of noise should be avoided as much as possible, it is important 1) 
to measure on one side of the body, i.e. not ‘crossing over’ from left carotid to right 
femoral, or right carotid to left femoral 2) not switching between left/right side on 
serial measurement periods on the same subject and 3) to use additional tools, 
such as an anthropometer, if measurement in a straight line using a tape is not 
possible. 
Overall, these findings do not hamper the clinical applicability of cf-PWV, but rather 
stress the importance of standardizing operating procedures. 
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Study objective n°2 
= to investigate the left-right distribution of atherosclerosis. 
The main finding was that the geometrical asymmetry that was suggested earlier 
(in the MRI study) was reflected by an asymmetry in atherosclerosis distribution. In 
a large population sample, this was seen at the femoral artery, where atherosclero-
sis was more prevalent on the right side (expressed by higher IMT values and in-
creased plaque presence), consistent with the anatomical asymmetry. At the carot-
id artery, the distribution was equal, reflecting the more symmetrical anatomy (at 
the measurement location). 
With regard to the clinical implications of this finding, it needs to be shown wheth-
er clinical atherosclerosis (i.e. symptomatic lesions, such as stenosis or peripheral 
artery disease) is also more prevalent on the right femoral artery. In addition, alt-
hough femoral IMT and plaques are predictive for atherosclerosis elsewhere, a 
relationship with clinical events (outcome data) is currently lacking. Outcome stud-
ies are also needed to indicate whether the predictive value of atherosclerosis of 
the femoral artery will differ between right and left side.    
Furthermore, it needs to be stressed that although on average there was no differ-
ence in atherosclerosis prevalence between left and right carotid artery, this is 
certainly not the case on an individual level. Indeed, a single person may show a 
substantial difference between left and right IMT values, or may have (a) plaque(s) 
unilaterally. What our results show is that on a population level, lesions are even-
tually equally distributed between left and right carotid artery, while on a popula-
tion level, the right femoral artery may on average be more frequently affected 
than the left.  
Overall, findings in this and other studies underscore the local character of athero-
sclerosis and might suggest to measure IMT and plaque always bilaterally, since a 
significant number of cases would be missed when considering one side of the 
body only. 
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Study objective n°3 
= to establish normal values for carotid artery stiffness. 
The main finding was that, in a healthy population, carotid artery stiffness increases 
already in early life (adolescence), plateauing near old age. The relationship with 
age is somewhat steeper in women than men, suggesting a more rapid decline of 
carotid artery elasticity in women. Including also subjects with one or more CV-RFs 
in the analysis showed that increased carotid artery stiffening is associated with (in 
decreasing order of importance) high levels of MAP, the presence of diabetes, un-
favorable lipid profile and increased BMI. 
Study objective n°4 
= to establish normal values for femoral artery stiffness. 
The main finding was that, in a healthy population, femoral artery stiffness changes 
little with age, only to increase significantly at about the age of 60. This rise in stiff-
ness is steeper and less gradual in women than men, suggesting a more sudden 
onset of femoral artery stiffening in women. Including also subjects with one or 
more CV-RFs in the analysis showed that increased femoral artery stiffening is as-
sociated with (in decreasing order of importance) high levels of BMI, MAP and 
unfavorable lipid profile. Presence of diabetes also showed a significant associa-
tion, but in men only. 
Comparing femoral with carotid stiffness showed that the relationship with age and 
other risk factors is different. In contrast to the rise in carotid artery stiffness early 
in life, femoral artery stiffening occurs only near old age. Also the determinants (or 
at least their hierarchy) are different. While BMI is the most important continuous 
factor influencing femoral artery stiffness, MAP has a relatively stronger impact on 
carotid artery stiffness. 
Overall, it needs to be shown with longitudinal studies what the CV risk is of being 
in a certain percentile of carotid or femoral artery stiffness, and of the transition 
from one percentile into another. In addition, the predictive value of femoral artery 
 172 
stiffness is based on one single study,
87
 and should be investigated more thorough-
ly.   
Study objective n°5 
= to examine cardiovascular structure and function in normal-tension glaucoma. 
The main finding was that no direct alterations in macro- or microcirculation could 
be demonstrated in NTG patients, when measured at rest, although they do suffer 
more frequently from signs and symptoms of vascular dysregulation. 
Overall, this finding suggests that measurements done at rest may not be sufficient 
to reveal vascular dysregulation in NTG, and functional tests may be necessary. 
8.2 Future perspectives 
Cf-PWV is the gold standard measure of arterial stiffness, mainly reflecting aortic 
stiffness. Reference values already exist,
106
 and operator guidelines have been 
tested and validated. However, although cf-PWV may theoretically be ‘ready’ for 
implementation in clinical practice, there are still some critical obstacles that need 
to be removed. When applying the ‘criteria for evaluation of novel markers of car-
diovascular risk’ (Table 8.1), published in Circulation,228 Laurent et al. have demon-
strated that cf-PWV still fails on two out of the six criteria:  
1) The verdict is still out on whether a cf-PWV-guided therapy will improve 
outcome in a randomized controlled trial. The ultimate test to demon-
strate this (i.e. participants receiving either a cf-PWV-based treatment or a 
conventional blood pressure-based treatment, both groups followed pro-
spectively in time), is now being launched in France, under the name of 
the SPARTE (the Statégie de Prévention Cardiovasculaire Basée sur la Ri-
gidité Arterielle) study.
229
  
2) The cost-effectiveness of implementing cf-PWV measurements in routine 
clinical practice needs to be evaluated. 
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However, when the same criteria are applied to other measures of vascular TOD, it 
is clear cf-PWV is still in pole-position (Table 8.2). Cf-PWV is the only measure that 
has been shown to significantly alter risk classification,
81
 which is a critical check-
point. This is not the case for carotid IMT. Although carotid IMT has added predic-
tive value, its net reclassification improvement (NRI) is not significant in the general 
population,
32
 casting doubt on its clinical utility for primary prevention. With regard 
to the other measures discussed in this thesis (i.e. femoral IMT, femoral DC and 
carotid DC), the potential to change predicted risk has not yet been sufficiently 
evaluated.  
The clinical value of measuring parameters of vascular TOD will need to be further 
evaluated in future studies. One remaining challenge is whether it will be possible 
for general practitioners to adopt the more time-consuming and cumbersome 
Table 8.1 
Phases of Evaluation of a Novel Risk Marker, adapted from Hlatky et al. 228 
1) Proof of concept: Do novel marker levels differ between subjects with and without out-
come? 
2) Prospective validation: Does the novel marker predict development of future outcomes in a 
prospective cohort or nested case-cohort/case-cohort study?  
3) Incremental value: Does the novel marker add predictive information to established, stand-
ard risk markers? 
4) Clinical utility: Does the novel risk marker change predicted risk sufficiently to change rec-
ommended therapy? 
5) Clinical outcomes: Does use of the novel risk marker improve clinical outcomes, especially 
when tested in a randomized clinical trial?  
6) Cost-effectiveness: Does use of the marker improve clinical outcomes sufficiently to justify 
the additional costs of testing and treatment. 
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Table 8.2 Criteria for evaluation of novel markers of cardiovascular risk applied to measures of 
vascular TOD. 
 Arterial stiffness  Arterial wall thickness 
Criterion 
Cf- 
PWV 
Carotid 
 DC 
Femoral 
 DC 
 Carotid 
 IMT 
Femoral  
IMT 
Proof of concept  85 86 98  27 43 
Prospective validation  95 87 87  230 ? 
Incremental value  231 87 87  232 ? 
Clinical utility  81 ? ?  32 ? 
Clinical outcomes  ? ? ?  ? ? 
Cost-effectiveness ? ? ?  233 ? 
Symbols indicate positive (), negative () or absent (?) evidence from literature. 
techniques into their daily clinical practice. In contrast to the conventional blood 
pressure measurement, the types of vascular TOD discussed in this thesis require 
more time and effort, both from physician and patient. Attempts to facilitate 
measurements (e.g. cuff-based methods to quantify aortic stiffness) have come at 
the cost of providing more questionable results. Examples include devices such as 
the Arteriograph
234
 or Mobil-o-graph,
235
 which claim to measure aortic stiffness by 
capturing signals in the upper arm, but have been called into question.
236
 On the 
other side of the spectrum, we find measurement of cf-PWV using the Sphygmocor 
device, which is far more time-consuming (requiring subjects to undress, a skilled 
operator to locate carotid and femoral arteries, setting up an ECG) but may also 
yield the most valid measure of a subjects’ aortic stiffness (close relationship with 
invasive aortic PWV).
237
 Finding a balance between the validity and ease of use is a 
challenge all parameters and devices must face, but often struggle with. However, 
reaching this balance will be crucial for becoming and staying routinely implement-
ed into daily clinical practice. In the coming years, it will be interesting to see which 
parameters and/or devices will be able to make the leap from research to clinical 
practice. 
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Samenvatting 
De rode draad in dit proefschrift is onderzoek naar arteriële structuur en functie.  
Concreet is het doel van deze thesis om cardiovasculaire (CV) risico stratificatie te 
verbeteren, door meetmethodes van vasculaire orgaanschade (arteriële stijfheid, 
verdikking van de slagaderwand) te helpen de overstap te maken naar de dagelijkse 
klinische praktijk. Dit doel wordt benaderd vanuit verschillende oogpunten, 
waaronder de methodologische en pathofysiologische apsecten van arteriële 
structuur en functie. 
De tekst bestaat uit 8 hoofdstukken, waarvan het eerste een algemene inleiding 
geeft en de probleemstelling aankaart (hoofdstuk 1), en het laatste deze vragen 
tracht te beantwoorden en concludeert (hoofdstuk 8). Tussenin bevinden zich een 
beschrijving van de gebruikte methoden (hoofdstuk 2), en de resultaten van vijf 
specifieke onderzoeken, die overeenkomen met de vijf studie objectieven 
(hoofdstukken 3-7). 
Hoofdstuk 1: Inleiding 
In Hoofdstuk 1 wordt de onderliggende drijfveer om onderzoek te doen in het 
cardiovasculaire veld blootgelegd: het feit dat cardiovasculaire ziektes tot op 
vandaag nog steeds de primaire doodsoorzaak zijn, zowel lokaal (in België) als 
wereldwijd. Cardiovasculaire ziektes worden gedefinieerd en de huidige methodes 
om het risico op cardiovasculaire sterfte te bepalen (d.i. risicostratificatie met 
behulp van risicofactoren) worden beschreven. Vervolgens maken we kennis met 
integrerende parameters, zoals ‘Systematic COronary Risk Evaluation (SCORE)’ en 
‘Framingham Risk Score (FRS)’, die een totaalbeeld geven van iemands risico 
profiel. Van de beperkingen van deze scores wordt dan overgegaan op ‘eind-
orgaanschade’, als een relatief nieuw hulpmiddel voor risicostratificatie. Er wordt 
dieper ingegaan op “verdikking van de slagaderwand” en “arteriële stijfheid” als 
types van vasculaire orgaanschade. Deze worden verder gedefinieerd en hun 
predictieve waarde wordt beoordeeld. De inleiding wordt besloten met de 
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probleemstelling en doelen: ondanks hun additieve predictieve waarde worden de 
besproken parameters van vasculaire schade nauwelijks gemeten in de 
dagdagelijkse klinische praktijk. Het primaire doel van dit onderzoek is daarom om 
hun klinische toepasbaarheid te verhogen door enkele hindernissen uit de weg te 
ruimen die momenteel de weg naar de kliniek nog versperren. Concreet betekent 
dit 1) voor regionale (carotidofemorale) arteriele stijfheid: het verfijnen van de 
huidige meetprocedures door na te gaan wat het effect is van lichaamszijde en 
lichaamsvormen; 2) voor verdikking van de slagaderwand: het testen van huidige 
meetprocedures m.b.t. verschillen tussen rechter en linker lichaamszijde; 3) en 4) 
voor lokale stijfheid: het opstellen van referentiewaarden, voor respectievelijk 
stijfheid van de halsslagader (carotis) en dijbeenslagader (femoralis); 5) een 
toepassing van het bovenstaande, door te onderzoeken of metingen van arteriële 
structuur en functie van nut kunnen zijn bij mensen met normale-druk glaucoom.  
Hoofdstuk 2: Methodes 
In Hoofdstuk 2 worden alle gebruikte methodes en populaties opgelijst. Concreet 
worden volgende zaken in detail beschreven; de gestandaardizeerde 
meetomgeving, manieren om brachiale en lokale (femoralis en carotis) bloeddruk 
te meten, methodes voor de bepaling van lokale diameter en distensie, het meten 
van regionale (carotidofemorale) stijfheid, het kwantificeren van pulsgolfreflecties, 
het berekenen van de totale perifere weerstand aan de hand van cardiale output 
en de gemiddelde bloeddruk, het meten van preklinische atherosclerose (IMT en 
plaques), en het bepalen van de arteriële padlengtes met behulp van MRI. Verder 
wordt ook een korte beschrijving van de gebruikte populaties gegeven (MRI-
vrijwilligers, deelnemers aan de Asklepios studie en normale-druk glaucoom 
patiënten).  
Hoofdstuk 3-7: Resultaten 
In Hoofdstuk 3 worden de resultaten van de MRI studie beschreven, waarin de 
arteriële padlengte van rechtercarotis tot rechterfemoralis vergeleken wordt met 
hetzelfde traject aan de linkerkant van het lichaam. Eveneens werd berekend wat 
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de rechtstreekse afstand, “in vogelvlucht”, tussen deze punten is, om metingen 
met een antropometer te simuleren. Deze analyse leerde ons dat er wel degelijk 
een verschil is in arteriële padlengte tussen beide lichaamszijden, maar dat dit 
verschil over het algemeen binnen de foutenmarge van de methode zelf (het 
meten van carotidofemorale pulsgolfsnelheid, cf-PWV) valt. Het belang van het 
meten van de afstand in rechte lijn, eventueel met behulp van een antropometer, 
werd wel aangetoond. Na toepassing van de 80%-regel blijkt deze afstand het 
dichtst aan te leunen bij de ‘echte’ arteriële padlengte. 
In Hoofdstuk 4 wordt een stap verder gegaan in het bekijken van bilaterale 
verschillen in gepaarde bloedvaten. De hypothese wordt getest dat een bilateraal 
asymmetrische geometrie op populatieniveau tot een scheve verdeling van 
atherosclerose zou leiden. Concreet verwachten we vooral links-rechts verschillen 
in atherosclerose op het niveau van de femoralis, aangezien de asymmetrie hier 
meer uitgesproken is, en dit bloedvat een meer gebogen traject volgt. Ter hoogte 
van de carotis zou de minder uitgesproken asymmetrie, gebufferd door het meer 
rechte verloop van deze bloedvaten ter hoogte van de meetlocatie, tot een meer 
evenredige links-rechts distributie van atherosclerose moeten leiden. Deze 
hypothese blijkt te kloppen op basis van resultaten van de Asklepios-studie, waarin 
de distributie van preklinische atherosclerose perfect symmetrisch is ter hoogte 
van de carotis (linker- en rechterkant evenveel plaques en IMT), maar significant 
verschillend is ter hoogte van de femoralis (meer plaques en hogere IMT waarden 
t.h.v. de rechter femoralis). Wat de klinische gevolgen van deze resultaten betreft, 
is voorzichtigheid geboden. Aangezien enkel gekeken wordt naar preklinische 
atherosclerose in gezonde (symptoomvrije) mensen, zal in de toekomst moeten 
onderzocht worden of hetzelfde patroon ook gevonden wordt voor klinische 
atherosclerose. Verder zal ook uit longitudinale (outcome) studies moeten blijken 
of er een verschil is in predictieve waarde tussen atherosclerose op de rechter vs. 
linker femoralis. Wat echter wel uit deze resultaten kan besloten worden is dat (1) 
deze de huidige richtlijnen bevestigen voor het meten van preklinische 
atherosclerose ter hoogte van de carotis (nl. data van linker-en 
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rechterlichaamszijde kan samengevoegd worden), en (2) het uitgesproken lokaal 
karakter van atherosclerose nog maar eens bevestigd wordt, geïllustreerd door de 
scheve verdeling ter hoogte van de femoralis. Deze laatste bevinding suggereert 
echter niet om enkel de rechterfemoralis te meten, maar onderstreept eerder het 
belang om steeds overal te meten, aangezien anders atherosclerose kan gemist 
worden. Het identificeren van de specifieke geometrieën die de rechter femoralis 
vermoedelijk meer vatbaar maken voor atherosclerose is een interessante piste 
voor verder mechanistisch onderzoek. 
Hoofdstuk 5 en Hoofdstuk 6 handelen over het opzetten van referentiewaarden 
voor vaatstijfheid van respectievelijk de arteria carotis (halsslagader) en arteria 
femoralis (dijbeenslagader). In deze projecten worden percentielen opgesteld van 
femoralis-en carotisdistensibiliteit (d.i. het omgekeerde van stijfheid), bekomen in 
gezonde proefpersonen, uit een verzameling van Europese studies. Deze curves 
tonen aan dat, in gezonde personen, de stijfheid van de femoralis constant blijft 
gedurende vele jaren, en slechts significant toeneemt rond de leeftijd van 60 jaar. 
In schril contrast hiermee neemt de stijfheid van de carotis al toe in 
jongvolwassenen, met een meer gematigde stijging bij ouderen. Uit een analyse 
van de invloed van cardiovasculaire risicofactoren blijkt BMI het meest bij te 
dragen tot verhoogde femoralisstijfheid, terwijl de gemiddelde arteriële druk de 
belangrijkste continue factor is voor carotisstijfheid. Of de invloed van BMI een 
louter mechanisch effect is (compressie door verhoogde (vet)massa), dan wel een 
intrinsieke verhoging van de arteriële stijfheid in obese individuen, kan op basis van 
deze resultaten niet worden besloten. Studies die focussen op de elasticiteit van 
het perivasculaire weefsel, en hun eventuele verband met zwaarlijvigheid, kunnen 
hier mogelijks een antwoord op bieden.    
In Hoofdstuk 7 wordt onderzocht of normale-druk glaucoom gepaard gaat met 
veranderingen in micro- en/of macrocirculatie. Concreet worden patiënten met 
normale-druk glaucoom en gematchte controles uitvoerig cardiovasculair 
geprofileerd, met onder andere metingen van lokale en regionale stijfheid, 
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pulsgolfreflecties, arteriële verdikking, hartfunctie en totale perifere weerstand. 
Resultaten van deze tests, aangevuld met persoonlijke klinische informatie uit een 
vragenlijst, leert ons dat hoewel er duidelijk aanwijzingen zijn voor vasculaire 
dysregulatie in normale-druk glaucoom, dit niet vertaald wordt in één of meerdere 
veranderingen in cardiovasculaire parameters in rust. Studies met dynamische 
functietesten lijken daarom aangewezen.     
 Hoofdstuk 8: Besluit 
In Hoofdstuk 8 worden de vraagstellingen van in Hoofdstuk 1 opnieuw aangehaald 
en beantwoord. In het algemeen heeft dit onderzoek bijgedragen tot de klinische 
toepasbaarheid van het meten van vasculaire orgaanschade, d.m.v. het valideren 
van huidige standaardisatieprocedures en het opzetten van referentiewaarden. Dit 
is echter slechts een deel van de puzzel, die nog niet voltooid is. Daarom wordt ook 
een aanzet gegeven naar toekomstperspectieven. Wanneer alle besproken 
parameters objectief worden getoetst, blijkt dat er, afhankelijk van de parameter, 
toch nog één of meerdere essentiële stap(pen) moeten genomen worden om te 
voldoen aan de minimale voorwaarden voor klinische toepassing als biomarker. 
Deze analyse toont dat, van alle parameters, regionale carotidofemorale stijfheid 
(cf-PWV) het verst staat op vlak van klinische toepasbaarheid. Echter moet nog 
steeds zwart op wit (via een gerandomiseerd onderzoek met controlegroep) 
aangetoond worden dat een therapie gebaseerd op cf-PWV-reductie significant 
beter is voor de zorg van de patiënt, en dat invoering van deze procedure 
kosteneffectief is. Beide stappen zijn essentieel om de poort naar het 
dokterskabinet open te breken. Tenslotte wordt ook erkend dat het gebruiksgemak 
van bv. cf-PWV nog niet optimaal is, en ook dit een mogelijk struikelblok kan 
vormen naar klinische implementatie toe. Hoewel dit probleem niet werd 
aangekaart in dit proefschrift, vormt het toch een belangrijke factor. Het juiste 
evenwicht vinden tussen gebruiksgemak en validiteit vormt één van de uitdagingen 
voor de toekomst.      
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Summary 
The central theme of this PhD project is research around arterial structure and 
function. In particular, the primary goal of this thesis is to improve CV risk stratifica-
tion by enhancing the clinical applicability of methods to measure vascular target 
organ damage (i.e. arterial stiffness and wall thickening). This objective will be 
approached from a broad perspective, involving methodological and pathophysio-
logical aspects of arterial structure and function.  
The manuscript is organized into eight chapters, the first of which provides a gen-
eral introduction and problem statement (Chapter 1), and the last answers and 
concludes these questions (Chapter 8). Descriptions of the methods (Chapter 2) 
and results from five studies, corresponding with five specific study objectives 
(Chapters 3-7) are included in between. 
Chapter 1: Introduction 
Chapter 1 stresses the importance of doing cardiovascular research, by showing 
that cardiovascular disease (CVD) is still the main cause of death, globally as well as 
on a local (Belgian) level. Different types of CVD are described and methods to 
perform risk stratification are given, starting with an overview of the classical risk 
factors for CVD and moving on to the more integrated parameters, such as the 
systematic COronary risk evaluation (SCORE) and the Framingham risk score (FRS). 
From the limitations of today’s systems, the concept of target organ damage (TOD) 
is introduced as a relatively new tool and aid in risk stratification. Two specific 
types of vascular TOD are then described in more detail, i.e. ‘arterial stiffness’ and 
‘arterial wall thickening’. The introduction is concluded with the problem state-
ment and aims of the thesis: despite their added predictive value, beyond classical 
risk factors, the measures of vascular TOD that were described in this thesis are 
only marginally implemented into daily clinical practice. Therefore, the primary aim 
of this thesis is to bring those parameters to the clinic by removing some of the 
obstacles hampering their clinical applicability. In particular, five specific study 
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objectives can be distinguished: 1) testing and fine-tuning of consensus guidelines 
to measure carotid-to-femoral stiffness by investigating the influence of body side 
and body contours; 2) checking for differences in atherosclerosis prevalence be-
tween left and right body side; 3) and 4) establishing reference values for local 
carotid and femoral stiffness respectively; and 5) an application of all of the above, 
investigating the utility of arterial structure and function measurements in patients 
with normal-tension glaucoma.  
Chapter 2: Methods 
Chapter 2 provides an overview of all the methods and populations used in this 
thesis. This includes a detailed description of the following procedures and/or envi-
ronments: the standardized measurement conditions, methods to quantify brachial 
and local (carotid and femoral) blood pressure, ways to asses arterial diameter and 
distension, measurement of regional (carotid-to-femoral) stiffness, estimation of 
wave reflections, calculation of total peripheral resistance by determining cardiac 
output and mean arterial pressure, measurement of preclinical atherosclerosis 
(intima-media thickness and plaques) and calculation of arterial path lengths using 
magnetic resonance imaging (MRI). A separate paragraph describes the popula-
tions worked with in this thesis (volunteers eligible for MRI, Asklepios study partici-
pants and normal-tension glaucoma patients). 
Chapters 3-7: Results 
Chapter 3 reports the results of the ‘MRI study’, in which the intra-arterial distance 
between right carotid and right femoral artery is compared with the same trajecto-
ry on the left side of the body. In addition, the direct distance is calculated on both 
sides of the body, simulating the superficial distance measured with an anthro-
pometer. An analysis of the results shows that although there is a small difference 
between left and right intra-arterial path length, this still remains within the mar-
gins of error of the method itself. More emphasized is the importance of obtaining 
a straight line (if necessary using an anthropometer), since this distance more 
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closely approximates the real travelled distance (after application of the 80-percent 
rule). 
Chapter 4 delves deeper into bilateral differences between paired arteries. In this 
chapter, we examine the hypothesis that the anatomical bilateral asymmetry sug-
gested in Chapter 3 will translate into a different distribution of atherosclerosis 
prevalence. In particular, we anticipated to see potential left-right differences at 
the level of the femoral artery (given its pronounced asymmetry and curved trajec-
tory), while the less asymmetrical and more buffered course of the carotid artery is 
expected to result in a more equal distribution of atherosclerosis. Data analyzed 
from the Asklepios study are in line with this hypothesis, showing an almost identi-
cal prevalence of (asymptomatic) atherosclerosis at right vs left carotid artery, in 
contrast to a different distribution between the femoral arteries. However, we 
must be cautious with drawing strong conclusions from these findings. It remains 
to be investigated whether the distribution of symptomatic, clinical atherosclerosis 
follows the same pattern, and what the clinical implications of a different distribu-
tion are in terms of outcome prediction. Nevertheless, these results do allow us to 
draw the following conclusions: 1) there is no substantial difference between left 
and right carotid IMT or plaque prevalence, so data from studies measuring on the 
left carotid can be pooled with data from the right side, 2) this is another example 
of the strong local character of atherosclerosis, as illustrated by the different distri-
bution between left and right femoral artery. The latter does not immediately sug-
gests measuring exclusively the right femoral artery and ignoring the left side, but 
rather stresses the importance of always measuring at all sites, in order not to miss 
any lesions. Furthermore, the identification of specific geometries rendering the 
right femoral artery more vulnerable to atherosclerosis than its left counterpart 
might be interesting for further mechanistic research. 
Chapter 5 and Chapter 6 describe results from the ‘reference values projects’, i.e. 
the assessment of age- and sex-specific normal values for carotid artery and femo-
ral artery stiffness respectively. In these two studies, percentile curves of femoral 
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and carotid distensibility coefficients (i.e. the inverse of stiffness) are established, 
based on pooled data from various European cohorts. These curves show that, in 
apparently healthy subjects, stiffness of the femoral artery remains relatively con-
stant during lifespan, only increasing significantly near the 6
th
 decade. In contrast, 
the evolution of carotid artery stiffness is characterized by an early rise, starting 
already in adolescence, with a subsequently more gentle increase near old age. 
Looking at associations with CV risk factors in the total population, increased body 
mass index (BMI) showed the strongest correlation with femoral artery stiffening, 
while mean arterial pressure was the most important factor influencing carotid 
artery stiffness. Whether the association with BMI reflects intrinsic stiffening of the 
arterial wall, rather than a consequence of mechanical constraints in obese sub-
jects (i.e. compression of the femoral artery by adipose tissue), cannot be conclud-
ed from our data. In the future, studies measuring strain of the perivascular tissue 
and its relationship with obesity may provide an answer to this question.   
Chapter 7 reports the results of the ‘Normal-tension glaucoma (NTG) study’, inves-
tigating whether NTG is associated with alterations in the micro- and/or macrocir-
culation. In particular, cardiovascular structure and function of NTG patients was 
compared to age- and sex-matched healthy controls, including measurements of 
local and regional stiffness, wave reflections, arterial wall thickening, cardiac func-
tion and total peripheral resistance. Results of these tests, complemented with 
information from a study questionnaire, show that although there are clear indica-
tions for systemic vascular dysregulation in NTG (based on the questionnaire), 
these were not translated into one or more alterations in cardiovascular parame-
ters at rest.   
Chapter 8: Conclusion 
In Chapter 8 the research questions that were proposed in Chapter 1 are recalled 
and answered. In general, this thesis has contributed to the clinical applicability of 
measures of vascular organ damage, by validating current operator procedures and 
establishing reference values. However, this corresponds to only a small piece of 
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the puzzle, which is not complete. Therefore, future perspectives are discussed. By 
testing all discussed parameters to objective criteria, we recognize that (depending 
on the parameter) one or more crucial steps still need to be taken before fulfilling 
all criteria a biomarker must meet to become implemented into routine clinical 
practice. This analysis also shows that, of all parameters, regional carotid-to-
femoral stiffness has made the most progress in recent years. However, it still 
needs to be demonstrated that therapy based on arterial stiffness reduction will 
eventually improve patient care, and whether this is cost-effective. Both of these 
steps are crucial for opening the gate to the doctor’s office. Another possible stum-
bling block, i.e. the methodological “ease of use” (or lack thereof) is also men-
tioned. Although this issue was not addressed in this thesis, we do recognize it will 
be important to improve the ease of use of current techniques, without the ex-
pense of losing validity. Striking the balance between ease of use and valid results 
will be one of the challenges for the future.      
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Appendix: Device-specific reference tables 
Table 0.1 reference values for DCcar (in 10
-3.kPa-1) from table 5.6, calibrated to the Wall Track System. 
   percentiles 
  Age (years) 2.5th 10th 25th 50th 75th 90th 97.5th 
Men (n=1,724) 20  16.1   23.0   29.1   35.9   42.7   48.8   55.7  
 30  10.3   15.9   20.9   26.4   31.9   37.0   42.6  
 40  7.4   12.1   16.3   20.9   25.5   29.7   34.4  
 50  6.1   10.1   13.7   17.6   21.6   25.1   29.1  
 60  5.7   9.1   12.2   15.5   18.9   22.0   25.4  
 70  5.6   8.6   11.2   14.1   17.0   19.6   22.6  
         
Women (n=1,877) 20  17.7   26.2   33.8   42.1   50.5   58.0   66.5  
 30  11.6   17.7   23.1   29.0   35.0   40.4   46.5  
 40  7.7   12.5   16.9   21.6   26.4   30.7   35.5  
 50  5.6   9.7   13.4   17.4   21.5   25.2   29.3  
 60  4.9   8.5   11.8   15.3   18.9   22.1   25.8  
 70  5.2   8.5   11.5   14.7   17.9   20.9   24.1  
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Table 0.2 reference values for DCfcar (in 10
-3.kPa-1) from table 5.6, calibrated to the Vivid7 system. 
   percentiles 
  Age (years) 2.5th 10th 25th 50th 75th 90th 97.5th 
Men (n=1,724) 20  21.8   29.7   36.8   44.6   52.4   59.4   67.3  
 30  16.0   22.4   28.2   34.5   40.8   46.6   53.0  
 40  13.1   18.5   23.3   28.6   33.9   38.7   44.0  
 50  11.9   16.5   20.6   25.0   29.5   33.6   38.1  
 60  11.6   15.5   18.9   22.8   26.6   30.1   33.9  
 70  11.7   15.0   18.0   21.2   24.5   27.5   30.8  
         
Women (n=1,877) 20  24.9   34.6   43.3   52.8   62.3   71.0   80.6  
 30  18.5   25.6   31.9   38.8   45.7   52.0   59.0  
 40  14.5   20.2   25.3   31.0   36.6   41.7   47.4  
 50  12.2   17.1   21.5   26.4   31.2   35.6   40.5  
 60  10.9   15.2   19.2   23.5   27.8   31.7   36.1  
 70  10.0   14.0   17.6   21.5   25.4   29.0   33.0  
 
 
Table 0.3 reference values for DCcar (in 10
-3.kPa-1) from table 5.6, calibrated to the Carotid studio system. 
   percentiles 
  Age (years) 2.5th 10th 25th 50th 75th 90th 97.5th 
Men (n=1,724) 20  20.1   28.0   35.0   42.8   50.5   57.6   65.4  
 30  14.0   20.4   26.1   32.4   38.6   44.3   50.7  
 40  11.0   16.3   21.1   26.3   31.5   36.3   41.6  
 50  9.8   14.3   18.3   22.7   27.1   31.1   35.6  
 60  9.4   13.2   16.6   20.4   24.2   27.6   31.4  
 70  9.5   12.7   15.6   18.8   22.0   25.0   28.2  
         
Women (n=1,877) 20  22.8   32.5   41.2   50.8   60.3   69.0   78.7  
 30  16.3   23.3   29.5   36.4   43.2   49.4   56.4  
 40  12.0   17.6   22.6   28.1   33.6   38.6   44.2  
 50  9.6   14.3   18.6   23.3   28.0   32.3   37.1  
 60  8.6   12.9   16.7   20.8   25.0   28.8   33.0  
 70  8.9   12.7   16.1   19.9   23.7   27.1   31.0  
 
 
 205 
Table 0.4 reference values for DCfem (in 10
-3.kPa-1) from table 6.6, calibrated to the Wall Track System. 
   percentiles 
  Age (years) 2.5th 10th 25th 50th 75th 90th 97.5th 
Men (n=634) 20  1.5   4.1   6.4   8.9   11.5   13.8   16.3  
 30  2.4   4.8   7.0   9.4   11.8   13.9   16.3  
 40  3.1   5.3   7.3   9.6   11.8   13.8   16.1  
 50  3.2   5.3   7.1   9.2   11.3   13.2   15.3  
 60  2.5   4.4   6.2   8.1   10.0   11.8   13.7  
 70  0.8   2.6   4.2   6.0   7.7   9.3   11.1  
         
Women (n=855) 20  1.4   4.7   7.7   10.9   14.2   17.1   20.4  
 30  2.2   5.5   8.4   11.6   14.8   17.8   21.0  
 40  2.9   6.1   8.9   12.1   15.2   18.1   21.2  
 50  2.9   5.9   8.7   11.7   14.7   17.4   20.5  
 60  1.5   4.3   6.9   9.7   12.5   15.1   17.9  
 70  -2.1   0.5   2.8   5.3   7.9   10.2   12.8  
 
Table 0.5 reference values for DCfem (in 10
-3.kPa-1) from table 6.6, calibrated to the Vivid7 system. 
   percentiles 
  Age (years) 2.5th 10th 25th 50th 75th 90th 97.5th 
Men (n=634) 20  5.7   9.1   12.1   15.4   18.8   21.8   25.2  
 30  6.1   9.2   12.1   15.2   18.3   21.1   24.3  
 40  6.2   9.1   11.8   14.7   17.6   20.2   23.1  
 50  6.0   8.7   11.1   13.8   16.5   18.9   21.7  
 60  5.4   7.9   10.1   12.6   15.0   17.3   19.8  
 70  4.3   6.5   8.6   10.8   13.1   15.1   17.4  
         
Women (n=855) 20  4.0   8.7   13.0   17.7   22.4   26.7   31.4  
 30  5.6   10.1   14.1   18.6   23.0   27.1   31.6  
 40  6.8   11.1   14.9   19.1   23.3   27.1   31.4  
 50  6.9   10.9   14.5   18.5   22.4   26.0   30.0  
 60  4.9   8.7   12.1   15.8   19.5   22.9   26.6  
 70  -0.2   3.3   6.5   9.9   13.4   16.6   20.1  
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